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ABSTRACT 
 
 
THE ROLE OF THE MURINE HOMEOBOX GENE CUX-1 IN KIDNEY 
DEVELOPMENT AND POLYCYSTIC KIDNEY DISEASE 
 
The murine homeobox gene cux-1 is evolutionarily conserved in drosophila, 
mice and humans.  Cux-1 contains four DNA binding domains (3 cut repeat domains 
and a homeodomain) and functions as a transcription factor that represses the 
expression of the cyclin kinase inhibitor p27 during S-phase of the cell-cycle.  Cux-1 
is highly expressed in proliferating cells within the nephrogenic zone of developing 
kidneys. The role of Cux-1 during kidney development and Polycystic Kidney 
Disease (PKD) is unclear.   
Cux-1 is a transcription factor that binds to DNA when it is 
dephosphorylated. Calcineurin A (CnA) is a phosphatase that might be involved in 
regulating Cux-1 as both are expressed during early kidney development.  Previous 
studies demonstrated that CnA knockout (-/-) mice display renal hypoplasia 
associated with ectopic expression of p27 in the nephrogenic zone.  The opposite 
phenotype was observed when Cux-1 is overexpressed. Therefore metanephric 
kidney cultures, overexpressing Cux-1 were grown in the presence of cyclosporine A 
to inhibit Calcineurin.  Overexpression of Cux-1 rescued growth inhibition due to 
Calcineurin inhibition. Calcineurin inhibition resulted in increased phospho-Cux-1 
levels suggesting that Calcineurin may regulate Cux-1 and thus revealing a new 
pathway in kidney development. 
 x
   The cpk mouse model is the most widely characterized model for PKD. A 
hallmark of PKD is increased cell proliferation.  The mechanism of cell proliferation 
in PKD is unclear although deregulation of cyclin kinase inhibitors appears to be 
involved.  Cux-1 is highly expressed in cpk kidneys, however it is unclear if Cux-1 is 
required for PKD.  The results here demonstrate that a mutation of Cux-1 (cux-
1∆CR1) which lacks a Cathepsin-L proteolytic cleavage site, results in severe PKD 
when crossed onto cpk mice.  Upregulation of Cux-1∆CR1 was observed and 
correlated with attenuated levels of p27 within cpk kidneys which suggests a 
potential mechanism for the acceleration of PKD.  Alteration of the PKD phenotype 
by Cux-1 suggests that Cux-1 may act as a candidate modifier gene of PKD.  The 
collection of studies presented within this body of work has helped to elucidate the 
importance of Cux-1 regulation by post-translational modification which requires 
further investigation as a critical factor in kidney development and PKD. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 xi
TABLE OF CONTENTS 
  
DISSERTATION CERTIFICATION ACCEPTANCE…….………………………..ii 
 
DEDICATION……………………………………………………………………….iv 
 
ACKNOWLEDGMENTS…………………………………………………………....v 
 
ABSTRACT………………………………………………………………………....iv 
 
TABLE OF CONTENTS……………………………………………………………xi 
 
LIST OF FIGURES………………………………………………………………...xiii 
 
LIST OF TABLES…………………………………………………………………..xv 
 
 
CHAPTER ONE: BACKGROUND         1 
 
THE DROSOPHILA CUT GENE…………………………………………...1 
CUT HOMOLOGUES…………………………………………………….....4 
MURINE MODELS FOR CUX-1…………………………………………...7 
CUX-1 FUNCTION………………………………………………………...20 
ROLE OF CUX-1 IN CELL-CYCLE REGULATION…………………….25 
REGULATION OF CUX-1 BY POST-TRANSLATIONAL- 
MODIFICATION…………………………………………………………...32 
SIGNAL TRANSDUCTION PATHWAYS INVOLVING CUX-1………..34 
ROLE OF CUX-1 IN KIDNEY DEVELOPMENT………………………...35 
POLYCYSTIC KIDNEY DISEASE………………………………………..39 
MODIFIER GENES………………………………………………………...43 
MODIFIER GENES IN POLYCYSTIC KIDNEY DISEASE……………..45 
ROLE OF CUX-1 IN POLYCYSTIC KIDNEY DISEASE………………..47 
GOAL OF THESE STUDIES……………………………………………....55 
 
CHAPTER TWO: EFFECT OF CUX-1 PHOSPHORYLATION     57  
ON  KIDNEY DEVELOPMENT 
   
ABSTRACT………………………………………………………………...57 
INTRODUCTION…………………………………………………………..58 
            MATERIALS AND METHODS…………………………………………...60 
 RESULTS…………………………………………………………………...64 
DISCUSSION……………………………………………………………….75 
 
 xii
 
 
CHAPTER THREE:  MUTATION IN CUX-1 MODIFIES THE MURINE        79 
POLYCYSTIC KIDNEY DISEASE PHENOTYPE 
  
ABSTRACT………………………………………………………………...79
 INTRODUCTION…………………………………………………………..80 
 MATERIALS AND METHODS…….…………………...………………...81
 RESULTS…………………………………………………………………...86 
DISCUSSION……………………………………………………………….97 
 
 
CHAPTER FOUR: CUX-1 MODIFICATION OF              100 
POLYCYSTIC KIDNEY DISEASE INVOLVES 
DOWNREGULATION OF THE  p27Cip/kip CYCLIN 
KINASE INHIBITOR 
 
  
ABSTRACT………………………………………………………….. …..100 
 INTRODUCTION…………………………………………………………101 
 MATERIALS AND METHODS…………………………………….........103 
RESULTS………………………………………………………………….106 
 DISCUSSION……………………………………………………………...115 
 
 
CHAPTER FIVE: SUMMARY, DISCUSSION AND CONCLUSIONS           119 
    
 
REFERENCES…………………………………………………………………….146 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiii
LIST OF FIGURES 
 
CHAPTER 1:                  Page 
 
1-1 The Cut superclass family of homeodomain proteins.          5 
1-2. Cut superclass of homeobox genes are evolutionarily      
conserved between species.                6 
1-3  Murine animal models used to study the homeobox gene Cux-1.     8 
1-4  Cux-1 CMV Transgenic mice develop organomegaly.   17 
1-5 Model for DNA binding domains of Cux-1 mediating   21 
transcriptional repression.   
1-6 Cell Cycle regulation.        26   
1-7 Regulation of the G1-S checkpoint of the cell-cycle.    28 
1-8  Model for Cathepsin-L mediated degradation pathway of Cux-1  
initiated during S-phase.         29 
1-9    Cux-1 DNA binding activity is regulated by                                                
phosphorylation/dephosphorylation mechanism.      30 
1-10 New nephrons develop in a centrifugal pattern.      35 
1-11 Cux-1 is highly expressed in the nephrogenic zone where cells are          
 proliferating.         36 
1-12 Model for Cux-1 function during nephrogenesis.    39 
1-13   Gene products of human polycystic kidney disease mutations.  40 
1-14   Gene products of PKD in humans and mice co-localize.   42 
1-15   Identification of modifying genes.      44 
1-16  Differential expression of Cux-1 and PCNA in the 
  cysts of 7 day old cpk  49 kidneys.       48  
1-17    p21 and p27 protein expression in cpk kidneys.      50 
1-18   Model for Cux-1 function in ADPKD.        52 
 
CHAPTER 2: 
 
2-1  Expression of Cux-1 in kidneys from CnA-  -/- mice.   65 
2-2.  Decreased cell proliferation in cyclosporin-treated kidney organ cultures  67 
from wild-type mice.   
2-3  Ectopic expression of p27 in cyclosporin-treated kidney      
organ cultures from wild-type mice.      68 
2-4.  Morphology of metanephric kidneys cultured in the presence   
  of cyclosporin A.        69 
2-5  Quantification of metanephric kidney growth. Organ culture   
  growth was quantified using the NIH image J program.   70 
 
 
 
 xiv
         Page 
 
2-6.  Increased phospho-Cux-1 in cyclosporin A (CsA) -treated kidney organ  
cultures.         71 
2-7  Inhibition of cell proliferation by cyclosporin A (CsA) is rescued    
  by ectopic expression of Cux-1.      73 
2-8  The nephrogenic zone is rescued in Cux-1 transgenic kidney   
  organ cultures treated with cyclosporin A (CsA).    74 
2-9  A potential model of Cux-1 regulation by calcineurin.   74 
 
CHAPTER 3: 
 
3-1.  Breeding strategy to generate cux-1ΔCR1/cpk     
  double homozygote animals.       82 
3-2.  Characterization of kidney size by established     
   quantitative measurements.       83 
3-3.  Epidermal Growth Factor Receptor (EGFR)       
regulation of Cux-1 expression.        87 
3-4.  Large Cux-1ΔCR1/cpk kidneys were observed at post-natal day 17. 88 
3-5.  Cux-1ΔCR1/cpk kidneys are significantly larger compared to cpk.  90 
3-6  Quantitative kidney size measurements in cpk kidneys.   91 
3-7  Renal function is reduced in Cux-1ΔCR1/cpk mice.    92 
3-8  Characterization of Cux-1ΔCR1/cpk cystic kidneys.    94 
3-9  Cyst derivation in cpk and Cux-1ΔCR1/cpk kidneys is similar.  95 
 
CHAPTER 4: 
 
4-1  Increased proliferation in cystic kidneys from               
cux-1ΔCR1/cpk mice.                 108 
4-2  Increased Cux-1∆CR1 protein in developing kidney and                      
downregulation of p27 in Cux-1∆CR1/cpk kidneys.             110 
4-3   Cux-1∆CR1 protein lacks a Cathepsin-L cleavage site.            111 
4-4.  Abnormal nuclear Cathepsin-L expression in PKD.              112  
4-5    Cux-1ΔCR1 protein binds to the p27 promoter when p27 is            
downregulated in cpk kidneys.                 113 
4-6  Increased apoptosis occurs in cux-1ΔCR1/cpk mice.                          114  
 
CHAPTER 5: 
 
5-1  A potential model of Cux-1 regulation by calcineurin.                       127 
5-2  cux-1ΔCR1 is a modifying gene for Polycystic Kidney Disease.           133 
5-3  Model for accelerated PKD observed in Cux-1ΔCR1/cpk kidneys.             137 
5-4   Summary of potential signaling pathways that regulate Cux-1.             145 
 xv
LIST OF TABLES 
 
         Page 
 
1-1  Classification of cut gene locus mutations       2 
1-2 Genes that are targets for Cux-1 repression     19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
 
CHAPTER ONE  
 
BACKGROUND 
 
 
The Drosophila cut gene 
 
Drosophila melanogaster has served as a convenient model for identifying 
genes and genetic interactions in the 20th century. Through the use of “gain of 
function” mutations, e.g. the conversion of antenna to an ectopic pair of second 
thoracic legs in the mutation Antennapedia, and “loss-of-function” mutations, 
insights have been gained into molecular mechanisms of Drosophila development. 
The Drosophila cut locus (1) is highly susceptible to mutation and is a region of 
genetic instability (2).  The cut locus was given its name from studies where 
mutations within the locus lead to loss of wing tissue resulting in an easily 
distinguishable “cut wing” phenotype (3).  Ectopic expression of Cut or the 
expression of an evolutionarily conserved mammalian  homologue rescues the Cut 
wing mutant phenotype (4, 5).  This demonstrated the requirement for cut expression 
in wing development. Several cut mutations have been characterized since 1925 that 
cause developmental defects in drosophila wings, legs, external sensory organs, 
Malpighian tubules, tracheal system and within the central nervous system (6-8).   
Mutation within the cut locus can be termed as viable or lethal mutation (Table 1-1).   
cut locus mutations are divided into five categories based upon the tissues affected, 
viability, location within the locus and complementation with other cut mutations as 
presented (3).  There are three types of lethal mutations resulting in the failure of the 
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embryo to develop, termed Lethal I, Lethal II and Lethal III (See Table 1-1).  A 
mutation is considered viable if embryonic lethality does not occur as a result of 
mutation. Kinked femur (kf) and cut wing (ct), are examples of viable cut mutations 
which lead to limb malformations in the leg and wing, respectively (9,10).  Viable 
mutations are similarly characterized by the loss of Cut expression.  Cut is highly 
expressed in exclusive regions within the Peripheral Nervous System (PNS), the 
Central Nervous System (CNS), Malphigian Tubules (the insect functional kidney), 
tracheal histoblasts, cells surrounding the spiracles, and adipose cells (11,12). 
Therefore, Cut expression is considered to be critical for embryogenesis and organ 
morphogenesis during fly development.   
 
 
 
 
 
  
 
 
Table 1-1. Classification of cut gene locus mutations 
Table 1-1.  Mutations within the drosophila cut locus have been classified 
within 5 categories which include Kf, ct, Lethal type I, Lethal type II, and 
Lethal type III.  Regions which are defective upon incurring a Kf, ct, 
Lethal type I, Lethal type II and Lethal type III mutation are listed in the 
above table.    Modified from Nepveu et al. (13) 
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Genetic studies conducted in drosophila suggest that cut may play an 
important role in determining cell-type specificity within the PNS, CNS, and 
Malphigian Tubules. This was supported by the observation that cut is expressed 
within developing precursor cells corresponding to different cell types within the 
PNS, CNS and Malphigian Tubules before these cells undergo different 
developmental programs (11). This pattern of expression suggests that cut plays a 
role in determining cell-type specificity.  The cut gene is also involved in 
development of the fly Antennae (14). Tissue specific expression of cut is directed 
by enhancers located upstream of the gene (3).  Defects within organ tissue caused 
by cut mutations may be the result of cells enrolled in the wrong developmental 
program (6, 12).   For example, embryonic lethal cut mutations caused the 
transformation of external sensory (es) organs into internal (chordotonal) sensory 
organs (12).  In addition, there was the observation that cut mutations convert the 
cells of the Malpighian tubules into gut cells, suggesting that cut is necessary for cell 
type specification and morphogenesis occurring during Malpighian tubule 
development (15).  Moreover, in cut wing mutants, loss of cut expression in the 
presumptive wing margin results in the loss of some adjacent epithelial cells 
(probably by apoptosis), thereby producing the truncated wing phenotype (4,5). 
Collectively, when all of these observations are considered together it is reasonable 
to consider the drosophila cut gene as a determinant of cell type specificity.  
Since when the “Cut wing” phenotype was first identified in Drosophila , 
numerous mutations associated with the partial or complete loss of cut expression 
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have been identified in Drosophila (2-14).  Table 1-1 shows a list of Drosophila 
mutations that lead to lethality with organ defects.  Our laboratory has been 
particularly interested in the cut mutation associated with the loss of the Malphigian 
tubules, the insect organ that functionally resembles a kidney (9,10).  Using this 
information we, and others, have been able to identify a role for one of the 
mammalian Cut proteins, Cux-1, in the regulation of kidney development (15-20).  
 
Cut homologues 
 
Studies in Drosophila have led to the discovery of genes, termed homeotic 
genes, which regulate development. Ectopic expression of homeotic genes, can lead 
to developmental malformations that disturb normal development (21, 22).  
Homeotic genes act to control complex developmental pathways by regulating gene 
expression. Many of the developmental control genes contain a “homeobox”, a 
homologous 180-bp nucleotide sequence of DNA conserved across species.   The 
homeobox encodes a 60 amino acid DNA binding domain motif called a 
homeodomain that characterizes this family of transcription factors.  Homeobox 
genes have been shown to regulate organogenesis and cell proliferation, pattern 
segment identity, and determine anterior-posterior axes and cell fate decisions during 
embryogenesis (16, 23,24).  Homeobox genes can be divided into two broad classes: 
hox genes and divergent homeobox genes. hox genes are located in clusters whereas 
divergent homeobox genes are located in discrete positions throughout the genome. 
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One member of the divergent homeobox gene family is the cut superclass 
(Figure 1-1).  The cut superclass of homeobox genes is comprised of four classes: 
“ONECUT” (with 1 cut domain and 1 homeodomain), “SATB” special AT rich 
binding protein  (with 1 “COMPASS” domain, 2 cut domains, and 1 homeodomain), 
“Cux” (with 3 cut domains and 1 homeodomain), and “CMP” (1 Compass domain 
and 2 homeodomains) (25). A comprehensive survey of the cut superclass genes 
were evaluated in different species.  (71)  Burglin and Cassata (25) reported that 
there are only two cut domain containing genes in Drosophila, one CUX and one 
ONECUT type. A neuron specific ONECUT homeobox gene was isolated in 
zebrafish with a cut domain that shares 88% amino acid identity with drosophila 
ONECUT (26). Caenorhabditis elegans has undergone an expansion of the ONECUT 
subclass genes and has a gene cluster with three ONECUT class genes, one of which, 
the CMP family, has lost the cut domain (25). Two of these genes contain a 
Figure 1-1.  The Cut superclass family of homeodomain proteins.  
The Cut superclass homeodomain transcription factor family tree consists 
of the ONECUT family members, the SATB family members, the CUX 
family members, and the CMP family members. Motifs include cut 
repeats (CR), homeodomain (HD) and Compass domain (COMP).  Image 
taken from Alcalay et al. (241).   
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conserved sequence motif, termed OCAM, which seems to be nematode specific. A 
recently uncovered C. elegans CUX gene has sequence conservation in its amino-
terminus with vertebrate CUX proteins. Since a homologous cut cDNA sequence 
was reported in C. Elegans but not in yeast, Cut proteins appear to be conserved 
amongst metazoans.  As represented in Figure 1-2, Cux protein homologues have 
been identified in a number of species including: human (CDP) (27), Dog (Clox) 
(28), rat (CDP2) (29), drosophila (Cut) (1) and mouse (Cux-1) (19).  While these 
homologues all contain a homeodomain and 3 cut repeats, there are several truncated 
Cut proteins that have been identified which include: testis Cux-1 (30), CASP (31) 
and Cux-1 P75 (32), Cux-1 P90 (33) and Cux-1 P110 (32).  In addition, there are 
other proteins that contain Cut repeats and a homeodomain such as Hepatocyte 
nuclear factor 6 (HNF6) (34), OC-2 (35), and SATB1 (36). To simplify the 
terminology, the term “cux-1” or “Cux-1” will be referred throughout the dissertation 
to represent all homologous forms of the Cux-1 gene and protein respectively.     
 
 
 
 
 
 
Figure 1-2.  Cut superclass of homeobox genes are evolutionarily conserved 
between species.  There is evolutionary conservation between species of CUT 
homologues within ONECUT, SATB, CUX and CMP CUT family members.  
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Murine models for Cux-1 
There have been 5 mouse models of Cux-1 that have been generated to date: 
Cux-1ΔCR1 (37), Cux-1∆C/∆HD (38, 39), CUTL1laCZ  (40), Cux-1 p75 transgenic 
(41), and Cut CMV/Cux-1 Transgenic (20)  (Figure 1-3).  Tufarelli et al. (37), 
designed a targeting construct to replace the first cut repeat (CR1) with a neomycin 
resistance cassette. Their goal was to introduce a nonsense mutation after position 
1319 of the 4.5-kb reading frame of Cux-1.  They expected to generate a truncated 
product of ~60 kDa with this construct. In contrast, mice expressed a mutant form of 
the protein, with an internal deletion of 246 amino acids encompassing the first cut 
repeat domain. The CR2, CR3, HD and C-tail of Cux-1 remained intact. They 
discovered that an exon skipping event had occurred resulting in the removal of 
exons 10 and 11.  The deletion, termed cux-1∆CR1, results in mice displaying a mild 
phenotype which is characterized by curly vibrissae and wavy hair.  Tufarelli et 
al.(37) observed that offspring of homozygote Cux-1∆CR1 females had a high 
degree of mortality.   There was no correlation between the genotype of the pups and 
their mortality. 
Animal lethality was rescued by fostering litters of mutant females to 
lactating CD1 females. Tufarelli et al. (37) found that at day 3 of lactation, the milk 
of homozygous mutant females had decreased levels of є-Casein, but by day 8 the 
levels of є-Casein were the same as in the wild-type milk.  However, since only a 
decrease in one subpopulation of caseins was observed, this result could not explain 
the high degree of lethality.  Histological analysis revealed no observable differences 
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between wild-type and mutant mammary glands. Since a structural defect in mutant 
mammary glands was not evident, the authors proposed that the impaired lactation 
defect might be a result of decreased milk production, production of milk with 
altered properties, behavioral changes, or a combination of these factors. The cause 
of the lactation defect in cux-1∆CR1 mutant mice is currently not known. The 
distribution of Cux-1∆CR1 mutant protein in mutant mice is similar to that of wild-
type.  However, the Cux-1∆CR1 protein is expressed in much higher levels than 
wild-type Cux-1 protein in spleen and thymus. The Cux-1∆CR1 protein appears to 
bind very tightly to DNA as Cux-1∆CR1 is less readily competed off with unlabeled 
oligonucleotide compared to wild type Cux-1.  
 
 
 
 
 
 
 
 
 
Figure 1-3. Murine animal models used to study the homeobox gene Cux-1. 
Image taken from Alcalay et al. (241). 
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A targeting construct was generated for the purpose of deleting a 4kb region 
encompassing the HD within exons 20 and 21 of cux-1 coding sequence. A stop 
codon within exon 20, which encodes the beginning of the homeodomain, was 
introduced to force premature translational termination. This deletion of the C-
terminus of Cux-1 includes the homeodomain while retaining CR1, CR2 and CR3 
domains. It results in mice with a more severe phenotype than cux-1∆CR1 mutant 
mice.  The mutation, termed cux-1∆C/∆HD, (38, 39) results in stunted growth.   
Homozygous mutant cux-1∆C/∆HD pups have a similar appearance to their 
littermates at birth. The cux-1∆C/∆HD pups nursed normally, and milk was observed 
within their stomachs during the first couple of days after birth, but they failed to 
thrive. By the end of the first post-natal week of life, many cux-1∆C/∆HD pups were 
smaller than their littermates. The cux-1∆C/∆HD runted phenotype may be a result 
of defective nutrient absorption within the gastrointestinal tract. However, 
histological sections stained with hematoxylin and eosin revealed no structural 
abnormalities in the small intestine of mutant mice. Moreover, no abnormalities were 
observed when other organs of the gastrointestinal (GI) tract were examined, such as 
the stomach and the colon.  Therefore, the authors concluded that the cux-1∆C/∆HD 
mutation did not affect development of these organs.  It is still not clear as to how 
cux-1∆C/∆HD animals have a runt phenotype.         
Most of the cux-1∆C/∆HD pups die within the first 10 days of postnatal life.  
Greater than 70% of cux-1∆C/∆HD pups failed to survive to weaning age. Therefore, 
in addition to severe weight loss, a high postnatal mortality rate of 60% to 70% was 
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observed.  The homozygous mutant mice that do survive to adulthood have a normal 
life span but are severely growth retarded and weigh 30 to 50% less than their 
normal littermates.  cux-1∆C/∆HD mice are born at mendelian frequency. They 
appear to die after birth as a result of a defect in lung development characterized by 
delayed differentiation of lung epithelia.  These in vivo results appear to have 
revealed a role for Cux-1 in lung maturation. cux-1∆C/∆HD hetereozygotes have a 
normal phenotype in that they have a normal appearance and are fertile. In contrast, 
cux-1∆C/∆HD mice have abnormal coat hair with males having severely reduced 
fertility. There was no significant difference in wild-type, hetereozygote and cux-
1∆C/∆HD homozygote testes weight. Histological and gross examination revealed 
that the testes and epididymis were normal in mutants. However, serum testosterone 
levels in mice heterozygote or homozygote for cux-1∆C/∆HD were significantly 
lower than those in wild-type male littermates. Yet, the lower testosterone levels did 
not correlate to reduced male fertility in cux-1∆C/∆HD hetereozygotes.  Therefore 
reduced testosterone levels may not be involved in the reduced male fertility 
phenotype.  The mechanism for reduced fertility in cux-1∆C/∆HD male mice is 
unknown.            
  Luong et al.(38) suggested that the deregulated hair cycle and severely 
diminished fertility implies that Cux-1 may be required for dermal and reproductive 
development.  In yet another very interesting finding, histopathological examination 
on cux-1∆C/∆HD bone marrow and sternebrae revealed hyperplasia of myeloid cell 
types (39).  In contrast to myeloid hyperplasia cux-1∆C/∆HD mice had reduced 
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thymic cellularity due to enhanced apoptosis, with loss of CD4(+)CD8(+) 
thymocytes. However, in maturing thymocytes, CD25 was ectopically expressed. 
 Tumor necrosis factor (TNF) was elevated in thymus of mutant mice which 
may suggest that TNF is a target gene for Cux-1 mediated repression.  There was a 
2- to 3-fold reduction in total bone marrow B-lineage due to enhanced apoptosis. The 
authors suggested that the observed immunological phenotypes were a result of 
underexpression of survival factors or overexpression of death-inducing factors. So 
Cux-1 may function to regulate normal hematopoiesis, presumably by modulating 
the expression levels of survival and/or apoptosis factors within a given 
microenvironment.  However, the mechanism behind these observations is still not 
clear. Hematoxylin-and-eosin-stained sections did not reveal histological defects in 
the major internal organs or the brains of cux-1∆C/∆HD mice.  cux-1∆C/∆HD 
homozygous mutant mice are very susceptible to bacterial infections and have 
purulent rhinitis characterized by mucosal and submucosal purulent infiltrates within 
the nasal turbinates (39).      
 cux-1∆C/∆HD pups initiate hair shedding during the 2nd to 3rd post-natal 
week. At the end of the first post-natal month, cux-1∆C/∆HD mice are completely 
bald except for very thin hair covering parts of the ventral region and head (38, 39).  
The coat hair will eventually grow back over a period of several months, with 
regrowth being more evident in female than in male cux-1∆C/∆HD mice. The hair 
that is regrown has a distinctively light gray color and often appears longer than the 
hair of wild-type animals. cux-1∆C/∆HD mutant mice have scant and distorted hair 
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that appears to be slender and broken off in contrast to wild-type mice where there 
was a thick mat of normal hair.  cux-1∆C/∆HD mutant hair had a variety of  
deformities that included kinky, twisted and flattened characteristics. The consistent 
pattern observed in these mice was the partial formation of the cuticle on some fibers 
with absence on other fibers, which led Luong et al. to suggest that the inner root 
sheath may not be normal. cux-1∆C/∆HD mutant mice did not possess vibrissae in 
their muzzle skin. Instead, only lance-shaped broken ends of hair fibers and 
irregularly wavy hairs were observed that were short and similar to the coat hair. 
Follicular dystrophy and progressive alopecia was observed in cux-1∆C/∆HD 
homozygotes as they aged. In some instances dystrophic fibers pushed out of 
growing follicles, twisted below the level of the sebaceous gland, and entered the 
dermis and hypodermis, with an inflammatory response being found in and around 
the fiber. Therefore, the cux-1∆C/∆HD mutation apparently causes abnormal 
formation of the coat and vibrissa hair fibers similar to that of the cux-1∆CR1 
mutation.         
 The function of Cux-1∆C/∆HD is different compared to wild-type Cux-1 
protein.  Immunofluorescence revealed that expression of the cux-1∆C/∆HD mutant 
protein is restricted to the cytoplasm instead of the nucleus where full length Cux-1 
is normally expressed (38,39).  The C-terminus of Cux-1 or the HD may be required 
for Cux-1 nuclear localization.  It is feasible that these regions of Cux-1 may contain 
critical nuclear localization signals (NLS) that play a major role in the localization of 
Cux-1 to the nucleus. Luong et al.(38) suggested that since Cux-1 expression within 
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the nucleus is absent, then Cux-1 protein function may also be absent.  This result 
was supported by the observation that DNA binding activity of HiNF-D was lost in 
nuclear extracts derived from mouse embryonic fibroblasts (MEFs) or adult tissues 
of homozygous mutant cux-1∆C/∆HD mice (38,39). They concluded that deletion of 
the C-terminus containing HD results in a molecular phenotype reflected by the 
absence of Cux-1 containing protein/DNA complexes. Histone H4 mRNA levels 
from wild-type, heterozygous, and homozygous mutant MEFs were similar, 
indicating that there is no difference in the amount of cells present in S phase.  This 
was supported by the observation that cux-1∆C/∆HD  MEFs had a growth pattern 
that was similar to wild type MEFS(38, 39).  The effect of cux-1∆C/∆HD mutation 
may be dependent on the specific cell-type.   
In contrast to cux-1∆C/∆HD mice (38,39), CUTL1laCZ mice (40) lack CR3 
and HD in addition to the C-tail being deleted. Mutant mice on inbred genetic 
backgrounds are born at a mendelian frequency. Similar to cux-1∆C/∆HD mice, 
CUTL1laCZ die shortly after birth because of delayed differentiation of lung epithelia.  
The CUTL1laCZ gene is crossed onto an outbred genetic background, there is a less 
pronounced delay in lung development which permits CUTL1laCZ mice to survive 
beyond birth.  Another similarity between cux-1∆C/∆HD and CUTL1laCZ is the 
overall growth inhibition runt phenotype as well as disruption of hair follicle 
morphogenesis resulting in an abnormal pelage(38-40).  CUTL1laCZ mice have a 
reduced inner root sheath (IRS), and the transcription of Sonic hedgehog and IRS-
specific genes were found to be deregulated in CUTL1laCZ mutant hair whisker 
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follicles. This result is consistent with the specific expression of CUTL1laCZ in the 
progenitors and cell lineages of the IRS. Similar to Cux-1∆C/∆HD protein, the Cux-
1-LACZ fusion protein expression was restricted to the cytoplasm and failed to 
repress gene expression (38-40). Both CUTL1laCZ and cux-1∆C/∆HD mutations are 
deletions of the C-tail encompassing the HD.  The difference between CUTL1laCZ 
and Cux-1∆C/∆HD is the absence of the CR3 domain. Since CUTL1laCZ and Cux-
1∆C/∆HD have similar phenotypes the loss of the CR3 domain has no effect on 
altering the phenotype observed when HD and the C-tail are removed.  Therefore, 
CR3 may play a very mild role in Cux-1 function.  In all three Cux-1 mutant models 
(cux-1∆CR1, CUTL1laCZ , cux-1∆C/∆HD) a defect in hair and follicle development 
was observed. Loss of CR1 resulted in a mild hair and follicle defect. In contrast, 
loss of CR3, HD and the C-tail of Cux-1 resulted in more severe defects. The loss of 
HD and the C-terminus results in a mutant protein that does not localize to the 
nucleus and can not repress promoter activity.  Since loss of CR1, the Cux-1∆CR1 
protein, results in what appears to be a more stable protein-DNA interaction then 
wild-type Cux-1, these results collectively support in vivo observations that CR1 
may function to inhibit stable DNA binding and that CR3 and HD domains are 
required for stable DNA binding interactions (32).  
Since Cux-1 is known to be highly expressed in proliferating cells it became 
a point of interest to determine how overexpression of Cux-1 might alter mouse 
development.  Therefore, our laboratory designed transgenic mice whereby 
expression of Cux-1 was driven by the CMV promoter (CMV/Cux-1 Transgenic) 
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(20).  The overexpression of Cux-1 resulted in transgenic mice with multiorgan 
hyperplasia and organomegaly (Figure 1-4), but not an overall increase in body size. 
Organomegaly was observed in heart, kidney testis, spleen, seminal vesicle and liver.  
Cux-1 Transgenic mice had Glomerular abnormalties which included the 
replacement of normal squamous epithelium of Bowman’s capsule with proximal 
tubule-like epithelial cells (20).  These cells were continuous with the proximal 
tubule epithelium and were observed in all glomerulae.  We found that increased 
expression of Cux-1 in mesangial cells results in cell proliferation and mesangial 
expansion. In addition, these changes are potentially related to disruption of 
podocyte architecture leading to loss of filtration. These results suggest that 
expression of Cux-1 is sufficient to induce the early events of mesangioproliferative 
glomerulonephritis. 
Transgenic kidneys also exhibited glomerular and tubular hypercellularity 
(20,42).  CMV/Cux-1 Transgenic kidneys had a significantly increased renal cortex, 
without an overall increase in nephron number.  However, there was an overall 
increase in the total number of cells in both the cortex and glomerulae which 
correlated with an increase in cell proliferation within these respective regions.  
Further analysis revealed that p27 mRNA and protein expression levels were 
downregulated in CMV/Cux-1 transgenic mice. Since the CMV/Cux-1 Transgenic 
mice had a similar phenotype to that of the p27 (-/-) mice our laboratory has focused 
on investigating the function of Cux-1 to regulate the cell-cycle. We found that 
increased levels of Cux-1 transfected into HEK293T cells, results in the reduction of 
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p27 promoter luciferase activity implicating p27 as a target gene for Cux-1 
repression.   We found that liver hepatomegaly within CMV/Cux-1 Transgenic mice 
correlated with an increase in cell proliferation (43). In addition, the increase in Cux-
1 expression in transgenic livers was associated with a decrease in p21, but not p27, 
expression. Within transgenic livers, Cux-1 was ectopically expressed in a 
population of small cells, but not in mature hepatocytes, and many of these small  
cells expressed markers of proliferation (43). Transgenic livers showed an increase 
in alpha-smooth muscle actin, indicating activation of hepatic stellate cells, and an 
increase in cells expressing chromogranin-A, a marker for hepatocyte precursor 
cells. Morphological analysis of transgenic livers revealed inflammation, hepatocyte 
swelling, mixed cell foci, and biliary cell hyperplasia (43). These results suggest that 
increased expression of Cux-1 may play a role in the activation of hepatic stem cells, 
possibly through the repression of the cyclin kinase inhibitor p21. 
The full length Cux-1 protein can be proteolytically processed by Cathepsin-
L into a p110, p90 or p75 protein (32, 33). The p75 protein isoform was found to be 
overexpressed in human breast cancers (41). Cadieux et al.(41) designed transgenic 
mice that overexpress p75 driven by the mouse mammary tumor virus-long terminal 
repeat. They found that 33% of mice from two transgenic lines and from backcrosses 
developed a similar disease characterized by splenomegaly, hepatomegaly, and 
frequent infiltration of leukocytes into nonhematopoietic organs such as the kidneys 
and lungs.  They also found an increase in the overall number of neutrophils in the 
blood, spleen, and bone marrow which correlated with anemia and  
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Figure 1-4. Cux-1 CMV 
Transgenic mice develop 
organomegaly. 
(A) Schematic of Cux-1 
transgenic driven by CMV 
promoter. (B) 
Organomegaly in Cux-1 
transgenic CMV mice. 
Image used from Ledford 
et al. (20).  
 
 18
thrombocytopenia.  Cadieux et al.(41) therefore concluded that Cux-1 p75 transgenic 
mice were susceptible to myeloproliferative disease-like myeloid leukemia and that 
overexpression of p75 might disturb hematopoietic homeostasis in some way. 
It is very interesting that the phenotype of spleenomegaly and hepatomegaly 
are observed in both CMV/Cux-1 Transgenic (20)  and Cux-1 p75 transgenic mice 
(41).  The phenotype observed in CMV/Cux-1 Transgenic might results from both 
the full length Cux-1 p200 protein and Cux-1 p75.  It is possible that overexpression 
of Cux-1 in the CMV/Cux-1 transgenic mice results in higher then normal Cux-1 p75 
levels.  To date, we have never analyzed p75 expression in CMV/Cux-1 Transgenic 
mice. It is also conceivable that Cux-1 p110 and Cux-1 p90 also may be abnormally 
expressed to help produce the CMV/Cux-1 transgenic phenotype.    
 The overexpression of Cux-1 p200 and the production of Cux-1 p110, Cux-1 
p90, Cux-1 p75 may be a tissue-specific event.  The observation that Cux-1 p75 
transgenic mice may have a myeloproliferative disease (41) is consistent with the 
function of Cux-1 to regulate the immune system in that hyperplasia of myeloid cell 
types and reduced thymic cellularity were observed in cux-1∆C/∆HD mice.  The 
mechanism for Cux-1 regulation of immunological processes still remains unclear.  
There has been a significant amount of information extracted from using 
mouse models to study the function of the murine homeobox gene Cux-1.  It is still 
not clear how the individual loss of CR2, CR3, and HD with the retention of the full 
length Cux-1 sequence, might affect mouse development.  Mice lacking both CR1 
and CR2 domains, CR2 and CR3 domains, and CR3 and HD domains may provide 
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additional insight into Cux-1 function.  Furthermore, the cleaved portion of Cux-1, 
Cux-1p110  has not been evaluated in animal models.  A transgenic mouse that 
overexpresses Cux-1 p110 may be very useful in defining the role of Cux-1 to act as 
a transcription factor during S-phase of the cell cycle. The role of Cux-1 p110 in 
participating in the progression of cells through the cell cycle towards cell division 
has not been evaluated in vivo when Cux-1 p110 is overexpressed.  The advent of 
Cre-Lox tissue specific expression systems may also be utilized to determine how 
tissue specific expression of Cux-1 may affect, hair development, organogenesis and 
sexual reproduction.  The current wealth of knowledge of the in vivo function of 
Cux-1 can only be overshadowed by the next accumulation of knowledge gathered in 
future studies.        
 
 
 
 
 
 
 
 
 
 
 
Table 1-2. Genes that are targets for Cux-1 repression.   
Modified from Nepvue (13). 
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Cux-1 function 
Cux-1 DNA binding activity was initially characterized as CCAAT 
displacement activity (44) or participating in complex with histone nuclear factor D 
(HiNF-D) (45) with binding activity disappearing when myeloid cells differentiated.  
Cux-1 binding activity was downregulated during fetal liver development (45) and 
osteoblast differentiation (46,47).  Table 1-2 shows a list of all genes that are targets 
for Cux-1 mediated repression.  Many of the targets of Cux-1 are genes that are 
repressed in proliferating precursor cells and are turned on as cells become 
terminally differentiated as Cux-1 activity ceases.  Cux-1 homologues predominately 
function as transcriptional repressors of many different genes (28, 44-49).  
Figure 1-3 shows that Cux-1 contains four DNA binding domains (CR1, CR2, 
CR3, and HD).  While CDP/Cux p200 only transiently binds to DNA and carries the 
CCAAT-displacement activity, p110 makes a stable interaction with DNA (27,43). 
Moon et al. (50, 51) demonstrated that full length Cux-1 protein, containing all four 
DNA binding domains, displays rapid and transient DNA binding activity.  The 
NH2-terminal end of the full-length protein harbors an autoinhibitory domain that 
inhibits DNA binding (52).  In vitro studies using CR fusion proteins demonstrated 
that Cux-1 domains (CR1CR2, CR3HD, CR1HD, CR2HD and CR2CR3HD) bind 
DNA with variable affinity (51). The CR2CR3 fusion protein did not efficiently bind 
to DNA. The CR1CR2 domains were found to bind a GC rich sequence (GC box) of 
DNA transiently and rapidly.  CR1 CR2 bound to two CA/GAT sites, organized as  
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Figure 1-5. Model for DNA binding domains of Cux-1 mediating transcriptional 
repression.  Passive repression involves CR1 and CR2 competing with SP1 for 
binding to a promoter. Active repression involves CR3 and HD stably binding to 
DNA and recruiting proteins such as HDAC1 in mediating repression of gene 
transcription.  
 
direct or inverted repeats.  The Sp1 transcriptional activator also binds the GC box 
(53).  Based primarily from work done in vitro, a model for Cux-1 DNA binding was 
proposed (13, 48, 54) based on the difference in Cux-1 DNA binding domain 
properties (Figure 1-5).   CR1 and CR2 are thought to compete with Sp1 for 
occupancy of a GC box.  The binding of CR1CR2 is considered “passive repression” 
because transcription is repressed indirectly by Cux-1 out-competing Sp1 for GC box 
binding. The presence of Cux-1 on the GC box instead of Sp1 would prevent Sp1 
from activating transcription. Since results from our lab demonstrated that ectopic 
expression of Cux-1 in CMV/Cux-1 Transgenic mice leads to the downregulation of 
p27 mRNA and protein levels (20), we predicted that Cux-1 would similarly bind to 
the p27 promoter.  Recently, by performing Chromatin Immunoprecipitation analysis 
(ChIP) we found that Cux-1 binds to a region of the cyclin kinase inhibitor p27 
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promoter that contains a GC box in the vicinity of a CCAAT box (Unpublished 
observation). It has also been demonstrated that Cux-1 binds the promoter of the 
cyclin kinase inhibitor p21 to a GC box (55).  Given that Cux-1 binds to the GC box 
of the promoter where Cux-1 is found to bind, it is very likely that Cux-1 binds 
transiently to p21 and p27 promoters and may passively repress gene expression by 
competing with Sp1 for promoter occupancy.  
The in vitro examination of independent Cux-1 binding domains determined 
that CR3HD stably bind DNA (54).   The product of stable Cux-1/DNA interaction is 
the ability of Cux-1 to possibly recruit histone deacytlases (HDAC) such as HDAC1 
(56). Two active transcriptional repression domains present within the C-terminus of 
Cux-1 appears to associate with HDACs (48, 56).  Two closely linked transcriptional 
repression domains are located within the distal C-terminal of Cux-1.  Mailly et al. 
suggested that the ability of Cux-1 to stably bind DNA and exhibit “active 
repression” involves the Cut homeodomain and the C-terminus of Cux-1 since 
HDAC1 can be pulled down by a GST-CDP/Cut fusion protein containing the 
homeodomain and C-terminus (48, 56).   HDAC1 could then deacetylate chromatin 
to repress gene expression.  The physical occupancy of Cux-1 at a promoter may 
provide a physical barrier to prevent transcriptional activators and the normal 
transcriptional machinery (i.e RNA Polymerase) from interacting with the promoter.  
Goulet et al. (32) demonstrated that the full length Cux-1 protein, termed P200, 
transiently binds to DNA. They found that a nuclear form of Cathepsin-L, a 
proteolytic enzyme that normally localizes to the lysosome, cleaves the Cux-1 P200 
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into a p75 and p110 forms.  More recently, it has been demonstrated that Cathepsin-
L can also cleave Cux-1 into a p90 protein (33).  In addition, a tissue-specific mRNA 
species was found to code for the p75 CDP/Cux isoform which contains only two 
DNA-binding domains: CR3 and HD (32, 41).  Molecular studies showed that the 
full-length protein, p200, binds rapidly but transiently to DNA and carries the 
CCAAT displacement activity (50, 51).   In contrast, the p110 and p75 isoforms 
behave like classical transcription factors that engage in slow but stable interactions 
with DNA (59).  The p110 protein may participate in transcriptional activation and 
can stimulate cell proliferation by accelerating entry into S phase (57,58).  It has been 
proposed that the N-terminus of Cux-1 contains an inhibitory DNA binding domain. 
(52)  Goulet et al. (32) suggested that the CR1 domain is an autoinhibitory domain 
which could prevent stable Cux-1 binding.  They reasoned that the full length P200 
protein might bind to DNA in a transient fashion because it contained the CR1 
domain which might inhibit stable DNA binding promoted by the CR3 and HD.  The 
p110 protein lacks the N-terminus and the CR1, but retains CR2, CR3 and HD and 
has been demonstrated to have a very stable interaction with DNA (32).  It is 
possible that CR1 and the N-terminus mask the CR3 and HD resulting in transient 
Cux-1 DNA binding. The removal of the N-terminus could then “activate” Cux-1 to 
bind to DNA by allowing CR3 and HD to freely bind to DNA resulting in a more 
stable Cux-1– DNA interaction.  Unfortunately, the Cux-1 protein has not been 
studied by X-ray Crystallography to date so the three-dimensional conformation of 
Cux-1 is currently not known.     
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Work from animal model studies has revealed important characteristics of Cux-
1 DNA binding activity.  Cux-1 protein lacking the C-tail, containing either the HD 
or both the CR3 and the HD, has reduced DNA binding activity (38, 40).  Expression 
of both of these proteins is restricted to the cytoplasm, suggesting that a nuclear 
localization sequence (NLS) may be present within the C- tail.  It should not be 
discounted that the CR3 and HD domains are important for Cux-1 localization within 
the nucleus.  Hypomorph deletions of CR3 and HD while retaining the C-tail have 
not as of yet been generated. Studies where the C-tail of Cux-1 is deleted in mice 
highlight the importance of both CR3 and HD domains for Cux-1 DNA binding as 
mutant Cux-1 exhibited limited DNA binding.  Tufarelli et al.(37) showed that the 
Cux-1ΔCR1 protein is less readily competed off with cold radio-labeled 
oligonucleotide then wild-type Cux-1 protein in electromobility-shift assay 
competition studies.  However, Cux-1ΔCR1 protein expression levels appeared to be 
higher then wild-type Cux-1 in both Spleen and Thymus and thus the observation 
that Cux-1ΔCR1 stably binds to DNA might be a concentration dependent result of 
increased Cux-1ΔCR1 expression.  Based upon the abundant evidence that Cux-1 
gene targets are repressed in cells containing high levels of Cux-1 (Table 1-2), the 
activity of Cux-1 mediated repression may be completely concentration dependent.  
Transition between the inactive and active states of Cux-1 for DNA binding in vivo 
appears to be governed by post-translational modifications and/or interactions with 
one or more protein partners (62-71).   Cux-1 may function as a transcriptional 
activator or repressor depending on the cell–type in which it is expressed.  
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 The function of Cux-1 as a transcription factor might depend upon cell-type 
and expression of proteins (29, 66) within a cell at specific stages of the cell-cycle. 
Results in mammals (20, 37-43) suggest that Cux-1 expression or activity is 
restricted to proliferating cells establishing an important role for Cux-1 in 
developmental organogenesis of such organs as the kidney (19, 20), lung (38-40) and 
liver (20, 43). The nature of how Cux-1 p110, p90 and p75 interact with nuclear 
proteins and form discrete protein complexes involved in transcriptional regulation is 
still not clear.  Much of the studies to date have involved analysis of the full length 
Cux-1 p200 and Cux-1 p110 in regard to protein-protein interactions as well as DNA 
binding interactions.  Studying truncated Cux-1 protein interactions during late G1 
and early S-phase may elucidate the function of Cux-1 to regulate the cell-cycle.   
 
Role of Cux-1 in cell-cycle regulation 
 
Regulation of the cell-cycle is critical to the life of an organism.  The cell-
cycle is tightly regulated to ensure proper replication of select cells (Figure 1-6). 
Inappropriate progression through the cell-cycle may lead to aberrant cellular 
proliferation.  The consequences of abnormal cell division can be catastrophic to an 
organism and may result in mortality.  Therefore cells are required to pass through 
two “checkpoints” before being permitted to divide.  The first checkpoint is between 
G1 and S-phase transition while the second is between G2 and M-phase. The G1-S 
checkpoint serves to prevent cells that incurred DNA damage from progressing 
through the cell cycle.  Missense, nonsense and deletion mutations in critical genes 
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may damage a parental cell.  The G1-S checkpoint restricts cell-cycle progression to 
cells with undamaged or repaired DNA (via base excision repair, homologous 
recombination repair etc.).  Moreover, the G1-S checkpoint ensures viable future 
generations of cells by not producing cells with lethal inheritable mutations.     
 
 
 
 
 
 
 
 
 
 
Figure 1-6. Cell Cycle regulation.  The cell cycle is tightly regulated by positive 
factors (cyclin-CDK complexes) which favor progression through the cycle and 
negative factors (cyclin kinase inhbitors- 2 families: INK4 or CIP/KIP) which restrict 
progression through the cell cycle. 
  
Cell cycle is regulated by nuclear proteins that can positively (cyclins and 
cyclin dependent complexes) or negatively (cyclin kinase inhibitors) control cell 
proliferation.  Cyclins become upregulated during the cell cycle and form complexes 
with cyclin dependent kinases (CDK) to specifically regulate genes involved in each 
successive phase of the cycle (Figure 1-6). During late G1 and early S-phase CDK 
4/6-cyclin D complexes phosphorylate the protein retinoblastoma (RB) releasing its 
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hold on the transcription factor E2F which activates genes involved in DNA 
synthesis (Figure 1-7).  In contrast, cyclin kinase inhibitors (CKIs) are nuclear 
proteins that bind to CDK-cyclin complexes to prevent the phosphorylation of RB. 
CKIs therefore prevent E2F release and gene regulation of components necessary for 
DNA synthesis resulting in cell cycle arrest and attenuated cell proliferation.    
There are two classes of CKIs, the CIP/KIP and ink4 family.  The CKIs p21 
and p27 regulate progression through the cell cycle at the G1-S transition.  Both p21 
and p27 contain an N-terminal CDK-binding domain. (75,76)  This domain allows 
p21 and p27 to bind to CDK2/4 and inhibit the formation of CDK2/4- cyclin D1 
complex.  This leads to inhibition of CDK2/4-cyclin D1 kinase activity which 
prevents the activation of transcription factors required for S-phase.   Gene Targets 
of Cux-1 mediated repression are repressed in proliferating precursor cells  (See 
Table 1-2) and are turned on as cells become terminally differentiated and Cux-1 
activity declines (27). A role for Cux-1 in cell-cycle progression was suggested from 
the findings that Cux-1 DNA binding activity oscillates during the cell cycle, 
reaching a maximum at the end of G1 and during the S Phase. (17) A recent model 
has been proposed (27,30,31,51) whereby full length Cux-1 p200 is cleaved by 
Cathepsin-L, during S-phase of the cell cycle, into an N-terminally truncated p110 
protein (Figure 1-8).  Cux-1 p200 has also been demonstrated to be cleaved into a 
p90 protein and a p75 protein.(49,30)  The p110 protein exhibited stable DNA 
binding interactions.(30)  Coqueret et al.(17) demonstrated that Cux-1 binds to the 
p21 cyclin kinase inhibitor promoter and represses p21 expression.  Overexpression 
 28
of Cux-1 in CMV/Cux-1 transgenic mice results in the down regulation of the p27 
cyclin kinase inhibitor (20).  When full length Cux-1 was overexpressed in 
increasing concentrations with a reporter p27 luciferase promoter, reduction of 
promoter activity was observed (20).  Since Cux-1 is highly expressed at the end of 
G1 and during early S phase (51) and can repress both p21 and p27 promoter activity 
(20, 55), Cux-1 appears to function to permit progression through the cell-cycle 
leading towards cell division through the repression of the cyclin kinase inhibitors 
p21 and p27.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-7.  Regulation of the G1-S checkpoint of the cell-cycle. The RB protein 
sequesters E2F transcription factor during mid G1. Growth factors such as EGF 
stimulate CDK 4/6. This complex phosphorylates RB removing its ability to bind 
E2F during late G1. E2F then activates genes required for progression into S-phase. 
Growth factor inhibitors rush as TGF-β can activate cyclin kinase inhibitors capable 
of preventing CDK-cyclins from phosphorylating RB. 
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Cux-1 is the DNA binding subunit of the HinF-D complex that forms during 
S-phase (69, 72,73). The HinF-D complex consists of Cux-1, CDK2/CyclinA and 
pRB/p107 (69).  The HinF-D complex is involved in the activation of histones 
during S-phase (72,73).  The HinF-D mediated pathway is a mechanism of gene 
regulation at G1/S that is independent of E2F (68).  Cux-1 DNA binding activity is 
highest during early S-phase and gradually declines as S-phase is completed (51).  It 
is possible that depending upon the cell type, there may be lower or higher amounts 
of Cux-1 p200, Cux-1 p110, Cux-1 p90, and/or Cux-1 p75 during S-phase.  
Moreover, the protein binding partners that various truncated forms of Cux-1 may 
interact with during S-phase is unclear.  It is possible that the Cathepsin-L cleavage 
products of Cux-1 undergo many unique post-translational modifications during S 
 
Figure 1-8. Model for 
Cathepsin-L mediated 
degradation pathway 
of Cux-1 initiated 
during S-phase.  Full 
length Cux-1 (p200) is 
proteolytically cleaved 
to Cux-1 (p110 protein) 
during S-phase by 
Cathepsin-L. This might 
be the initial step 
required for Cux-1 
proteolysis. Cux-1 
(p110) protein stably 
binds DNA while Cux-1 
(p200) binds transiently 
to DNA. 
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phase which could determine Cux-1 DNA binding ability directly and involvement 
in complex protein-protein interactions.    
When Cux-1 is phosphorylated Cux-1 DNA binding is inhibited (55, 59, 60).  
In contrast, when Cux-1 is dephosphorylated Cux-1 DNA binding is permitted 
(Figure 1-9).  Coqueret et al. (55) found that cdc25A dephosphorylates Cux-1 which 
would permit Cux-1 DNA binding during S-phase.  At the beginning of S-phase 
Cux-1 p200 is cleaved to Cux-1 p110 (32).  Santaguida and Nepveu (73) found that 
Figure 1-9. Cux-1 DNA binding activity is regulated by 
phosphorylation/dephosphorylation mechanism.  PKC, Casein Kinase II, cyclin 
A CDK1 and PKA phosphorylate Cux-1 resulting in decreased Cux-1 binding to 
DNA. In contrast, when Cux-1 is dephosphorylated by cdc phosphatase Cux-1 
binds to DNA.  
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Cyclin A/CDK2 does not phosphorylate Cux-1 p110.  Moreover, they determined 
that Cyclin A/CDK2, is expressed during S-phase of the cell-cycle, did not inhibit 
Cux-1 DNA binding activity and transcriptional activity. However, Cyclin A/CDK1, 
which is highly expressed during G2 of the cell-cycle, phosphorylated Cux-1 p110 
protein resulting in the inhibition of DNA binding and transcriptional activity (73). 
These results may help to explain why Cux-1 p110 DNA binding activity is maximal 
during S-phase and decreases in G2.    
Cux-1 clearly plays a role in regulating the cell-cycle by repression of p21 
and p27 cyclin kinase inhibitors.  However, the exact mechanism is unclear.  It is 
possible that Cux-1 forms various complexes with different proteins and/or may act 
as an independent factor depending on cell type. Nishio et al. (75) reported that Cux-
1 interacts with G9a Histone Lysine Methyltransferase (HKMT) at the site of the p21 
promoter. HKMT can methylate Histone 3 lys-9 within the Cux-1 regulatory site of 
the p21 promoter.   Methylation of the amino acid lysine results in gene-silencing. 
Therefore this is one possible manner by which Cux-1 can mediate repression of p21 
expression.  We found that Cux-1 interacts with TLE-4, (70) the mammalian 
homologue of the drosophila gene Groucho, in rat kidney epithelial cells that 
consistituitively express Notch correlated with downregulation of p27. However, 
evidence of Cux-1 and TLE-4 interaction as a requirement for regulation of p27 
promoter activity is still not clear.  The pRB protein has been suggested to function 
as a co-repressor when bound to Cux-1 as Cux-1 pRB interactions were required for 
repression of Histone 4 (H4) expression (79).  Cux-1 has been reported to be a 
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member of different protein complexes.  Cux-1 is part of the NF-mUNR complex to 
repress immunoglobulin (77).  It is a complex consisting of the histone 
acetyltransferase p300, CBPAF and CBP (63).  Cux-1 may play a role as a structural 
component of chromatin through its interaction with nucleosomal DNA and 
association with nuclear matrix attachment regions (13).  The role of Cux-1 in the 
nucleus appears to depend on the stage at which a cell is in within the cell-cycle.  
Cux-1 is highly expressed during late G1 and early S-phase.  
 
 
Regulation of Cux-1 by post-translational modification  
Numerous transcription factors such as nuclear factor kappaB undergo an 
“activation/inhibition-degradation” pathway during critical stages of the Cell-Cycle 
(13, 78-86).  Proteolytic cleavage, phosporylation/dephosphorylation, acetylation and 
ubiquitization pathways serve as post-translational modification mechanisms to 
activate or inhibit protein activity during time-points that are appropriate for proper 
cellular function.  There are atleast three ways by which Cux-1 can undergo post-
translational modification; Proteolytic cleavage/processing (32, 33, 51), 
phosphorylation/dephosphorylation (59-61) and Acetylation (63).  The post-
translational modification of Cux-1 seems to play an important role in the function of 
Cux-1. Goulet et al.(32) found that a nuclear form of Cathepsin-L is present during 
S-Phase of the cell-cycle and can proteolytically cleave full length Cux-1 (p200) to a 
p110 and p75 protein.  The p75 protein undergoes rapid degradation while the P110 
protein was found to stably bind to DNA.  The cleavage of Cux-1 by Cathepsin-L 
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appears to regulate the ability of Cux-1 to bind to DNA and act as a transcription 
factor.  Therefore, the regulation of nuclear Cathepsin-L may serve as a determinate 
factor of Cux-1 function.  Weak Cux-1/ DNA binding was observed in G0 and early 
G1, unless cell extracts were previously treated with alkaline phosphatase. In 
contrast, strong Cux-1/DNA binding was observed in S-phase and was shown to 
result both from an increase in Cux-1 expression and dephosphorylation by the 
Cdc25A phosphatase.        
 Cux-1 function appears to be regulated by phosphorylation and 
dephosphorylation (Figure 9).  Phosphorylation of Cux-1 by Casein Kinase II (59) 
and PKC (60) has been demonstrated in vitro and in vivo. The phosphorylation of 
Cux-1 restricts Cux-1 DNA binding ability whereas dephosphorylation by cdc25A 
phosphatase permits Cux-1 DNA binding ability (55).   PKC phosphorylates Cux-1 
on Threonine 415 within CR1, Threonine 804 within CR2 and Serine 987 of CR3 
(60). cAMP mediated PKA has also been demonstrated to phosphorylate Cux-1 (61).  
Casein Kinase II phosphorylates Cux-1 on Serine 400 of CR1, Serine 789 of CR2 
and Serine 972 of CR3 (59).  Calcineurin is a Serine/Threonine phosphatase.  In 
addition to phosphorylation of Cux-1 resulting in the inhibition of Cux-1 binding to 
DNA, it was also determined that acetylation also inhibits Cux-1 DNA binding.  
PCAF-mediated acetylation of the homeodomain of Cux-1 was shown to inhibit 
DNA binding (63).   
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Signal transduction pathways involving Cux-1   
In Drosophila, multiple genetic interactions between Cut and the Notch and 
Wingless signaling pathways occur during wing development. To begin to determine 
whether Cux-1 regulation by the Notch signaling pathway is conserved in mammals, 
we compared the expression patterns of Cux-1, the murine Notch receptors (Notch 1-
4), and the murine ligands (Jagged 1, Jagged 2, and Delta 1) during murine 
embryogenesis and kidney development (70).  We demonstrated that Cux-1 
expression overlaps with that of Notch signaling pathway components in multiple 
tissues during embryonic development. Furthermore, Cux-1 was significantly up-
regulated in the rat kidney epithelial cell line RKE expressing a constitutively active 
Notch 1, and this finding was associated with a reduction of p27. Moreover, Cux-1 
interacts with the Groucho homolog TLE-4, a co-repressor recruited by Notch 
effector proteins.  Taken together, these results suggest that Cux-1 may function in 
the context of the Notch signaling pathway in multiple tissues during mammalian 
embryogenesis.  Cathepsin-L, cAMP mediated PKA, Casein Kinase II, PKC, PCAF, 
Cyclin A CDK1, cdc25 phosphatase all have direct effects on the function of Cux-1 
to bind to DNA. These signaling factors are downstream mediators of potentially 
many upstream signaling pathways within a cell that could involve cross-talk 
between signaling pathways.  
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Figure 1-10. New nephrons develop in a centrifugal pattern.  Developing  
Nephrons begin to grow along the outer edge of the kidney in an area termed the 
nephrogenic zone. Mature nephrons can be found within the interior region of 
developing kidneys.  
 
Role of Cux-1 in kidney development 
 
In Drosophila, malpighian tubules are the insect excretory organs that serve 
as primitive kidneys.  Deletions of the cux-1 gene prevent formation of malpighian 
tubules indicating that cux-1 is required for normal development (8).  In mammals, 
renal development proceeds through three stage specific structures: the pronephros, 
the mesonephros, and the metanephros (Reviewed in 87-89).  The first two stages are 
transient and involute in utero, while the remaining metanephros develops into the 
definitive kidney.  The kidney develops by a reciprocal induction mechanism 
(Figure 1-10). 
  Development is originated by the metanephric mesenchyme triggering 
ureteric bud projection from the wolffian duct into the metanephric mesencyhme.  
The induction of the metanephros can be viewed as a dialogue between the ureteric 
bud and the metanephric mesenchyme.   GDNF is synthesized and secreted by the 
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metenphric mesenchyme and binds tyrosine kinase RET receptors present on the 
wolffian duct and ureteric buds.  GDNF receptor binding on the wolffian duct 
induces initial ureteric budding into the metanephric mesenchyme as well as 
secondary ureteric bud branching once the ureteric bud has entered the mesenchyme.  
The tips of these branches induce the loose mesenchymal cells to form epithelial 
aggregates.  Each aggregated nodule of cells will proliferate and differentiate into a 
unique structure of a renal nephron.  Each condensate first elongates into a “comma” 
shape, and then forms a characteristic S-shaped tube.  Soon afterwards, the cells 
begin to differentiate into regionally specific cell types that include distal and 
proximal tubule cells.  The ureteric bud then fuses with distal tubular cells and will 
eventually give rise to the renal collecting ducts and to the ureter, which drains urine 
from the kidney.  While the ureteric bud is connecting to distal tubules, newly 
differentiated cells (podocytes, endothelial cells, mesangial cells) participate in 
developing the glomerulus located adjacent to proximal tubule cells.  Collectively, 
this developmental process leads to the development of the nephron, the functional 
unit of the kidney, and is termed nephrogenesis 
 
 
 
 
 
 
A     B
Figure 1-11. Cux-1 is highly 
expressed in the nephrogenic 
zone where cells are proliferating. 
(A) in situ hybridization of wild-
type postnatal day 3 kidney shows 
that Cux-1 mRNA is highly 
expressed along the outer edges of 
the kidney in the nephrogenic zone.  
(B) Cells are undergoing cell 
proliferation in the outer edges of 
the kidney as indicated with PCNA 
labeling. 
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Murine nephrogenesis, the synthesis of new nephrons, begins at embryonic 
day 11.5 (E11.5) and continues until postnatal day 7 (P7). Cux-1 is highly expressed 
in proliferating cells of the nephrogenic zone (20) where the formation of new 
nephrons takes place.  In our early studies, we demonstrated that maximum Cux-1 
expression is detected early (E13.5) during nephrogenesis and then diminishes to 
basal levels towards the completion of nephrogenesis.  Cux-1 is highly expressed in 
the nephrogenic zone, where cells are dividing and the synthesis of new nephrons is 
occurring (Figure 1-11).  Since Cux-1 is expressed only in proliferating cells and not 
differentiated cells during nephrogenesis, we proposed that Cux-1 may act as a 
terminal repressor of differentiation.  It is then plausible that abnormal expression 
and/or activation of cux-1 during early renal development and/or in mature kidneys 
may produce aberrant cell proliferation. In the developing kidney, Cux-1 expression 
overlaps with that of the Notch pathway components in the condensing mesenchyme, 
in pretubular aggregates (comma and S-shaped bodies), and in the presumptive 
podocytes of capillary loop stage glomeruli (70). Our laboratory is currently 
investigating if Cux-1 expression is regulated by the Notch signaling pathway during 
early kidney development.   
Overexpression of Cux-1 in CMV/Cux-1 transgenic mice resulted in kidneys 
that were enlarged 50% by 6 weeks of age, with the increased growth primarily 
restricted to the renal cortex (20).  Proliferating cells were found in proximal and 
distal tubule epithelium throughout the cortex, and the squamous epithelium that 
normally lines Bowman's capsule was replaced with proximal tubule epithelium. 
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CMV/Cux-1 transgenic kidneys exhibited nephrons with lengthened tubules.  
However, the total number of nephrons was not increased. In the developing kidneys 
of transgenic mice, Cux-1 was ectopically expressed in more highly differentiated 
tubules and glomeruli, and this was associated with reduced expression of the cyclin 
kinase inhibitor, p27. Transient transfection experiments revealed that Cux-1 is an 
inhibitor of p27 promoter activity (20). These results suggest that Cux-1 regulates 
cell proliferation during early nephrogenesis by inhibiting expression of p27. 
Therefore, given the nature of Cux-1 expression during nephrogenesis and the 
expression pattern of p27, our lab has proposed a model for the function of Cux-1 
during kidney development (Figure 1-12).  Recently, we have demonstrated that 
Cux-1 binds to the p27 promoter at a region where sp1 is known to bind. Therefore, 
our model for Cux-1 function during nephrogenesis is that during early renal 
development when Cux-1 expression is elevated, Cux-1 in a concentration dependent 
manner can out compete sp1 transcription factor for promoter occupancy and repress 
p27 expression resulting in the increased cell proliferation occurring during early 
nephrogenesis. In contrast, during late nephrogenesis, when Cux-1 is expressed at 
relatively lower levels, sp1 can then outcompete Cux-1 for promoter occupancy 
resulting in the activation of p27 promoter and the inhibition of cell proliferation 
leading to the increase in differentiation that is observed at the conclusion of 
nephrogenesis. Evidence to date has demonstrated that Cux-1 is involved in 
regulating cell proliferation during kidney organogenesis (19, 20).  
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Figure 1-12. Model for Cux-1 function during nephrogenesis. During early stages 
of nephrogenesis when Cux-1 levels are elevated, Cux-1 may out compete Sp1 
transcription factor for p27 promoter occupancy of a GC box resulting in repression 
of p27 and increased cell proliferation. In contrast, during the later stages of 
nephrogenesis when Cux-1 levels are attenuated, Sp1 may bind in a concentration 
dependent manner to p27 promoter leading to p27 expression and decreased 
progression through the cell cycle. Image taken from Alcalay et al. (241). 
 
Polycystic Kidney Disease 
 
Polycystic Kidney Disease (PKD) is one of the most common genetic, life 
threatening disease.  PKD occurs in humans regardless of sex, age, race or ethnicity.  
PKD is characterized by enlarged bilateral cystic kidneys.  The growth of many large 
epithelial-lined cysts from nephron collecting ducts results in polycystic kidneys.  
Human PKD can be inherited as an autosomal dominant (AD) or autosomal 
recessive (AR) trait.  ADPKD and ARPKD result from mutations in a single gene.  
ADPKD occurs in 1:1000 individuals and occurs primarily as a result of mutations in 
p27 gene
Early nephrogenesis
Cux-1 X
p27 gene
Late nephrogenesis
Increased cell proliferation
Sp1
Sp1
Decreased cell proliferation and terminal differentiation
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one of two genes, PKD1 or PKD2 (90).  Mutations in PKD1 located on human 
chromosome 16 are associated with 85% of all cases, whereas mutations in PKD2 on 
chromosome 4 represent all other cases (91-98).  ARPKD (1:20,000 live births) 
occurs primarily from mutations in a single gene, PKHD1 (polycystic kidney and 
hepatic disease 1), which is located on chromosome 6 (96).  PKD1 encodes an 11 
transmembrane G-coupled receptor termed Polycystin-1 (99) while PKD2 encodes a 
Calcium channel named Polycystin-2 (100) (Figure 1-13). 
 
 
 
 
 
 
 
 
 
Animal models have proven to be useful tools to examine human PKD. 
Murine PKD models have been demonstrated to have comparable cyst morphology, 
cyst localization, and disease progression (101).  The congenital polycystic kidney 
(cpk) C57BL/6J (B6) mouse is the most extensively characterized PKD model.  The 
cpk gene mutation is a spontaneous mutation within chromosome 12 on the B6 strain 
background (102). The cystic phenotype of cpk homozygotes appears to resemble 
Fibrocystin
COOH
NH2
Figure 1-13 . Gene products of human polycystic kidney disease 
mutations. Polycystin-1 and -2 are associated with ADKPD, whereas 
Fibrocystin is the protein mutated in ARPKD. 
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human ARPKD (103, 104).   Mutation within PKHD1 (Polycystic kidney hepatic 
disease-1) gene results in human ARPKD. PKHD1 encodes a protein named 
Fibrocystin whose function is still not clear. However, Fibrocystin seems to function 
similar to the Notch and Polycystin-1 system in that the intracellular domain can 
localize to the nucleus (105, 106).   Similar to the PKHD1 mutation in humans, 
ARPKD progression in cpk kidneys is biphasic. Transient proximal tubule cystic 
dilations occur during early development followed by a transition to collecting duct 
cysts sometime during the first post-natal week of life as disease progresses (107).  
By 3 weeks of age, affected cpk mice have kidneys that are 10 times normal size and 
the mice die due to renal failure usually during the fourth week. The cpk gene is 
predicted to encode a novel 145 amino acid hydrophilic protein with no significant 
similarity to previously characterized proteins or protein domains (101).  It has been 
suggested that cpk is an inactivating mutation that disrupts tubulo-epithelial 
differentiation in the kidney (108).  However, the function of the cpk gene product 
(cystin) is unknown.  Cystin is similar to gene products mutated in human PKD in 
that Polyductin, Polycystin-1 and Polycystin-2 localize to the primary apical cilia of 
tubular epithelial cells (Figure 1-14) (109,110).  The similar localization of cystin, 
polyductin and the polycystins suggest convergence of similar pathways where 
mutation leads to cyst formation.   
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The mechanisms involving cyst development and progression within PKD 
are unclear. ADPKD patients carry one mutant allele of either the PKD1 or PKD2 
gene.  There has been evidence suggesting that a “second hit” may occur within 
discrete nephron tubular epithelium leading to dedifferentiation and aberrant cell 
proliferation (111).  It is evident that cyst formation is a complex multi-factorial 
process involving disruption in planar cell polarity (112), increased cell proliferation 
(113) and increased fluid secretion (114, 115).  ADPKD and ARPKD patients 
inheriting similar genetic mutations within the same family have highly variable 
phenotypes (116, 117).  Moreover, murine models for PKD carrying identical 
genetic mutations have been found to posses different phenotypes depending upon 
the genetic strain background in which the PKD mutant gene is placed (101).  
Therefore, it has been suggested that the observed alterations in PKD phenotypes 
may be the result of the presence of modifying genes.   
Ca+2
Urine flow
=Fibrocystin
=cystin
=Polycystin-2
=Polycystin-1
Nephron tubular epithelium
 
Figure 1-14. Gene products of PKD in humans and mice co-localize. 
Polycystins-1 and -2, Fibrocystin and cystin localize to primary apical cilia of 
nephron tubule epithelial cells 
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Modifier Genes  
 
Modifying genes might cause more extreme (enhanced) phenotypes, less 
extreme (reduced) phenotypes, novel (synthetic phenotypes), or wild-type (normal) 
phenotypes (Reviewed in 117).  Modification occurs when mutation of one gene 
alters the phenotype of another gene (118, 119). 
  There are two strategies for determining a candidate modifying gene; a 
“forward genetics” or “reverse genetics” approach (Figure 1-16A).  Forward 
genetics is performed when a phenotype is identified and a genotype is unknown.  
Murine PKD models on inbred strain genetic backgrounds are very useful because 
they exhibit a specific phenotype that can be modified when crossed with another 
genetic background.  For example, the cpk gene, when crossed onto different genetic 
backgrounds (CD1, Balb/c, DBA/2J, CAST/Ei) results in an altered phenotype 
(pancreatic and biliary ductal cysts) compared to the B6 background from which it 
originated (103,104, 108).  The authors concluded that phenotypic differences 
between strains may be attributed to the presence of modifying genes.     
Phenotype modification is identified when extreme phenotypes are observed 
(Figure 1-15B).  In the case of PKD, modification is clear if the disease is 
ameliorated or exacerbated.  For example, cystic kidney weight is used as a 
phenotypic marker to indicate PKD severity (103, 104, 120, 121).   Populations of 
animals carrying the same extreme phenotype can be grouped together and analyzed 
for genetic similarity by positional cloning.  Genetic regions observed in large 
numbers of animals with the identical extreme phenotype (negative or positive) are 
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termed quantitative trait loci (QTL).  The hallmark of this forward genetics approach 
is that candidate modifying genes, located within QTL, can be identified when the 
locus is mapped.   
 
 
 
 
 
 
 
Figure 1-15. Identification of modifying genes. (A). A forward genetics approach 
is performed when the phenotype is known. Positional cloning is then utilized to 
identify candidate modifying genes located with a QTL. A reverse genetics approach 
is performed when a candidate modifier gene is identified.  A candidate modifier 
gene is then confiemed as a modifier gene when it alters an established phenotype. 
(B) A phenotype can be quantified as the mean representation of a population.  If the 
candidate modifying gene alters the mean phenotype negatively (red) or positively 
(blue), the candidate gene is then confirmed to be a modifying gene. 
 
A disadvantage of the forward genetics approach is that genes located within 
the QTL need to be fully characterized.  This amounts to an exhaustive procedure 
that first requires defining the function of each QTL gene.  The generation of 
knockout and/or transgenic mice of each QTL gene may be required.  Extensive 
functional analysis of a gene product will then determine if the gene is in the 
pathway of the PKD gene.  Another disadvantage of forward genetics is that once a 
QTL gene function is determined to be involved within the pathway, the gene will 
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need to be mutated in animals to verify that the mutant gene itself does not produce 
an abnormal phenotype.  An abnormal phenotype may contribute to the PKD 
phenotype and will qualify as an additive mutation instead of a modification. After 
this step has been accomplished, a reverse genetics approach is then required to 
demonstrate that a candidate gene is a modifying gene.  Reverse genetics is 
performed when a genotype is known but the phenotype is unknown.   Typically, to 
determine a modifying gene for PKD, a QTL candidate modifier gene is introduced 
with the PKD gene on the same strain genetic background (termed congenic).  If the 
PKD phenotype is altered then the gene is confirmed as a modifying gene.  So far 
many QTL have been identified in PKD.  To date many QTLs have been identified 
(122-128), however no candidate modifying genes have been confirmed to modify 
PKD.  This may be due to the complication in characterizing a QTL gene, generating 
a mutation within the gene that still carries a normal phenotype and then confirming 
modification by introducing the mutation onto mice with PKD.   
 
 
Modifier genes in Polycystic Kidney Disease 
 
Modifying genes are thought to contribute to the variable phenotypes 
observed in PKD patients (101, 129).  Murine PKD models are convenient for 
analyzing mutations that modify cystic phenotype.  Mice can be inbred containing 
identical genetic backgrounds.  This permits a controlled environment whereby 
factors (i.e. food intake, genetic heterogeneity) that interfere with the determination 
of a modifying gene are reduced.  
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The murine cpk and oak-ridge polycystic kidney (orpkd) models for ARPKD 
have cystic kidneys where epidermal growth factor receptor (EGFR) tyrosine kinase 
activity is elevated (130).  Similar to the cpk gene product cystin, the orpkd gene 
product polaris is located in primary apical cilia (131).  In both models and in human 
ARPKD, EGFR was found to have increased tyrosine kinase activity (130). EGFR is 
normally localized specifically to the basolateral surface of renal epithelial cells 
lining collecting tubules (132).  However, in humans with ARPKD and in animal 
models for ARPKD (cpk and orpkd) a phenomenon occurs whereby cystic cells are 
thought to have altered cellular polarity (131, 132).  This is thought to contribute to 
the mislocalization of EGFR to the apical membrane.   
The wa-2 point mutation (valine?glycine at position 743) in EGFR 
decreases tyrosine kinase activity (133).  Mislocalization of EGFR to the apical 
membrane does not affect the wa-2 mutation in reducing EGFR activity (132, 131).  
Richards et al. (131) demonstrated that wa-2 improves kidney function associated 
with decreased cyst formation in orpkd.  The authors found the wa-2 mutation is 
most potent in reducing cysts in collecting ducts where EGFR is mislocalized to the 
apical surface.  In contrast, cysts remained present in wa-2/orpkd proximal tubules 
where EGFR is not mislocalized to the apical surface.  These results suggest 
modification of cyst formation requires both EGFR mislocalization and wa-2 
mutation.  Therefore, wa-2 is not considered a modifier gene of orpkd because 
modification does not exclusively require the wa-2 gene.  
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In general, a gene is defined as a modifier gene if its mutation alters the 
phenotype of another gene present in a pathway (134).  The altered cellular polarity 
and mislocalization of EGFR (131, 132) is likely to be derived from a separate 
pathway caused by orpkd that does not involve the EGFR pathway.  The wa-2 
mutation resulting in reduction of EGFR activity and decreased cyst formation 
requires both EGFR mislocalization and wa-2.  Therefore, wa-2 is not a modifier 
gene but instead is considered an additive mutation.  An example of an additive 
mutation would be any mutation contributing to the PKD phenotype that is involved 
in a pathway separate from the PKD pathway.  As a result of the development of 
mouse genetics involving knockout and transgenic technologies, additive mutations 
are relatively easier to determine than modifying genes. 
 
Role of Cux-1 in Polycystic Kidney Disease 
 
Cell proliferation is important in polycystic kidney disease.  Cyst-lining 
epithelial cells abnormally proliferate in rodents and humans.   Rodents have proven 
to be very useful tools to analyze human disease.  Murine PKD models have been 
described in which the mutant phenotype closely resembles human PKD with respect 
to cyst morphology, cyst localization, and disease progression (reviewed in 118, 
119).  Since the most extensively characterized PKD model is the congenital 
polycystic kidney (cpk) C57BL/6J (B6) mouse, Cux-1 expression levels within cpk 
kidneys were evaluated.  Cux-1 mRNA and protein were ectopically expressed 
during the later stages of cystic disease (19, 135).   Ectopic expression of Cux-1 in 
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cyst lining epithelial cells suggested that Cux-1 may play a role in polycystic kidney 
disease.   In contrast, Cux-1 expression was restricted to interstitial cells during early 
stages in cpk cystic kidneys (Figure 1-16) (135). 
Cux-1 expression in cyst-lining epithelial cells during late stages of PKD, co-
localized with PCNA while also staining positive for TUNEL (135).  Since Cux-1 
normally co-localizes with PCNA positive cells that are proliferating during kidney 
development and cystic epithelial cells are dedifferentiated and rapidly divide, the 
 
 
 
 
 
 
 
 
 
Figure 1-16. Differential expression of Cux-1 and PCNA in the cysts of 7 day old 
cpk kidneys.  7 day old cpk kidneys were labeled for Cux-1 (green) and PCNA (red). 
Cux-1 and PCNA co-calize in the nephrogenic zone, but not in the medulla where 
cysts are forming. Cells lining the cysts are PCNA positive while Cux-1 expression 
is restricted to interstitial cells. Image taken from Sharma et al. (135). 
 
 
 
 
 49
coexpression of Cux-1 in cystic epithelial cells was not surprising.  Cystic epithelial 
cells undergo apoptosis during the later stages of cpk cystic disease (135, 136).  
Apoptosis occurring within cpk cyst-lining epithelial cells may occur as a result of 
cyst expansion leading to the destruction of nephrons.   Moreover, apoptosis within 
cystic epithelial cells may serve as a compensatory mechanism to eliminate cells 
engaged in aberrant cell proliferation pathways.  Ostrom et al. ( 137) demonstrated 
that reduced Pax2 gene dosage increases apoptosis and slows the progression of 
renal cystic disease.  The involvement of Cux-1 in apoptotic pathways within cyst-
lining cells and polycystic kidneys is currently unknown.   
Pkd1 null mice develop polycystic kidneys during embryogenesis (138).  We 
found that Cux-1 is ectopically expressed in cyst-lining epithelial cells within Pkd1 
null kidneys (135).  In both early and late embryonic kidneys from Pkd1 null mice, 
Cux-1 was highly and ectopically expressed in normal-appearing tubule epithelium, 
interstitial cells, and in the epithelial cells lining the cysts, where it co-localized with 
proliferating cell nuclear antigen (PCNA). Increased Cux-1 expression in Pkd1 null 
kidneys was also associated with a decrease in p27 expression. In contrast, in cpk 
kidneys  p27 levels were found to be highly expressed (Figure 1-17) (135). 
Upregulation of p27 levels may be a consequence of high TGFβ levels which 
progressively increase with age in cpk kidneys and may induce cyclin kinase 
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Figure 1-17.  p21 and p27 protein expression in cpk kidneys.  The cyclin kinase 
inhibitor p27 is highly expressed during the late stages of cpk cystogenesis.  Image 
taken from Sharma et al. (135). 
 
inhibitor upregulation (139).   During the later stages of cystogenesis, Cux-1 and p21 
were co-localized in cyst lining cells (135).  These results suggest that cyst 
development in Pkd1 null mice and cpk mice proceeds through different 
mechanisms. In Pkd1 null mice, ectopic expression of Cux-1 is associated with 
increased cell proliferation (135).  In contrast, in cpk mice, ectopic expression of 
Cux-1 is associated with apoptosis (135). A correlation between increased apoptosis 
and cpk disease progression has been demonstrated (135, 136, 140).  Since Cux-1 
becomes ectopically expressed only during later stages in cpk mice and is present 
within cells undergoing apoptosis (135, 136), it is possible that Cux-1 becomes 
upregulated when cells undergo apoptosis.  Overexpression of Cux-1 alone does not 
lead to polycystic kidneys.  Transgenic mice that overexpress Cux-1 driven by the 
CMV promoter have organs that are hyperplastic (20).  The ectopic expression of 
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Cux-1 within cpk cyst lining cells may be a consequence of those cells becoming 
dedifferentiated.  Cux-1 may be induced by altered signaling pathways within 
dedifferentiated cyst lining epithelial cells as these cells become programmed to 
enter the cell cycle and divide.  It is also possible that Cux-1 participates in pathways 
that indirectly contribute to the overall cystic phenotype.   The role of Cux-1 in the 
cpk mouse model for ARPKD is not clear.    
Cux-1 participation in pathways involved in cyst formation and progression 
occurring with PKD are not known.  The epidermal growth factor pathway has been 
suggested as a pathway that participates in the severity of cpk polycystic kidney 
disease (130-132, 141) Point mutation within the epidermal growth factor receptor 
(EGFR) results in mice with wavy hair, curly whiskers and a lactation defect (133) 
which is the exact same phenotype observed in mice carrying a 246 amino acid 
deletion of Cux-1 (termed cux-1ΔCR1) (37).  This suggests that Cux-1 might be 
involved in the EGFR pathway.   
The role of cyclin kinase inhibitors (CKI) and aberrant cell-cycle regulation 
occurring within Polycystic Kidney diseases has become well established with CKI 
being targeted as a potential treatment (142-147).  Cux-1 is highly expressed during 
G1-S phase transition and regulates the cell cycle by repressing the cyclin kinase 
inhibitors p21 and p27.    Bhunia et al. (148), showed that expression of polycystin-1 
activates the JAK-STAT pathway, thereby upregulating p21 (waf1) and inducing cell 
cycle arrest in G0/G1. This process requires Polycystin-2, a channel protein, as an 
essential cofactor.  Mutations that disrupt polycystin-1/2 binding prevent activation 
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of the pathway (98, 102, 149).  Mouse embryos lacking Pkd1 have defective STAT1 
phosphorylation and p21(waf1) induction (148). These results suggest that one 
function of the polycystin-1/2 complex is to regulate the JAK/STAT pathway which 
may help to explain how mutation in either gene can result in deregulated growth.  
The observation that abnormal cell-cycle regulation is occurring in PKD 
(142-147) is further supported by Li et.(142) who showed that the ADPKD protein 
polycystin-2 (PC2) regulates the cell cycle through direct interaction with Id2, a 
member of the helix-loop-helix (HLH) protein family that is known to regulate cell 
proliferation and differentiation. Since Cux-1 represses the cyclin kinase inhibitor 
p21 (55) and PKD1 is involved in the JAK STAT pathway where p21 is upregulated 
(148), our laboratory has proposed a model (Figure 1-18) for Cux-1 and p21 
expression.  
 
 
 
 
 
 
 
 
 
 
Cux-1
Polycystin-1X
p21waf1
cell proliferation
p27kip1
JAK-STAT
?
 Figure 1-18. Model for Cux-
1 function in ADPKD.   
Mutation in Polycystin-1 
results in decreased JAK-
STAT signaling and reduced 
p21 expression which favors 
rapid progression through the 
cell cycle leading towards 
aberrant cell proliferation. 
Mutation in Polycystin-1 
results in the ectopic 
expression of Cux-1 directly 
or indirectly related to the 
JAK-STAT pathway. Cux-1 is 
known to repress the cyclin 
kinase inhibitors p21 and p27 
which would favor aberrant 
cell proliferation occurring in 
ADPKD. 
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Cux-1 function is regulated by phosphorylation and dephosphorylation.  
Phosphorylation of Cux-1 by Casein Kinase II (59) and PKC (60) restricts Cux-1 
DNA binding ability whereas dephosphorylation by cdc25A phosphatase permits 
Cux-1 DNA binding ability (55).  Casein Kinase II and PKC seem to participate in 
the Polycystin1/2 complex pathway.  Casein Kinase II is involved in the 
phosphorylation of Polycystin-2 and modulates Polycystin-2 calcium channel 
activity (150, 151).  In sensory cilia of Caenorhabditis elegans male-specific 
neurons, the LOV-1 (PKD-1) and PKD-2 genes are required for mating behavior( 
152, 153).  Hu et al. (151) identified the regulatory subunit of the serine-theonine 
casein kinase II (CK2) as a binding partner of LOV-1 and human PC-1. They 
discovered that Casein Kinase II and the calcineurin phosphatase TAX-6 modulate 
male mating behavior and PKD-2 ciliary localization.  The role of Casein Kinase II 
in PKD is still not clear. 
PKC appears to play an important role in PKD pathways (154, 155).  
Polycystin 1 mediates PKC alpha-dependent and c-Jun N-terminal kinase-dependent 
activation of the transcription factor AP-1 (154).  Arnould et al. (154, 155), found 
that PKD2-mediated AP-1 activity was dependent upon activation of the mitogen-
activated protein kinases p38 and JNK1 and protein kinase C (PKC) epsilon, a 
calcium-independent PKC isozyme.  Since Casein Kinase II (59) and PKC (60) have 
been demonstrated to phosphorylate Cux-1, it is possible that PKC and/or Casein 
Kinase II phosphorylation in PKD pathways might contribute to inhibition of Cux-1 
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function both directly or indirectly.  The regulation of Cux-1 within cyst-lining 
epithelial cells may involve PKC and Casein Kinase II activity within those cells.   
Several studies demonstrated that polycystin-1 is involved in heterotrimeric 
G protein signaling (156, 157).  It has been shown that the Polycystin-1 C-terminus 
binds and activates heterotrimeric G proteins in vitro (156) and that the activation of 
JNK and AP-1 by polycystin-1 is mediated via Gα and Gβγ subunits (157). 
Stimulation of cAMP and MAP kinases results in pathways leading to cell 
proliferation. cAMP may have a central role in cyst growth by stimulating both fluid 
secretion and cell proliferation (158-161).   Polycystin-1 C-tail has been implicated 
in regulating ERK activity (162).  Moreover, Calcium restriction of human ADPKD 
cells results in cAMP activation of the b-RAF/ERK pathway switching cells that are 
not in a proliferative state to a cAMP dependent growth-stimulated phenotype (163).  
According to these studies, cultured cyst epithelial cells from ADPKD kidneys show 
increased rates of cell proliferation in response to cAMP, which activates B-Raf 
instead of inhibiting Raf-1.   B-Raf then activates the MEK/ERK pathway and cell 
proliferation. This "PKD  phenotype" is replicated in mouse M-1 cortical collecting 
duct cells stably transfected to overexpress of a short, polycystin-1 cytosolic C-
terminal tail construct (164), suggesting that this cAMP-responsive PKD phenotype 
involves disruption of polycystin function in these cells.   It is possible that Cux-1 
may be an endpoint in cAMP and MAP kinase pathways given the expression of 
Cux-1 in proliferating cells.   cAMP can activate the  protein kinase A(PKA) 
pathway.  Cux-1 is phosphorylated by cAMP stimulated protein kinase A (PKA) 
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activity which is dependent for cell proliferation and motility (61).  Furthermore, 
upregulation of transforming growth factor beta (TGF-β) mRNA is found in PKD 
rodent models (139, 165).  Since Cux-1 is a known target of TGF-β activity (166, 
167) the TGF-β pathway is another pathway in PKD that might lead to Cux-1 
activity. Given that aberrant cell proliferation is a hallmark of PKD and Polycystin-1 
regulates p21 (148), a cyclin kinase inhibitor that is similarly targeted by Cux-1(55), 
there is a high possibility that Cux-1 may be involved in PKD.  Therefore, the 
evidence to date suggests that it is very likely that Cux-1 could be involved in 
multifactorial signaling pathways in polycystic kidney diseases. 
 
Goal of these studies 
 
Cux-1 is involved in kidney development within drosophila and mice.  The 
signaling pathways that may exist upstream and downstream of Cux-1 during kidney 
development have yet to be fully evaluated.  Cux-1 is abnormally expressed in 
human and mouse models for polycystic kidney disease.  However, it has never been 
demonstrated that Cux-1 overexpression or gene deletion alters the PKD phenotype. 
Therefore, the mechanisms by which Cux-1 may function in kidney development 
and polycystic kidney disease remain nebulous.  The collective goal of this body of 
work was to 1) Determine if post-translational modification of Cux-1 affects 
kidney development, 2) Determine if Cux-1 can alter the PKD phenotype, and 
3) Evaluate how Cux-1 may function within PKD.  Collectively, these studies 
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have revealed the importance of post-translational modification of Cux-1 during 
kidney development and polycystic kidney disease.  
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CHAPTER TWO  
 
Effect of Cux-1 phosphorylation on Kidney Development 
 
Abstract 
 
Cux-1 is a murine homeobox gene structurally related to Drosophila cut. 
Cux-1 is highly expressed in the nephrogenic zone of the developing kidney, where 
its expression coincides with cell proliferation. Cux-1 functions as a transcriptional 
repressor of the cyclin kinase inhibitors (CKI) p21 and p27. Cux-1 DNA binding 
activity is negatively regulated by phosphorylation, and dephosphorylation of Cux-1 
results in increased DNA binding. Transgenic mice ectopically expressing Cux-1 
develop renal hyperplasia associated with the down-regulation of the CKI p27. 
Calcineurin A (CnA) (-/-) mice display renal hypoplasia associated with the ectopic 
expression of p27. CnA is a serine/threonine phosphatase activated by intracellular 
calcium.  Inhibiting CnA with cyclosporin A (CsA) leads to nephron deficit in rat 
metanephric organ cultures and apoptosis in various renal cell lines. To determine 
whether the ectopic expression of p27 in CnA-  -/- kidneys results from the down-
regulation of Cux-1, metanephroi from embryonic Cux-1 transgenic and wild-type 
mice were harvested and cultured with CsA for 5 days. CsA treatment significantly 
inhibited growth of wild-type metanephroi. In contrast, CsA-treated Cux-1 
transgenic kidney cultures were not growth inhibited, but showed high levels of cell 
proliferation in the nephrogenic zone. Moreover, in CsA-treated Cux-1 transgenic 
kidney cultures, p27 was not expressed in the nephrogenic zone, but only up-
regulated in maturing glomeruli and tubules. Taken together, our results demonstrate 
 58
that ectopic expression of Cux-1 can rescue the effects of CsA inhibition of CnA and 
suggest that Cux-1 may be regulated by calcineurin A.     
 
Introduction 
Cux-1 is a murine homeobox gene that is structurally related to Drosophila 
cut. Mammalian homologues of cut function primarily as transcriptional repressors 
of many different genes, including genes encoding the cyclin kinase inhibitors (CKI) 
p21 and p27 (20, 55, 46, 168, 169). The binding of Cux-1 to the promoters of these 
genes appears to be limited to tissues or stages of development where the target 
genes are not expressed (13).   At later stages of development, Cux-1 proteins are 
down-regulated or lose their ability to bind DNA, and transcription of the target 
genes is permitted. Cut proteins repress transcription by two different mechanisms: 
(1) passive repression, whereby cut proteins compete with transcriptional activators 
for the same binding site (known targets of passive repression by Cux-1 are Sp1 (GC 
box) and NF-Y (CCAAT box), or (2) active repression, by means of a carboxy-
terminal domain after binding to DNA at a distance from the transcription start site 
(48).          
 During kidney development, Cux-1 is highly expressed in the nephrogenic 
zone, in uninduced and condensing mesenchyme, comma- and S-shaped bodies, and 
branching ureteric buds. At later stages of development, Cux-1 is down-regulated 
such that expression is minimal in maturing glomeruli and tubules (19). This finding 
is associated with the up-regulation of the cyclin kinase inhibitor p27 in maturing 
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glomeruli and tubules, which induces cell cycle arrest and terminal differentiation. 
Previously, we generated transgenic mice ectopically expressing cux-1 under the 
direction of the CMV immediate early gene promoter. These mice express Cux-1 in 
maturing glomeruli and tubules in developing kidneys, resulting in renal hyperplasia, 
associated with the down-regulation of p27 (20).    
 Within the cut repeats, there are evolutionarily conserved consensus 
phosphorylation sites for protein kinase C (PKC) and casein kinase II (59, 60). 
Moreover, PKC and casein kinase II were shown to phosphorylate Cux-1 on specific 
serine and threonine residues in the cut repeats. Phosphorylation of Cux-1 resulted in 
an inhibition of DNA binding activity, and a concomitant inhibition of repression, 
while treatment with alkaline phosphatase restored DNA binding. Analysis of Cux-1 
binding activity in vivo demonstrated that Cux-1 bound DNA when in a 
dephosphorylated state, but did not bind DNA when phosphorylated. These results 
demonstrated that Cux-1 activity is regulated by phosphorylation and suggests that 
specific phosphatases may play a role in Cux-1 activity. 
Calcineurin is a SER/THR phosphatase that exists as a heterodimer of a 
catalytic subunit, called calcineurin A (CnA), and a regulatory subunit, called 
calcineurin B (CnB) for review see 170 ). Calcineurin phosphatase activity is 
initiated only when CnB is bound to both calmodulin and calcium. There are three 
isoforms of CnA, , , and , that display some tissue specificity. CnA-  and CnA-  
are widely expressed, while the isoform appears to be restricted to testis and brain 
(171). Mice carrying a targeted deletion of CnA-  exhibit severe defects in postnatal 
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kidney development, including reduced cell proliferation and increased apoptosis in 
the nephrogenic zone, contributing to an overall reduction of the nephrogenic zone 
(172). Additional changes include an absence of mesangial cells in the glomeruli that 
develop during postnatal kidney development. The cell cycle defect is thought to 
result from the ectopic expression of the cyclin kinase inhibitor p27 (172). In 
contrast, mice carrying a targeted deletion of CnA-  have normal kidneys (172). To 
determine whether the ectopic expression of p27 in the nephrogenic zone of CnA (-
/-) kidneys might result from the down-regulation of Cux-1, we examined Cux-1 
expression in kidneys isolated from CnA-  null mice. To determine whether 
increased Cux-1 expression would rescue the cell proliferation defect observed in the 
kidneys of CnA-  null mice, we evaluated cell proliferation in kidney organ cultures 
from Cux-1 transgenic mice treated with cyclosporin A, a specific inhibitor of 
calcineurin. 
 
Materials and Methods 
Antibodies 
Commercial reagents used were rabbit anti-CDP (Cux-1; Santa Cruz # sc-
13024), rabbit anti-p27 (Santa Cruz #sc-528), mouse anti-PCNA (SIGMA # P-8825), 
and goat anti-Pax-2 (Santa Cruz #sc-7747). 
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Organotypic Kidney Cultures 
Metanephric organ cultures were established from mouse embryos as 
described (173). Embryos were dissected from timed pregnant mice at 12.5 or 14.5 
days post coitum (dpc). Embryonic age was verified according to Theiler (174). 
Fifteen paired metanephric kidneys and associated ureteric buds were microdissected 
from wild-type or Cux-1 transgenic mice and placed in a 24-well tissue culture plate 
containing medium (50/50 DMEM/F12, 2 mM L-glutamine, 10 mM Hepes, 5 g/ml 
insulin, 5 μg/ml transferrin, 2.8 nM selenium, 25 ng/ml prostaglandin E, 32 pg/ml 
T3, and 250 μg/ml). Kidneys were placed on 0.4 μM PET track-etched membranes 
(Beckton Dickinson) in medium for 24 hr and then replaced with medium containing 
either 500 ng/ml CsA or vehicle (100% ethanol). Organ cultures were replenished 
with fresh treatment medium every 24 hr and photographed using a Leica M240 
microscope and captured with an Optronics Magnafire digital camera. 
Preparation of Phosphoproteins and Western Blot Analysis 
Total protein lysates from 15 paired wild-type metanephric kidney cultures 
grown in media  containing either 500 ng/ml cyclosporin A or vehicle (100% 
ethanol) were applied to PhosphoProtein purification columns using the QIAGEN 
PhosphoProtein Purification Kit, according to the manufacturer's directions. In some 
cases, lysates were first incubated with calf intestinal phosphatase (5 μg protein/2 
units). Total protein lysates or purified phosphorylated proteins (42 μg) were 
solubilized in sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample 
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buffer and electrophoresed on 4-15% gradient polyacrylamide gels. Phosphoproteins 
were transferred to a polyvinylidene difluoride membrane as described previously 
(20). The immunoblot was blocked in 5% bovine serum albumin in TBST buffer (10 
mM Tris-Cl; 150 mM NaCl, pH 7.5; 0.1% Tween 20). Primary antibodies were 
added at a dilution of 1:100 for Cux-1, PhosphoSerine, and PhosphoThreonine in 
blocking solution. After overnight incubation at 4°C, filters were washed twice at 
room temperature with TBS-Tween/Triton buffer (20 mM Tris-Cl; 500 mM NaCl; 
0.05% Tween 20; 0.2% Triton X-100, pH 7.5), washed twice at room temperature in 
TBS buffer, and incubated with secondary antibodies (1:10,000 dilution in TBST) 
for 1 hr at room temperature. After four additional washes in TBS-Tween/Triton 
buffer, bound antibody was detected by Super Signal West Pico chemiluminescent 
Substrate (Pierce) according to manufacturer's directions, followed by exposure to 
autoradiography film. Total Cux-1 and phospho-Cux-1 protein levels were scanned 
and quantitated using Gelpro 4.5 software (Media Cybernetics). 
  
Morphologic Studies  
For quantitation of metanephric size, kidney organ cultures from wild-type or 
Cux-1 transgenic mice, treated with cyclosporin A or vehicle, were photographed 
under light microscopy at identical magnification. Organ culture pictures were 
quantified using the NIH image J program. Metanephroi were outlined manually, and 
the surface areas were calculated by pixel counting. Net growth was determined as 
the mean percentage of net surface area before treatment (baseline) subtracted from 
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net surface area after treatment. Collective repeated measures analysis of variance 
(ANOVA) was performed during treatment with one-way ANOVA performed on 
each treatment day to determine a difference between treatment groups. P ≤0.05 was 
considered as a difference in treatment and was followed with post hoc analysis by 
the Least Significant Difference test, where P ≤0.05 again was considered 
statistically significant. 
 
Immunofluorescence 
Metanephroi were fixed in 4% paraformaldehyde and embedded in paraffin. 
Five-micrometer-thick tissue sections were deparaffinized with xylene and 
rehydrated with graded ethanols. To obtain adequate signal, the slides were treated 
with antigen unmasking solution (Vector) according to the manufacturer's protocol. 
To block endogenous autofluorescence, sections were incubated with 1 M NH4Cl for 
30 min. Sections were washed in phosphate buffered saline (PBS) and blocked with 
10% normal serum (in PBS from the species the secondary antibody was raised in) 
for 1 hr. After washing in PBS, the slides were incubated for 1 hr with primary 
antibodies in a humidified chamber. Antibody dilutions were 1:50 for CDP Ab, 
1:3,000 for PCNA Ab, and 1:100 for p27 Ab, in 2% blocking serum in PBS. Slides 
were incubated at room temperature with 100 μl of primary antibody in a humid 
chamber and then washed 4 times in PBST. For Cux-1 and PCNA double-labeling 
experiments, sections were washed with PBST and incubated simultaneously with 
biotin-conjugated horse anti-rabbit and Texas-Red conjugated horse anti-mouse 
 64
secondary antibodies (Vector). Sections were then washed with PBST and incubated 
with fluorescein isothiocyanate-conjugated avidin (Vector). Sections were then 
washed, mounted with Vectashield (Vector), and viewed with a fluorescence 
microscope. Images were captured with an Optronics Magnafire digital camera. 
 
Results 
To determine whether the reduced nephrogenic zone and increased 
expression of p27 in CnA (-/-) mice resulted from alterations in Cux-1 expression 
or activity, we examined Cux-1 expression in kidneys isolated from CnA (-/-) mice. 
In kidneys isolated from 4-day-old wild-type mice, Cux-1 was highly expressed in 
the nephrogenic zone where it colocalized with proliferating cell nuclear antigen 
(PCNA; Figure 2-1B-D). In kidneys isolated from CnA (-/-) mice, Cux-1 
continued to be expressed in the nephrogenic zone (Figure 2-1F). However, in 
contrast to wild-type, PCNA was expressed in far fewer cells in CnA (-/-) kidneys 
and did not colocalize with Cux-1 (Figure 2-1G,H). Previous studies have shown 
that the DNA binding activity of Cux-1 is regulated by PKC and casein kinase II (59, 
60).  DNA binding activity was reduced in the presence of PMA, an activator of 
PKC, but mutation of the PKC sites resulted in DNA binding that was not reduced 
by PMA treatment. One possibility is that the absence of CnA results in Cux-1 
being maintained in the phosphorylated inactive form and suggests that CnA may 
positively regulate Cux-1 activity.  
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Figure 2-1. Expression of Cux-1 in kidneys from CnA-  -/- mice. A-H: Four-
day-old kidneys from wild-type (A-D) and Calcineurin A (CnA) -  -/- (E-H) mice 
were labeled with antibodies against Cux-1 (B,F) and proliferating cell nuclear 
antigen (PCNA, C,G). D: The merged image shows that Cux-1- and PCNA-
expressing cells were colocalized in the nephrogenic zone of the wild-type 
kidneys. H: In contrast, there were fewer PCNA-positive cells in the CnA-  -/- 
kidneys, and Cux-1-expressing cells did not colocalize with PCNA. NZ, 
nephrogenic zone. Scale bar = 100 m. Image taken from Alcalay et al. (242). 
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The antibiotic cyclosporin A (CsA) competitively binds calcineurin to 
inactivate its phosphatase activity (175).   Previous studies have shown that 
inhibiting CnA with CsA leads to nephron deficit in rat metanephric organ cultures 
(176). Figure 2-2 shows that metanephroi grown in the presence of CsA continued 
to express Cux-1, but the expression of PCNA was markedly reduced. We next 
examined the expression of Pax-2, a marker for condensing mesenchyme and early 
nephric structures in the nephrogenic zone, and p27, a marker for maturing glomeruli 
and tubules, in the vehicle (control) and CsA-treated kidney organ cultures. Figure 3 
shows that Pax-2 was expressed in the nephrogenic zone of vehicle-treated 
metanephroi, while p27 was expressed in maturing glomeruli and tubules in a region 
characterized by the absence of Pax-2.  In contrast to the control kidney, the region 
of Pax-2 expression was significantly smaller in the CsA-treated metanephroi (Fig. 
3F). Moreover, p27-positive cells were found at the periphery of the developing 
kidney culture and within the Pax-2-positive cells (Figure 2-3G,H). These results 
indicate that CsA treatment results in a reduction in the nephrogenic zone and in 
ectopic expression of p27 and demonstrate that CsA treatment of metanephroi in 
organ culture phenocopied the CnA (-/-) phenotype. Thus to begin to determine 
whether the ectopic expression of p27 in the nephrogenic zone of CnA (-/-) kidneys 
results from the down-regulation of Cux-1 activity, metanephric kidneys isolated 
from transgenic and wild-type mice were treated with cyclosporin A. CsA- or 
vehicle-treated metanephroi were examined daily by light microscopy. Initially, all 
wild-type metanephroi were matched for gestational age and had a similar 
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appearance (Figure 2-4A,G). By 24 hr, the CsA-treated metanephroi were visibly 
smaller than the vehicle-treated metanephroi (Figure 2-4B,H). While the vehicle-
treated metanephroi continued to increase in surface area, the CsA-treated 
metanephroi were growth inhibited (Figure 2-4A-L). Similar to wild-type kidneys, 
all Cux-1 transgenic metanephroi were matched for gestational age and had a similar 
appearance (Figure 2-4 M,S). However, in contrast to wild-type kidneys, 
metanephroi isolated from Cux-1 transgenic mice continued to grow when treated 
with CsA (Figure 2-4M-X).  
 
Figure 2-2. Decreased cell proliferation in cyclosporin-treated kidney organ 
cultures from wild-type mice.  A-H: Sections of kidney organ cultures treated with 
vehicle (control, A-D) or cyclosporin A (CsA, E-H) for 5 days were labeled with 
antibodies against Cux-1 (B,F) and proliferating cell nuclear antigen (PCNA, C,G). 
D: The merged image shows that Cux-1 and PCNA were coexpressed in the vehicle-
treated cultures, in regions corresponding to the nephrogenic zone. H: Similar to 
kidneys from CnA-  -/- mice, there were fewer PCNA-positive cells in the CsA-
treated kidney cultures. NZ, nephrogenic zone. Scale bar = 100 m. Image taken 
from Alcalay et al. (242). 
 
 
 68
 
 
 
 
 
 
 
 
Figure 2-3. Ectopic expression of p27 in cyclosporin-treated kidney organ 
cultures from wild-type mice. A-H: Sections of kidney organ cultures treated with 
vehicle (control, A-D) or cyclosporin A (CsA, E-H) for 5 days were labeled with 
antibodies against Pax-2 (B,F) and p27 (C,G). B-D: Pax-2 is expressed in condensed 
mesenchyme and early nephric figures in the nephrogenic zone of control kidney 
cultures (arrows, B,D). C,D: In contrast, p27 is expressed in maturing glomeruli (g) 
and tubules and is excluded from the nephrogenic zone in vehicle-treated cultures. F-
H: In the CsA-treated kidney cultures, the region of Pax-2 expression was reduced, 
corresponding to a decrease in the nephrogenic zone (F,H). G,H: In addition, p27 
was ectopically expressed at the periphery of the kidney culture in the nephrogenic 
zone (arrowheads). This finding is similar to the previously described ectopic 
expression of p27 in the CnA-  -/- mice (172). NZ, nephrogenic zone; g,h 
glomerulus. Scale bar = 100 m. Image taken from Alcalay et al. (242). 
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Figure 2-4. Morphology of metanephric kidneys cultured in the presence of 
cyclosporin A. A-X: Metanephroi were harvested from embryonic wild-type (A-L) 
or Cux-1 transgenic (M-X) mice and cultured in the presence of cyclosporin (G-L,S-
X) or vehicle (A-F,M-R). Serial light micrographs of paired metanephroi are shown. 
B-F: Metanephroi from wild-type mice treated with vehicle (control) showed 
significant growth and differentiation after growth for 24 (B), 48 (C), 72 (D), 96 (E), 
and 120 hr (F). H-L: Metanephroi from wild-type mice treated with 500 ng/ml 
cyclosporin A showed some growth inhibition after 24 hr (H) and were severely 
growth inhibited after 48 (I), 72 (J), 96 (K), and 120 hr (L) of treatment. M-X: In 
contrast, both vehicle (M-R) and cyclosporin A (S-X) Cux-1 transgenic kidney 
cultures showed extensive growth and differentiation after 24 (N,T), 48 (O,U), 72 
(P,V), 96 (Q,W), and 120 hr (R,X) treatment with 500 ng/ml cyclosporin A. Image 
taken from Alcalay et al. (242).  
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Figure 2-5. Quantification of metanephric kidney growth. Organ culture growth 
was quantified using the NIH image J program. Net growth per day was 
determined as the percentage of total area before treatment (baseline) subtracted 
from total area after treatment collected as a mean of 15 paired wild-type or Cux-1 
transgenic metanephroi in six experiments. Net growth per treatment group was 
determined as the total mean of all percentage growth data during treatment. Results 
are represented as means ± SEM. The asterisk denotes mean net Cux-1 transgenic 
vehicle-treated kidney net growth to be significantly (P < 0.001) greater than 
vehicle-treated wild-type net growth. The double asterisk denotes mean cyclosporin 
A (CsA) -treated Cux-1 transgenic net growth to be significantly (P < 0.001) greater 
than wild-type treated CsA net growth. Image taken from Alcalay et al. (242). 
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Figure 2-6. Increased phospho-Cux-1 in cyclosporin A (CsA) -treated 
kidney organ cultures. A: Western blot of total protein lysate from 
metanephric kidney cultures grown for 48 hr in medium containing either 
500 ng/ml CsA or vehicle (control). No change in Cux-1 expression was 
observed. B: Western blot of phosphorylated protein from metanephric 
kidney cultures grown for 48 hr in medium containing either 500 ng/ml 
CsA or vehicle. Phosphoproteins were purified from total kidney organ 
culture using the QIAGEN PhosphoProtein Purification Kit, according to 
the manufacturer's directions. Total phosphoproteins were separated by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to 
polyvinylidene difluoride (PVDF) membrane, and phospho-Cux-1 was 
detected using an anti-Cux-1 antibody. Increased levels of phospho-Cux-
1 were observed in CsA-treated kidney cultures (CsA), compared with 
vehicle-treated kidney cultures (control). Treatment of kidney cultures 
with CsA and PMA did not result in increased phospho-Cux-1 
(CsA/PMA). However, pretreatment with calf intestinal phosphatase 
resulted in reduced phospho-Cux-1 (CsA/CIP). Results shown are 
representative of three independent experiments. Image taken from 
Alcalay et al. (242). 
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The surface areas of 15 paired wild-type or Cux-1 transgenic metanephroi 
treated with or without CsA from six separate experiments were compared. The 
percentage change in mean size of vehicle and CsA-treated metanephroi from wild-
type or transgenic animals were paired to control for differences in gestational age. 
Figure 2-5 shows that vehicle-treated wild-type metanephroi showed an increase in 
net percentage growth, while CsA treatment resulted in a decrease in net percentage 
growth. In contrast, both vehicle- and CsA-treated transgenic metanephroi showed 
an increase in net percentage growth, although the extent of growth was reduced 
with CsA treatment (Figure 2-5). The differences between percentage net growth of 
vehicle- and CsA-treated metanephroi were statistically significant.   
To determine whether inhibition of calcineurin by cyclosporin changed the 
phosphorylation state of Cux-1, we evaluated Cux-1 isolated from vehicle- or 
cyclosporin-treated metanephric kidney cultures. Figure 2-6A shows that the levels 
of total Cux-1 protein were similar between vehicle- or CsA-treated kidney cultures. 
However, when phosphorylated Cux-1 protein was assessed, we observed a greater 
than fivefold increase in phosphorylated Cux-1 in the CsA-treated kidney cultures 
compared with the control cultures (Figure 2-6B). Pretreatment of kidneys with both 
CsA and PMA did not significantly increase the levels of phosphorylated Cux-1 
(Figure 2-6B). However, no phosphorylated Cux-1 was detected after treatment with 
calf intestinal phosphatase (Figure 2-6B). 
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Figure 2-7. Inhibition of cell proliferation by cyclosporin A (CsA) is rescued by 
ectopic expression of Cux-1. A-H: Sections of kidney organ cultures from Cux-1 
transgenic mice treated with vehicle (control, A-D) or CsA (E-H) were labeled with 
antibodies against Cux-1, to detect both endogenous and ectopic Cux-1 (B,F) and 
proliferating cell nuclear antigen (PCNA), to detect proliferating cells (C,G). D: 
Cux-1- and PCNA-positive cells were coexpressed in the vehicle-treated cultures, in 
regions corresponding to the nephrogenic zone. H: In contrast to CsA-treated wild-
type kidney cultures, which showed reduced cell proliferation (see Fig. 2G), CsA-
treated Cux-1 transgenic kidney cultures showed high levels of cell proliferation and 
colocalization of Cux-1 and PCNA. NZ, nephrogenic zone. Scale bar = 100 m. 
Image taken from Alcalay et al. (242). 
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Figure 2-8. The nephrogenic zone is rescued in Cux-1 transgenic kidney organ 
cultures treated with cyclosporin A (CsA). A-H: Sections of wild-type (A-D) and 
Cux-1 transgenic (E-H) kidney organ cultures were labeled with antibodies directed 
against p27. p27 is normally not expressed in the nephrogenic zone, but is up-
regulated in maturing glomeruli and tubules, where it is associated with cell cycle 
arrest and terminal differentiation. B,F: p27 expression was absent from the 
nephrogenic zone of vehicle (control) -treated wild-type (B) and Cux-1 transgenic 
(F) kidney organ cultures. D: p27 was ectopically expressed at the periphery of the 
CsA-treated wild-type kidney organ cultures, similar to CnA-  -/- kidneys (172). H: 
In contrast, p27 expression was absent from the nephrogenic zone of CsA-treated 
Cux-1 transgenic kidney organ cultures. Arrows indicate the distance between the 
edge of the kidney and the outermost p27 expressing cells. NZ, nephrogenic zone; g, 
glomerulus; c, comma-shaped body. Scale bar = 100 m. Image taken from Alcalay 
et al. (242). 
 
 
 
Figure 2-9. A potential model of Cux-1 regulation by calcineurin. Our previous 
results show that Cux-1 down-regulates the expression of the cyclin kinase inhibitor 
p27 (20). Because p27 induces cell cycle arrest, increased Cux-1 expression or 
activity would result in increased cell cycle progression. Our present results show 
that inhibition of the phosphatase calcineurin by cyclosporin A (CsA) results in 
increased phospho-Cux-1, which is unable to bind DNA (55, 59), and suggests that 
Cux-1 activity may be regulated by calcineurin. In addition to down-regulation ofp27 
by Cux-1, CsA treatment may also result in p27 activation independent of Cux-1. 
Image taken from Alcalay et al. (242). 
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To determine the basis for the rescued growth of Cux-1 transgenic 
metanephroi in the presence of CsA, we examined Cux-1 expression and cell 
proliferation in vehicle- or CsA-treated transgenic kidney cultures. Figure 7 shows 
that, similar to wild-type, Cux-1 was expressed throughout the nephrogenic zone in 
both vehicle- and CsA-treated metanephroi (Figure 2-7B,F). However, in contrast to 
wild-type kidney cultures, PCNA was not down-regulated in CsA-treated Cux-1 
transgenic metanphroi, but was colocalized with Cux-1 (Figure 2- 7G,H). We next 
examined p27 expression in vehicle- and CsA-treated wild-type and Cux-1 
transgenic metanephroi. p27 is normally expressed in maturing glomeruli and 
tubules, after the down-regulation of Cux-1. While p27 was absent from the 
nephrogenic zone of vehicle-treated kidneys (Figure 2-8B,F), p27 was ectopically 
expressed in the nephrogenic zone of CsA-treated wild-type kidney organ cultures 
(Figure 2-8D), similar to CnA (-/-) kidneys. In contrast, p27 was not expressed in 
the nephrogenic zone of the CsA-treated Cux-1 transgenic kidney organ cultures 
(Figure 2-8H).  
 
Discussion 
Cux-1 is a murine homeobox gene that is related to the Drosophila cut gene. 
Mammalian Cut protein expression appears to be restricted to proliferating cells in 
many different tissues (13) where they function as cell cycle-dependent 
transcriptional repressors. Targets of Cux-1 repression include the cyclin kinase 
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inhibitors p21 and p27 (59, 60).       
 During nephrogenesis, maturing nephrons proceed through an orderly 
sequence of developmental stages that can be distinguished morphologically. These 
stages are renal vesicle (stage I), comma- and S-shaped body (stage II), developing 
capillary loop (stage III), and maturing glomerulus (stage IV). The developing 
kidney displays a spatial gradient of differentiation in which nephrons at the earliest 
stages of development (stage I and II) are restricted to the nephrogenic zone 
immediately beneath the renal capsule, while progressively more mature nephrons 
(stage III and IV) are located toward the center of the kidney (177). We have 
previously shown that Cux-1 is highly expressed in the nephrogenic zone of 
developing kidneys, where it is associated with cell proliferation (19). In addition, 
transgenic mice ectopically expressing Cux-1 in the developing kidney exhibit renal 
hyperplasia, resulting from aberrant repression of p27 in maturing glomeruli and 
tubules.         
 Previous studies have demonstrated that loss of CnA results in disruption of 
the cell cycle in kidney development (172). The nephrogenic zone of developing 
kidneys isolated from CnA (-/-) mice showed decreased proliferation and increased 
cell death that was associated with increased levels of p27. In addition, glomeruli 
present in the CnA (-/-) mice were devoid of mesangial cells. In contrast, Cux-1 
transgenic mice exhibit mesangial cell hyperplasia. Moreover, mesangial cells 
isolated from Cux-1 transgenic mice are not growth restricted in the absence of 
serum, but progress through the cell cycle (70).     
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 To determine whether the decreased cell proliferation in kidneys from CnA 
(-/-) mice resulted from the down-regulation of Cux-1, we examined Cux-1 
expression in CnA (-/-) kidneys and in kidney cultures treated with the antibiotic 
CsA. CsA specifically inhibits calcineurin, and previous studies have shown that 
administration of CsA to pregnant rabbits during the period when nephrogenesis is 
initiated results in defects in the nephrogenic zone (176). Both in CnA (-/-) kidneys 
and in kidneys treated with CsA, our results showed that Cux-1 was expressed 
throughout the nephrogenic zone (Figure 2-1), similar to the expression in wild-type 
or vehicle-treated kidneys. However, in contrast to wild-type or vehicle-treated 
kidneys, Cux-1 expression was not associated with cell proliferation in CnA (-/-) 
kidneys(Figure 2-1) or in kidneys treated with CsA(Figure 2-2).   Moreover, kidney 
cultures treated with CsA showed increased levels of phosphorylated Cux-1(Figure 
2-6), compared with vehicle-treated kidneys, although the total amount of Cux-1 was 
not different between CsA and vehicle-treated kidneys. Because the ability of Cux-1 
to bind DNA is negatively regulated by phosphorylation, these results suggest that 
Cux-1 activity may be regulated by calcineurin. The loss of calcineurin, either in the 
CnA (-/-) mice or by pharmacologic inhibition, would then result in the 
maintenance of Cux-1 in an inactive state. A potential model of Cux-1 regulation by 
calcineurin is shown in Figure 2-9.       
 To determine whether increased Cux-1 expression could overcome the loss of 
calcineurin, we cultured kidneys isolated from Cux-1 transgenic mice with 
cyclosporin. In contrast to wild-type kidneys, the transgenic kidneys were not growth 
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inhibited, but continued to increase in size(Figure 2-5). Moreover, CsA-treated Cux-
1 transgenic kidneys showed extensive cell proliferation in the nephrogenic zone, 
with reduced expression of p27 (Figure 2-8). We have previously shown that Cux-1 
expression in kidneys isolated from Cux-1 transgenic mice is significantly elevated 
when compared with wild-type mice (20). One possibility is that the amount of Cux-
1 protein produced by the transgenic kidneys exceeds the rate of phosphorylation, 
resulting in significant levels of active Cux-1 protein that is able to bind DNA and 
repress target genes, including p27. Taken together, these results demonstrate that 
the ectopic expression of Cux-1 rescued the cell proliferation defects in the 
nephrogenic zone induced by cyclosporin, and suggest that Cux-1 may be regulated 
by calcineurin during kidney development in vivo. 
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CHAPTER THREE 
 
MUTATION IN CUX-1 MODIFIES THE MURINE POLYCYSTIC  
KIDNEY DISEASE PHENOTYPE 
  
Abstract 
The murine transcription factor Cux-1 is structurally related to Drosophila cut 
and contains 4 DNA binding domains (3 cut repeats, 1 homeodomain).  Cux-1 is 
highly expressed in cells undergoing proliferation during kidney development  
Polycystic kidney disease (PKD) is characterized by increased mitotic activity and 
dedifferentiation of tubular epithelia, leading to cyst formation.  Previously, we 
observed ectopic Cux-1 expression in cpk and Pkd-1 null kidneys, two murine 
models of PKD.  Since Cux-1 might be involved in the PKD pathway, it is possible 
that mutation in cux-1 modifies cystic disease. To test this, we crossed mice carrying 
a deletion of the first cut repeat (cux-1ΔCR1) with cpk cystic mice to generate mice 
homozygote for both genes (termed cux-1ΔCR1/cpk).  Cystic kidneys were collected 
from cux-1ΔCR1/cpk mice at post-natal day 10 with kidney weight measured as 
percent body weight.   Cystic kidneys were sectioned and labeled for Cux-1 and 
PCNA, a marker for cell proliferation.  In addition, blood serum was collected to 
determine blood urea nitrogen levels (BUN), an indicator of renal function.  Results 
demonstrated that cux-1ΔCR1/cpk cystic kidneys were significantly larger than cpk 
kidneys. Moreover, cux-1ΔCR1/cpk mice had higher BUN levels than cpk indicating 
more severe renal failure.  Taken together, these results suggest that the cux-1ΔCR1 
gene modifies cpk cystic disease.   
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Introduction 
Polycystic kidney disease (PKD) is a term applied to a group of inherited 
disorders characterized by the presence of renal cysts, however, multiple organs are 
usually affected. Human autosomal dominant polycystic kidney disease (ADPKD) 
results from mutations in one of two genes, PKD1 or PKD2 that encode polycystin-1 
and Polycystin-2 proteins, respectively (178-181). Human autosomal recessive 
polycystic kidney disease (ARPKD) results from mutations within a single gene, 
PKHD1 (polycystic kidney and hepatic disease 1), encoding fibrocystin/polyductin 
(182-183). Proteins that are mutated in human PKD (Polycystin-1, Polycystin-2, 
fibrocystin/polyductin), and in animal models of PKD (Cystin, Polaris), co-localize 
to the primary cilia (110, 184-186).  This suggests that mutations in ciliary proteins 
affect common or overlapping signaling pathways resulting in PKD (187). The 
process of cyst formation in PKD is thought to involve various mechanisms 
including cell proliferation, fluid secretion, dedifferentiation, abnormal basement 
membrane formation, matrix remodeling, apoptosis, and alteration in cellular 
polarity (98, 188, 189).  Growing evidence suggests that PKD is a developmental 
disorder (101, 138, 148, 184, 190-193).     
 The cpk gene, when crossed onto different genetic backgrounds (CD1, 
Balb/c, DBA/2J, CAST/Ei) results in an altered phenotype (pancreatic and biliary 
ductal cysts) compared to the B6 background from which it originated (103, 104, 
108, 194).  The authors concluded that phenotypic differences between strains may 
be attributed to the presence of modifying genes.  Phenotype modification is 
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identified when extreme phenotypes are observed (Figure 1-16).  In the case of 
PKD, modification is clear if the disease is ameliorated or exacerbated.  For 
example, cystic kidney weight is used as a phenotypic marker to indicate PKD 
severity (103, 104, 120, 121).  The wa-2 point mutation (valine?glycine at position 
743) in EGFR decreases tyrosine kinase activity (133).  Richards et al. (131) 
demonstrated that wa-2 improves kidney function associated with decreased cyst 
formation in orpkd.  The authors found the wa-2 mutation is most potent in reducing 
cysts in collecting ducts where EGFR is mislocalized to the apical surface.    
The wa-2 mice carry the same phenotype as cux-1ΔCR1 in wavy hair, curly 
whiskers, with a lactation defect occurring in females.  Mutant cux-1ΔCR1 mice do 
not develop PKD and have normal kidney (37). Cux-1 protein is ectopically 
expressed in PKD1 knockout and cpk cystic kidneys suggesting that it may be 
involved in the PKD pathway (19, 135). From this observation cux-1ΔCR1 could be 
considered as a candidate modifying gene for PKD.  In the present study a reverse 
genetics strategy was approached to generate cpk mice carrying a hypomorphic allele 
of cux-1 to determine if mutation within cux-1 affects the progression of disease.  
 
Materials and Methods 
Animals 
To determine if the cux-1ΔCR1 gene is a candidate modifier gene of PKD we 
decided to use a reverse genetics strategy.  As an initial step, the cux-1ΔCR1 gene 
was crossed onto mice carrying the cpk gene (cpk/+) to generate homozygotes for 
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both cux-1ΔCR1 and cpk (termed cux-1ΔCR1/cpk) present on a mixed B6/129S4 
background.  cpk /+ and Cux-1ΔCR1 /+ mice were purchased from Jackson 
Laboratory (Bar Harbor, ME), and stock colonies are maintained at the University of 
Kansas Medical Center. Identification of +/+, cpk /+, and  cpk genotypes was 
determined by PCR, as previously described (184). The presence of the Cux-1ΔCR1 
mutation was identified by Southern blot analysis, as described (37).  Males 
homozygous for Cux-1ΔCR1 and heterozygous for cpk were crossed with female 
mice heterozygous for both cux-1ΔCR1 and cpk to generate double homozygote cux-
1ΔCR1/cpk mice (Figure 3-1). All Cux-1ΔCR1, cpk, and cux-1ΔCR1/cpk mice 
analyzed were on the same B6129SF1/J mixed genetic background.  All protocols 
were approved by the University of Kansas Medical Center Animal Care and Use 
Committee. The University of Kansas Medical Center is fully accredited by the 
American Association of the Accreditation of Laboratory Animal Care. 
 
 
 
 
 
 
Figure 3-1. Breeding strategy to generate cux-1ΔCR1/cpk double homozygote 
animals. 
 
X
cux-1ΔCR1/cpk 
(-/-) (-/-) 
cux-1ΔCR1 / cpk  
(+/-)       (+/-) 
cux-1ΔCR1/cpk  
(-/-) (+/-) 
1
8
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Kidneys were harvested from 10 day old (P10) cux-1ΔCR1/cpk mice because this is 
the earliest time-point where cystic kidneys can be distinguished from non-cystic 
kidneys.  Kidney weight was then standardized as a percentage of total body weight.  
Characterization of cystic phenotype   
Cystic kidneys were collected from 3-day-old and 10-day-old cpk and Cux-
1ΔCR1/cpk mice. Kidney length/Crown rump measrurements (see Figure 3-2) were 
collected. Animal body weight (BW) was measured in grams and converted to 
milligrams followed by the collection and weight measurement of bilateral kidneys 
in milligrams. Total cystic kidney weight (KW) was divided by body weight and 
calculated to determine KW as a percent BW. Kidney length measurements of 
bilateral kidneys were performed and divided by crown-rump measured in 
centimeters (cm). Cystic kidney mid-sagittal sections (5μm) were utilized to stage 
cysts, as described previously (195). Cysts were considered early stage if there were 
less than 50 cyst-lining epithelial cells, intermediate if there were 51-200 cyst-lining 
epithelial cells, and advanced stage if greater than 200 cyst-lining cells. 
 
 
 
 
 
 
 
KL
>>
><
CR
KIDNEY TRAIT METRICS:
KW/BW Kidney weight/Body weight
KL Kidney length
KL/CR Kidney Length/Crown Rump length
Figure 3-2. Characterization of kidney size by established quantitative measurements. 
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Protein analysis  
 Whole cell lysates (30μg) and nuclear extracts (20μg) of Human epidermal 
carcinoma cells (A-431) were purchased from Santa Cruz and loaded on 4-15% 
SDS-PAGE gels.  Standard western blot protocol was performed with PVDF 
membranes being subjected to Cux-1 (Santa Cruz), p27 (Santa Cruz) and EGFR 
(Cell Signaling).  β-actin (sigma) and ponceau-S were used to verify equivalent 
protein loading.  In an additional experiment whole cell lysates from Cux-1ΔCR1 
kidneys were also analyzed for EGFR protein expression. 
Serum chemistry 
Blood was collected by intra-cardiac puncture and immediately 
centrifuged at 2000Xg for serum collection. Blood urea nitrogen (BUN) was 
determined using an autoanalyzer (Physicians Reference Laboratory, LLC, Overland 
Park, KS, USA). 
 
Experimental Animals 
cpk and cux-1ΔCR1 mice were obtained from Jackson Laboratories with 
stock colonies maintained at the University of Kansas Medical Center animal 
facilities.  The Cux-1ΔCR1 gene present on the B6/129 strain was crossed three 
times onto the B6 background.  Males homozygous for cux-1ΔCR1 and 
heterozygous for cpk were genotyped as previously described2, and crossed with 
female mice heterozygous for both cux-1ΔCR1 and cpk to generate double 
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homozygote cux-1ΔCR1/cpk mice.   All protocols were approved by the University 
of Kansas Medical Center Animal Care and Use Committee.  The University of 
Kansas Medical Center is fully accredited by the American Association of the 
Accreditation of Laboratory Animal Care. 
 
Characterization of cystic phenotype  
Cystic kidneys were collected from 10 day-old cpk kidneys.  Animal body 
weight (BW) was measured in grams and converted to milligrams followed by the 
collection and weight measurement of bilateral kidneys in milligrams.  Total cystic 
kidney weight (KW) was divided by body weight and calculated to determine KW as 
a percent BW.  Kidney length measurements of bilateral kidneys were performed and 
divided by crown-rump measured in centimeters (cm).   
 Blood was collected by intra-cardiac puncture and immediately centrifuged at 
2000Xg for serum collection.  Blood urea nitrogen (BUN) analysis was performed 
by Physicians Reference Laboratory; Overland Park, KS. 
 Cystic kidney mid-sagittal sections (5μm) stained with hematoxylin and 
eosin were utilized to stage cysts as described previously (195).  Cysts were 
considered early stage if there were less than 50 cyst-lining epithelial cells, 
intermediate if there were 51-200 cyst-lining epithelial cells, and advanced stage if 
greater than 200 cyst-lining cells.    
 Dolichos Biflorus Agglutinin (Vector) labeling and Lotus Tetraglobin Lectin 
(Vector) were used to label for collecting duct- and proximal tubule-derived cells 
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respectively.  All whole kidney images were taken using a "camera" while 
histological pictures were performed by utilizing a Leica optronics® microscope and 
DMR camera system. 
Statistics 
  In all studies, a one-way ANOVA was performed.  If significance between 
the genotypes existed (P≤0.05) post-hoc analysis by least significant difference 
(LSD) was performed to determine statistical significance (p≤0.05) between groups. 
All statistical analyses were performed using the Statview® statistical program. 
 
Results 
Reduced EGFR tyrosine kinase activity has been implicated in the 
progression of PKD particularly in the cpk and orpk models of the disease.  A point 
mutation in EGFR (termed the wa-2 mutation) results in the reduction of EGFR 
tyrosine kinase activity with animals carrying an identical phenotype to that of 
mutant Cux-1 mice (termed cux-1ΔCR1) which carry a 246 amino acid deletion of 
Cux-1.  Therefore, it is possible that Cux-1 is involved in the EGFR pathway. 
Preliminary results determined that there were normal amounts of EGFR in 
cux-1ΔCR1 kidneys (Figure 3-3A).  To determine if Cux-1 is involved in the EGFR 
pathway, human epidermal carcinoma cells (A-431 cells) were treated with 
epidermal growth factor (EGF) ligand.  Our results showed that stimulation with 
EGF attenuated Cux-1 protein levels when EGFR is upregulated (Figure 3-3B,C).  
Cux-1 expression is attenuated in EGF stimulated cells (Figure 3-3c) is supported by 
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reports showing EGF stimulation inhibits cell proliferation in A-431 cells (196, 197).    
Since Cux-1 is involved in p27 expression in renal systems we looked at p27 levels 
within EGF treated epidermal carcinoma cells and found that p27 protein was also 
upregulated (Figure 3-3D). 
 
 
 
 
In previous studies, our laboratory demonstrated that Cux-1 is ectopically 
expressed in cystic cells during the later stages of cpk cystic disease and during 
embryogenesis of PKD1 homozygote knockout mice (19, 135).  Mutation in these 
cyst producing genes results in the ectopic expression of Cux-1.  This suggests the 
involvement of Cux-1 in PKD pathways.  If Cux-1 is involved in the PKD pathway, 
it is possible that mutation in cux-1 modifies cystic disease.  In addition, since the 
wa-2 mutation within EGFR carries a similar phenotype to cux-1ΔCR1 (37, 133), it 
prompted us to predict that cux-1ΔCR1 would attenuate cyst growth similar to that 
observed in wa-2/orpkd cystic kidneys (131).   
Figure 3-3. Epidermal Growth 
Factor Receptor (EGFR) 
regulation of Cux-1 expression.  
(A) Similar levels of the 175KD 
EGFR protein were detected in 2-
month cux-1ΔCR1 (ΔCR1) and 
wild-type (WT) kidney lysates.  
Stimulation of human epidermal 
carcinoma cells (A431) with 
5ng/ml EFG ligand resulted in (B) 
the upregulation of EGFR, (C) 
downregulation of Cux-1 and (D) 
the cyclin kinase inhibitor p27.  
(E) Equivalent levels of β-actin 
protein confirm equal loading of 
nuclear lysates (C, D).  
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We crossed cux-1ΔCR1 mice with cpk mice to generate mice homozygous for 
both genes (cux-1ΔCR1/cpk).  The cux-1ΔCR1 gene, present on a 129J genetic 
background, was backcrossed onto the B6 background where cpk is present, resulting 
in a 75% B6 25% 129J mixed genetic background. Mice carrying the Cux-1ΔCR1 
mutation have curly whiskers, wavy hair, and lactation defects (37), but have normal 
kidneys (see Chapter 1).  Surprisingly, when this mutation was combined with the 
cpk mutation, the double homozygous (cux-1ΔCR1/cpk) mice developed cystic 
kidneys that were significantly larger than the cystic kidneys from mice carrying 
only the mutation in cpk at post-natal day 17 (Figure 2-4).  This qualitatively 
suggested that the cux-1ΔCR1 gene accelerated polycystic kidney disease (PKD).  
  
 
 
 
 
 
 
 
 
 
 
Figure 3-4. Large Cux-1ΔCR1/cpk kidneys were observed at post-natal day 17. 
 
PKD disease severity has been linked to and directly correlated with kidney 
size.  Larger cystic kidneys represent a more severe stage of the disease whereas 
smaller sized kidneys represent mild PKD.  Mrug et al. demonstrated this correlation 
when quantifying kidney size by kidney length (KL), kidney length/ crown-rump 
(KL/CR) and kidney weight taken as a percentage of body weight (KW/BW).  They 
Wild-type   cpk cux-1ΔCR1/cpk 
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quantified cpk kidney size from well over 400 different animals using these 
parameters at post-natal day 10 and found that kidney size is consistent.  Therefore, 
any alteration in the renal cystic KW/BW would represent a modification of the 
disease.       
Bilateral kidneys were harvested at post-natal day 10 (P10) and KW and BW 
measurements were collected to calculate KW standardized as a percentage of BW, 
to quantify renal cystic disease severity (16,33). By gross appearance, kidneys from 
cux-1ΔCR1/cpk mice were significantly larger than kidneys from cpk mice on the 
same mixed B6/129 background or pure B6 alone (Figure 3-5A,B).  cux-1ΔCR1/cpk 
cystic kidneys were significantly larger then cpk kidneys regardless if cpk was 
present on B6/129 or B6 backgrounds. In contrast to the effect of the presence of 
cux-1ΔCR1 homozygosity with cpk, partial gene dosage of cux-1ΔCR1 did not 
increase cystic kidney size. The presence of cpk on the mixed B6/129 background 
resulted in an increase in kidney size compared to cpk on B6.   The increase in 
kidney size apparently occurs early in development as cux-1ΔCR1/cpk kidneys were 
significantly larger then cpk kidneys both at post-natal days 3 and 10. (Fig. 5A, B).  
KL and KL/CR levels were elevated but did not reach statistical significance 
(p≤0.05).   
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Figure 3-5. Cux-1ΔCR1/cpk kidneys are significantly larger compared to cpk. 
(A) Hematoxylin and eosin staining of midsagittal cystic kidney sections showing 
the appearance of larger cysts with cux-1ΔCR1/cpk kidneys compared to cpk. (B) 
Gross appearance of kidney size depicting cux-1ΔCR1/cpk kidneys to be larger then 
those of cpk. (C) KW/BW analysis revealed significantly larger Cux-1ΔCR1/cpk 
kidneys compared to cpk. (*) Denotes statistical significance determined by ANOVA 
and LSD post-hoc analysis (p≤0.05). 
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A    B
C    D
cpk   cux-1ΔCR1/            cpk   cux-1ΔCR1/   
    cpk           cpk 
  cpk   cux-1ΔCR1/cpk          cpk   cux-1ΔCR1/cpk 
Figure 3-6. Quantitative kidney size measurements in cpk kidneys. (A Kidney 
weight (KW) standardized as a percentage of Body Weight (BW) represented as 
mean values ± SEM. (*) Denotes that kidneys from cux-1ΔCR1/cpk 10-day-old 
mice were significantly larger (P≤0.0001) than kidneys from cpk 10-day-old mice 
in, and (B) that kidneys from cux-1ΔCR1/cpk 3-day-old mice were significantly 
larger (P≤0.05) than kidneys from cpk 3-day-old mice.  (C) KL, and (D) KL/CR 
demonstrated modestly increased size. (*) Denotes statistical significance 
determined by ANOVA and LSD post-hoc analysis (p≤0.05).
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Reduced renal function and increased kidney size correlate with the  
progression of PKD.  Many studies have demonstrated that large cystic kidneys are 
directly correlated with reduced renal function (103, 104, 120, 121).  Blood urea 
nitrogen (BUN) and blood Creatinine (CR) are physiological markers used for the 
quantitative analysis of renal function.  To determine if the larger cystic kidneys 
observed in cux-1ΔCR1/cpk mice results in reduced renal function, BUN and CR 
levels were assessed. BUN and CR levels were elevated in cux-1ΔCR1/cpk mice 
(Figure 3-6) demonstrating that in addition to having significantly large cystic 
kidneys cux-1ΔCR1/cpk mice have reduced renal function.   
 
 
 
 
 
 
 
 
 
Large cystic kidneys observed in cux-1ΔCR1/cpk mice may develop as a 
result of increased numbers of cysts, increased cyst size or both an increase in the 
number and size of cysts. To further analyze the cux-1ΔCR1/cpk phenotype, mid-
saggital sections of cystic kidneys were stained with Haematoxylin and Eosin.  There 
A    B
  cpk   cux-1ΔCR1/cpk          cpk   cux-1ΔCR1/cpk 
Figure 3-7. Renal function is 
reduced in Cux-1ΔCR1/cpk 
mice. (A) Blood Urea  Nitrogen 
(BUN) and (B) Creatinine (CR) 
measurements were collected 
and represented as mean values  
± SEM. (*) Denotes BUN in 10-
day-old Cux-1ΔCR1/cpk mice 
were significantly greater 
(P≤0.001) than BUN in 10-day-
old cpk mice. A modest rise in 
mean blood CR was observed. 
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cysts in cux-1ΔCR1/cpk kidneys appeared to be larger compared to cpk kidneys 
(Figure 3-6). When cysts were counted from midsaggital sections of cpk kidneys 
(Figure 3-7A, B). Cysts were then counted to determine if cux-1ΔCR1/cpk kidneys 
have a greater number than cpk kidneys.   Histological analysis showed that the 
numbers of cysts between cux-1ΔCR1/cpk and cpk kidneys were statistically similar. 
There even appeared to be relatively reduced numbers of cysts in cux-1ΔCR1/cpk 
kidneys.  Since cysts from cux-1ΔCR1/cpk kidneys appeared larger or more 
developed then cysts from cpk kidneys (Figure 3-4A and Figure 3-7A) we decided 
to quantify cysts morphology.  
Although the overall number of renal cysts was not different between cpk and 
cux-1ΔCR1/cpk mice (Figure 3-7b) the size of the cysts appeared to be increased in 
the kidneys from cux-1ΔCR1/cpk mice. Cyst numbers were quantified in regard to 
the developmental stage of each individual cyst. The developmental stage of the 
renal cysts in cux-1ΔCR1/cpk and cpk mice was determined by counting the number 
of cells lining the cysts (see Chapter 3 materials and methods). The numbers of 
intermediate stage of development cysts between cux-1ΔCR1/cpk and cpk were 
statistically similar. However, the results showed that kidneys from cux-1ΔCR1/cpk 
mice had increased numbers of cysts in a more advanced developmental stage in 
comparison to age-matched kidneys from cpk mice (Figure 3-7c). This was 
associated with a reduced numbers of early stage cysts in the kidneys from  
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Figure 3-8. Characterization of cux-1ΔCR1/cpk cystic kidneys. a, b: 
Representative midsagittal sections of cystic kidneys isolate from 10-day-old cpk (a) 
and cux-1ΔCR1/cpk (b) mice. c. The overall number of cysts is unchanged in mid 
sagittal sections of kidneys from 10-day-old cpk and cux-1ΔCR1/cpk mice. d: 
Numbers of cysts present in Early, Intermediate and Advanced stage of development. 
Cysts were considered early stage if there were less than 50 cyst-lining epithelial 
cells, intermediate if there were 51-200 cyst-lining epithelial cells, and advanced 
stage if greater than 200 cyst-lining cells. (*) Denotes there are significantly less 
early forming cysts in cux-1ΔCR1/cpk and (**) denotes significantly more advanced 
stage well developed cysts. Each bar represents the mean of three different animals 
of the indicated genotype ±SEM. e-h. cux-1ΔCR1/cpk cysts are predominately 
derived from collecting-duct origin.  
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Figure 3-9. Cyst derivation in cpk and cux-1ΔCR1/cpk kidneys is similar. Mid-
sagittal sections of kidneys from cpk (e and g) and cux-1ΔCR1/cpk (f and h) mice 
were labeled for lotus tetragonolobus agglutinin (LTA) to identify proximal tubules 
(e and f) or dolichus bifluorus agglutinin DBA to identify collecting ducts (g and h). 
Bar, 200μm. 
 
cux-1ΔCR1/cpk mice compared to kidneys from age-matched cpk mice. These results 
support the idea that cux-1ΔCR1 accelerates PKD cyst progression. 
Cystogenesis occurs during two stages in cpk kidneys.  Proximal tubules 
develop small cystic dilations during the late fetal stage continuing through the first 
neonatal week of life. However the larger definitive cysts, exclusively derived from 
the collecting ducts, occur in the later stages of the disease.  Cux-1 is expressed at 
embryonic day 13.5 (E13.5) prior to the observation of proximal tubule cystic 
dilations initiating at E16.5.  Since cux-1ΔCR1 carries the same promoter as wild-
type cux-1 (37) and high levels of Cux-1 correlating with cell proliferation occur 
during early nephrogenesis (19), it is plausible that proximal tubule derived cysts are 
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more abundant than collecting duct cysts in cux-1ΔCR1/cpk kidneys.  Another 
possibility for the larger cux-1ΔCR1/cpk cystic kidneys is that there are more 
proximal tubule-derived cysts in addition to the typical number of collecting duct 
cysts.  To begin to address these possibilities, Dolichos Biflorus Agglutinin (DBA) 
labeling and Lotus Tetraglobin Lectin (LTL) were used to label for collecting duct- 
and proximal tubule-derived cells respectively.  The pattern of cystogenesis 
characteristic of the cpk mutation was unchanged within cux-1ΔCR1/cpk kidneys on 
the mixed B6/129 background  (Figure 3-4A and Figure 3-7A). Cysts were found 
both within the outer cortex and interior medulla.  However, when the cpk gene is 
present on the B6 background cysts are primarily located in the interior renal 
medulla (Figure 3-4A).  cpk mice undergo two phases of cystic disease (104, 198). 
Initially, cpk mice develop proximal tubule cysts that resolve by postnatal day 7. 
This is followed by a second phase of cystogenesis, in which cysts develop primarily 
from collecting ducts, resulting in massive enlargement of the kidneys.  To 
determine if cyst derivation is altered in cux-1ΔCR1/cpk LTA and DBA labeling 
were performed (See Chapter 3 Materials and Methods) to examine the presence of 
proximal-tubule and collecting-duct cysts respectively.  In kidneys from both cux-
1ΔCR1/cpk and cpk mice, the cysts were primarily restricted to the collecting ducts, 
with few proximal tubule cysts, although the collecting duct cysts in the cux-
1ΔCR1/cpk kidneys were larger than those in the cpk kidneys (Figure 3-8).  
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Discussion  
 The results from this chapter demonstrate that mutation in Cux-1 can alter 
PKD.  We crossed the cux-1ΔCR1 gene onto cpk mice and observed modification of 
the PKD phenotype. The cux-1ΔCR1 gene was crossed onto cpk in part due to the 
effect of the wa-2 gene (133), a point mutation in EGFR resulting in decreased 
tyrosine kinase activity (130), reduces the PKD phenotype in another model for 
ARPKD, the orpk mice.  In addition, since cux-1ΔCR1 mice (37) have a similar 
phenotype to that of the wa-2 mice (133) it is possible that Cux-1 is involved in the 
EGFR pathway.  To initially test this idea we examined Cux-1 expression in the 
presence or absence of EGF stimulation with human epidermal carcinoma cells. Our 
results here are the first to link Cux-1 within the EGFR pathway.  The observation 
that Cux-1 expression is attenuated in EGF stimulated cells (Figure 3-3c) is 
supported by reports showing EGF stimulation inhibits cell proliferation in A-431 
cells (196, 197).  Cux-1 is highly expressed when EGFR is not activated by EGF and 
A-431 cells are undergoing cell division.  Therefore, altered Cux-1 expression 
occurring during the activation of EGFR is consistent with studies demonstrating the 
expression of Cux-1 in proliferating cells (19, 20, 135).  The results here suggest that 
EGFR activity regulates Cux-1 protein expression.      
cux-1ΔCR1 mice carry an in-frame deletion of Cux-1, encompassing exons 
10 and 11 (37). These mice display wavy hair and curly vibrissae, and females are 
unable to support pups because of lactation defects (reviewed in Chapter 1). 
However, the kidneys of these mice are phenotypically normal. The cux-1ΔCR1 
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phenotype is similar to previously described mouse mutants in the EGFR pathway, 
including waved-1 (wa-1)(199) and waved-2 (wa-2) (133,200). When examined, 
however, no change in the expression of EGFR in the Cux-1ΔCR1 mice was found 
(37) which is supported by our observations (Figure 3-3A). Nevertheless, it is 
unclear whether Cux-1 is regulated by EGF in vivo, or if Cux-1 may target ligands of 
EGFR. The role of EGFR in polycystic kidney disease has been well described (107, 
130, 131, 201,202). Moreover, blocking EGFR activity, either genetically using the 
wa-2 mutation (131), or pharmacologically, results in decreased cyst formation and 
improved kidney function in the orpk model for autosomal recessive PKD (203, 
204).    
To determine whether cux-1ΔCR1 would similarly alter cyst progression, we 
crossed the cux-1ΔCR1/cpk mice with cpk mice to generate cux-1ΔCR1/cpk mice. 
Our results show that an in-frame deletion of Cux-1, encompassing exons 10 and 11 
(37), modifies the progression of polycystic kidney disease in cpk mice. However, 
rather than slowing the progression of cystogenesis, the presence of the cux-1ΔCR1 
mutation accelerated cyst growth on a mixed B6/129 background (Figure 3-5). 
Interestingly, the presence of the cux-1ΔCR1 mutation seems to have no effect on 
kidney development, as kidneys isolated from cux-1ΔCR1 mice were phenotypically 
normal. The absence of a renal phenotype in the cux-1ΔCR1 mice suggests that the 
cux-1ΔCR1/cpk mutation modifies PKD progression in cpk mice.  Recently, a 
candidate modifier gene for the cpk mutation was identified. Kinesin family member 
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12 was mapped to a major effect quantitative trait loci (QTL) complex on 
chromosome 4 (128). However, Cux-1 is located on chromosome 5 and does not 
map to a QTL for the modification of renal disease in cpk mice (205). Thus, it is 
unclear to what degree the cux-1ΔCR1 mutation is a candidate modifier of the cpk 
mutation.  It is possible that the cux-1ΔCR1 mutation perturbs or enhances genes on 
chromosome 5.  Given the nature of the cux-1ΔCR1/cpk mice being on a 75% B6/ 
25% 129J genetic background it is possible that cpk and cux-1ΔCR1 genes are 
involved in interactions with any number of additional genes resulting in 
multifactorial epistasis events.  
PKD kidney size and reduced renal function directly relate to the severity of 
disease (103, 104, 120, 121). The presence of cux-1ΔCR1 gene with cpk results in 
mice with reduced renal function and larger cystic kidneys.  Our results suggest that 
the cux-1ΔCR1 gene accelerates cyst growth in cpk kidneys, but does not induce cyst 
formation.  There are an equivalent number of cysts in cpk and cux-1ΔCR1/cpk 
kidneys.  However the existing cysts in cux-1ΔCR1/cpk kidneys are in a more 
advanced stage of development compared to cpk cysts.  Studies to determine 
potential mechanism(s) involved in cux-1ΔCR1 acceleration of cystogenesis and 
modification of the PKD phenotype are addressed in the ensuing Chapter 4.   
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CHAPTER FOUR 
 
CUX-1 MODIFICATION OF POLYCYSTIC KIDNEY DISEASE INVOLVES 
DOWNREGULATION OF THE  p27Cip/kip CYCLIN KINASE INHIBITOR 
  
Abstract 
 
Polycystic kidney diseases (PKD) are inherited as autosomal dominant or 
autosomal recessive traits and are characterized by progressive enlargement of renal 
cysts.  Aberrant cell proliferation is a key feature in the progression of PKD.  Cux-1 
is a homeobox gene that is related to Drosophila cut, and is the murine homologue of 
human CDP (CCAAT Displacement Protein).  Cux-1 represses the cyclin kinase 
inhibitors p21 and p27, and transgenic mice ectopically expressing Cux-1 develop 
renal hyperplasia.  However, Cux-1 transgenic mice do not develop PKD.  Cux-1 
expression is upregulated in cystic kidneys of embryonic Pkd1 null mice where 
expression corresponds to cell proliferation.  In contrast, Cux-1 expression is not 
elevated until later stages of cystogenesis in cpk mice.  Previously we have 
demonstrated that a 246 amino acid deletion of Cux-1 (termed Cux-1ΔCR1) 
accelerates PKD in the cpk model for autosomal recessive PKD.  Here, we show 
evidence that downregulation of the cyclin kinase inhibitor p27 occurs in cux-
1ΔCR1/cpk kidneys.  Furthermore, in contrast to cpk kidneys, Cux-1ΔCR1 protein is 
ectopically expressed in proliferating cyst-lining epithelial cells. This might be 
possible because Cux-1ΔCR1 protein lacks a Cathepsin-L processing site.  Analysis 
of nuclear Cathepsin-L protein expression levels were inversely correlated with Cux-
1 expression.  These results suggest a mechanism in which reduced Cux-1 processing 
 101
by Cathepsin-L results in the accumulation of Cux-1, down regulation of p27, and 
increased cell proliferation in ADPKD. 
 
Introduction  
 
The murine transcription factor Cux-1 is structurally related to Drosophila 
Cut and contains 4 putative DNA binding domains (3 cut repeats, 1 homeodomain) 
(13, 17, 19, 29).  Cux-1 represses the expression of the cyclin kinase inhibitor (CKI) 
p21 in S phase and is part of the network controlling G1-S transition (55). Cux-1 also 
represses the CKI p27 (20).  Ectopic expression of Cux-1 in transgenic mice results 
in the downregulation of p27 associated with multiorgan hyperplasia (20). In the 
kidney, Cux-1 expression is spatially and temporally regulated, with highest 
expression in the nephrogenic zone, where it is associated with cell proliferation (19, 
20). During normal kidney development, p27 is absent from the nephrogenic zone, 
but is expressed in maturing glomeruli and tubules following the down regulation of 
Cux-1 (19, 206). Thus, Cux-1 is a cell cycle dependent transcription factor that 
promotes cell proliferation during the early stages of nephrogenesis by repressing 
p27 gene expression. 
There are several truncated isoforms of Cux-1 (reviewed in Chapter One) in 
addition to the full-length isoform, called Cux-1 (p200). A nuclear isoform of the 
cysteine protease cathepsin-L has been identified that proteolytically processes Cux-
1(p200) in S-phase (32). While the full-length Cux-1 protein (p200) contains 3 cut 
repeats and the homeodomain, the proteolytically processed Cux-1 (p110 or p90) 
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contains only cut repeats 2 and 3, together with the homeodomain (51). Cux-1 (p200) 
exhibits transient DNA binding activity and functions as a transcriptional repressor, 
whereas p110 stably binds DNA and can function as a transcriptional activator (51). 
Cux-1 isoforms develop from alternate splicing (CASP) (31), alternate promoter use 
(p75) (84), or proteolytic processing (p150) (207). Another Cux-1 transcript, found 
exclusively in testis, encodes a 55 kD protein, however, it is not known whether it 
originates by alternate splicing or an alternate promoter (30). 
Previously we found that Cux-1 (p200) is highly expressed in cystic kidneys 
isolated from both Pkd1 null and cpk mice, murine models of ADPKD and ARPKD, 
respectively (135). In cystic kidneys from Pkd1 null mice, Cux-1 is highly expressed 
in both cyst-lining cells and in normal appearing tubule epithelium where expression 
of Cux-1 is associated with increased cell proliferation.  In cystic kidneys from cpk 
mice, Cux-1 is not abnormally expressed until the later stages of cystogenesis (post-
natal day 20) where expression of Cux-1 is associated with increased apoptosis in 
cyst-lining cells. However, CMV/Cux-1 transgenic mice do not develop cystic 
kidney disease (20), raising the possibility that the upregulation of Cux-1 may be 
necessary, but not sufficient, for the development of cystic disease. 
Tufarelli et al. (37) demonstrated that a mutant form of Cux-1 (termed Cux-
1ΔCR1) protein has a higher affinity for biding to DNA compared to wild-type Cux-
1.  They also demonstrated that Cux-1ΔCR1 protein is expressed at higher levels 
than wild-type Cux-1 protein within Spleen and Thymus.  In Chapter 3, the data 
demonstrated that cux-1ΔCR1 accelerated PKD in the cpk mouse model. Cysts from 
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cux-1ΔCR1/cpk kidneys were large, in a more advanced developmental stage 
compared to cpk cysts, and thus contributed to the larger cux-1ΔCR1/cpk size.  In 
this Chapter I will show data engendering correlations with theories which may help 
to explain the occurrence of accelerated cystogenesis in cux-1ΔCR1/cpk mice.   
  
Materials and Methods 
 
 
Immunohistochemistry 
Immunohistochemistry was performed as previously described (44). Kidney 
sections were immersion fixed in 4% paraformaldehyde and blocked in paraffin. 
Sections were washed in PBST and blocked in 10% normal goat serum (NGS) at 
room temperature for 1hour. Rabbit Cux-1 (Santa Cruz), mouse PCNA (Sigma) or 
Rabbit Cathepsin-L (CALBIOCHEM) primary antibody was applied to sections 
incubated at room temperature for 1hr at a concentration of 1:100, 1:3000 and 1:50 
respectively. Biotinylated goat anti-rabbit (1:400) was used to detect Cux-1 and 
Cathepsin-L antibody. A horse anti-mouse texas red conjugated secondary antibody 
(Vector) was utilized to detect PCNA antibody (1:400). Sections were then washed 
in PBST and incubated with either FITC conjugated avidin (Vector) or incubated 
with avidin-biotin-peroxidase complex (ABC-Elite: Vector) and DAB. All sections 
were washed with PBST and then mounted with either Vectashield medium with 
Dapi (Vector) or dehydrated with graded ethanols, mounted with Permount (fisher), 
and covered with glass coverslips. All images were captured with an Optronics 
Magnafire digital camera. 
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Western Blot Analysis 
Human ADPKD and normal human kidney (NHK) were harvested and 
nuclear extracts prepared as previously described2.  Briefly, nuclear extracts (45ug) 
were loaded onto 4-15% SDS-PAGE gels and transferred to PVDF membranes 
where they were blocked in 5% milk PBST20.  Membranes were probed with either 
Cux-1 (1:50), Cathepsin-L (1:2000) or p27 (1:100) (Santa Cruz) primary antibody 
followed by PBST20 washes and HRP-peroxidase (1:10,000) secondary antibody 
application.  Densitometry was performed using Scion Image®.  Relative protein 
level intensity from extracts of three different Cux-1∆CR1/cpk and cpk animals were 
normalized for p27 protein analysis. 
 
Apoptosis analysis 
Sections were processed for Terminal deoxynucleotidal transferase 
(TdT)-mediated dUTP-nick-end labeling (TUNEL) with the ApopTag Red InSitu 
Apoptosis Detection kit (Intergen Co.) according to manufacturer's instructions. 
Sections were counterstained with DAPI, cover-slipped, and visualized on a 
fluorescence microscope. Images were captured with an Optronics Magnafire digital 
camera.  Midsagital sections were analyzed for the numbers of positive TUNEL 
labeled cyst-lining epithelial cells taken as a percentage of all cyst-lining epithelial 
cells counted within 20 random 40X fields.  A Caspase-3 cleaved active form 
(Calbiochem) detection by western blot was performed using the standard western 
blot protocol previously described.  
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Electrophoretic mobility shift assay  
Electromobility shift assay was conducted with nuclear extracts from cpk and 
cux-1ΔCR1 kidneys for binding to p27 promoter and Cux-1 consensus 
oligonucleotides.  Sense and antisense oligonucleotides for p27 
(5’CAGCCTGGGGCGGCTCCCGCCGCCGCAACCAAT 3’) and Cux-1 consensus 
DNA binding site (5’AAAAGAAGCTTATCGAT3’) were annealed by incubating 
overnight in a thermocycler (850C for 1 sec, 850C for 5 min, 200C for 6 hrs).  The 
resulting double stranded oligonucleotides included 5’ overhanging extensions to 
facilitate labeling with Klenow fragment of DNA polymerase I and [α-32P]dCTP .  
The double-strand oligo probes were labeled using the random primed DNA labeling 
kit (Roche).  Unincorporated nucleotides were removed by spin column G25 
(Amersham).  The counts were measured in liquid scintillation counter (3X104 cpm 
were used per 30 μl reaction). Reaction:  5 μg of nuclear extract was added to 
binding buffer containing 10μg BSA, 1 μg poly(dI–dC) · (dI–dC), 50mM Tris HCl 
pH 7.5, 250mM NaCl, 25% Glycerol, 5mM DTT, 5mM EDTA in a 30 μl reaction. 
Then, radiolabeled probe was added and incubated for 30 min at room temperature.  
For cold competition reaction, 50 molar excess of annealed oligo was added 15 
minutes prior to adding the radiolabeled probe.  The reaction products were analyzed 
on a 4% non-denaturing polyacrylamide gel using 0.5x TBE (25 mM Tris-HCl, 25 
mM boric acid, 0.5 mM EDTA) as running buffer. Gel was dried and radiolabeled 
bands were visualized by autoradiography.  
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Statistics  
In all studies, a one-way ANOVA was performed.  If significance between 
the genotypes existed (P≤0.05) post-hoc analysis by least significant difference 
(LSD) was performed to determine statistical significance (p≤0.05) between groups. 
All statistical analyses were performed using the Statview® statistical program. 
 
Results 
Cell proliferation is a key feature of cyst growth (146, 148, 189,208).  
Moreover, there is a direct correlation between levels of cell proliferation and 
progression of cystic disease (120, 121, 146, 209,). Thus, one possibility is that the 
increased cyst size observed in the kidneys from cux-1ΔCR1/cpk mice resulted from 
increased proliferation of the cyst lining epithelial cells. In the developing kidney, 
Cux-1 is expressed in the nephrogenic zone where it co-localizes with markers for 
cell proliferation, but is downregulated in maturing glomeruli and tubules (19). 
However, in Pkd1 null kidneys, Cux-1 is ectopically expressed in the cyst lining 
cells, and in normal appearing mature tubule epithelia, where it is associated with 
cell proliferation (133). Figure 4-1 d-f shows that Cux-1∆CR1 protein co-localized 
with PCNA in the cyst lining cells of kidneys isolated from 10-day-old cux-
1ΔCR1/cpk mice.  In contrast, wild type Cux-1 protein was not expressed in the cyst 
lining cells of kidneys isolated from 10-day-old cpk mice (Figure 4-3a-c), as 
described previously (133).  
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The expanded expression of the Cux-1ΔCR1 protein in the cystic kidneys 
was surprising since this deletion would not be expected to affect the regulatory 
elements in the Cux-1 gene.  Moreover, the levels of Cux-1ΔCR1 mRNA are not 
different from that of wild type Cux-1 (p200) mRNA (37).   However, the levels of 
Cux-1ΔCR1 protein appear to be elevated in some tissues compared to Cux-1 (p200). 
To determine whether the Cux-1ΔCR1 protein was elevated in the kidney, we 
performed Western blot analysis on nuclear extracts from newborn kidneys isolated 
from wild type and cux-1ΔCR1 mice. Figure 4-2A shows that significantly more of 
the Cux-1ΔCR1 protein was present in newborn kidneys from cux-1ΔCR1 mice than 
the Cux-1 (p200) protein in wild type mice. Furthermore, Cux-1 (p200) was 
abundantly expressed in human ADPKD cells compared to normal human kidney 
(NHK) cells (Figure 4-2B).  There were lower levels of Cux-1 degradation product 
in ADPKD cells where Cux-1 (p200) was expressed compared to NHK cells. This 
may suggest that Cux-1 (p200) might be more stable in ADPKD cells in contrast 
with Cux-1 (p200) in NHK cells. 
It is unclear how Cux-1ΔCR1 protein levels are elevated in cpk cyst lining 
cells, within developing kidney, spleen and thymus.   Nuclear Cathepsin-L 
proteolytically cleaves Cux-1 (p200) during S-phase of the cell cycle (32). After 
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Figure 4-1. Increased proliferation in cystic kidneys from cux-1ΔCR1/cpk mice. 
a-c: Detection of Cux-1(p200) (a) and PCNA (b) in kidneys from 10-day-old cpk 
mice. At early stages of cyst development in cpk  mice, Cux-1(p200) is expressed in 
the  interstitial cells (a), but is absent from the cyst lining cells, where PCNA 
labeling indicates cell proliferation (b). The merged image (c) shows no overlap of 
Cux-1(p200) with PCNA. d-f:  The mutant Cux-1ΔCR1 protein is expressed in both 
the interstitial cells and the cyst lining cells (d). The cyst lining cells are 
proliferative, as indicated by PCNA labeling (e), and the merged image shows co-
localization of Cux-1ΔCR1 and PCNA in cyst lining cells (f). Arrows in (d-f) 
demonstrate co-expression of Cux-1ΔCR1 protein with PCNA in cystic epithelial 
cells. (a-f) Bar=50 µm. 
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close evaluation of Cux-1 (p200) sequence compared to Cux-1ΔCR1 we found that 
the deletion producing the Cux-1ΔCR1 protein contained a Cathepsin-L cleavage site 
(Figure 4-3).  Therefore, since Cux-1ΔCR1 protein lacks a Cathepsin-L cleavage 
site, it might be possible that Cux-1ΔCR1 has a longer degradation half life resulting 
in the accumulation of Cux-1ΔCR1 protein in PKD.  Nuclear Cathepsin-L expression 
may correlate with Cux-1 (p200) expression. To begin to address this issue, we 
looked at nuclear Cathepsin-L expression in pkd1 null kidneys, human ADPKD 
cystic cells, and cpk kidneys (Figure 4-4b).  The results indicated that nuclear 
Cathepsin-L levels are attenuated in PKD1 knockout kidneys and human ADPKD.  
This is a very interesting finding because it establishes an inverse relationship 
between Cux-1 (p200) expression levels and Cathepsin-L in wild-type kidney and 
NHK cells in relation to PKD1 knockout kidney and ADPKD cells (Figure 4-2 and 
Figure 4-4c).    Diminished nuclear Cathepsin-L expression levels in PKD appear to 
manifest in the ectopic expression of Cux-1 (p200).  However, cpk kidneys presented 
with a mild increase in nuclear Cathepsin-L protein expression (Figure 4-4d).   The 
mild increase in Cathepsin-L may help provide insight into why Cux-1p200 is not 
ectopically expressed in cpk kidneys. The fact that Cux-1ΔCR1 is ectopically 
expressed in cpk kidneys might be a result of the absence of a Cathepsin-L 
proteolytic cleavage site in Cux-1ΔCR1 protein. 
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Figure 4-2. Increased Cux-1∆CR1 protein in developing kidney and 
downregulation of p27 in Cux-1∆CR1/cpk kidneys. The level of Cux-1(p200) and 
Cux-1∆CR1 protein during kidney development were evaluated. (A) Western blot 
for Cux-1 in kidney nuclear extracts from postnatal-day 7 wild type (lane 1) and 
Cux-1∆CR1 (lane 2) mice. There is significantly more Cux-1∆CR1 in developing 
kidneys from Cux-1∆CR1 mice than Cux-1(p200) in developing kidneys from wild 
type mice. (B)The levels of Cux-1(p200) were evaluated in normal human kidney 
(NHK) and human ADPKD cells.  Cux-1(p200) is abundantly expressed in ADPKD. 
(◄) Denotes Cux-1 degradation products.  
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                 Figure 4-3.  Cux-1∆CR1 protein lacks a Cathepsin-L cleavage site. 
 
Cux-1 (p200) protein when overexpressed in transgenic mice results in renal 
hyperplasia associated with the downregulation of p27 cyclin kinase inhibitor.  The 
p27 gene is a target for Cux-1(p200) mediated repression. Therefore, to determine 
whether the increased expression of the Cux-1ΔCR1 protein in cpk mice altered the 
expression of p27, we compared the expression of p27 in kidneys isolated from cux-
1ΔCR1/cpk and cpk mice (Figure 4-5A). We found that p27 expression was reduced 
by two-fold in the kidneys from cux-1ΔCR1/cpk mice in comparison to cpk.  Since 
Tufarelli et al (37) demonstrated that Cux-1ΔCR1 protein binds to promoter DNA 
with a higher affinity then Cux-1(p200) we wanted to evaluate the ability of Cux-
1ΔCR1 to bind p27 promoter in cpk kidneys.  We found that there was more 
Cux1ΔCR1protein bound to the p27 promoter in comparison to Cux-1(p200) within 
cpk kidneys (Figure 4-5B).   
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Figure 4-4. Abnormal nuclear Cathepsin-L expression in PKD.  (A) wild-type 
embryonic kidneys express Cathepsin-L within the nucleus of cells (?). (B) Age 
matched 18 day embryonic kidney from PKD1 knockout mice.  Cathepsin-L 
expression is less abundantly nuclear and can now be observed in the cytoplasm 
(◄).  (C) Western blot for Cathepsin-L within nuclear extracts of NHK and ADPKD 
show reduced nuclear Cathepsin-L in ADPKD cystic cells.  (D) Western blot for 
Cathepsin-L within nuclear extracts from wild-type and cpk kidneys at post-natal day 
3 revealed modest elevation of nuclear Cathepsin-L levels in cpk kidneys. 
 
While there is limited apoptosis in the cysts of 10-day-old cpk mice, 
apoptosis is increased at later stages of cyst growth, where it is thought to contribute 
to cyst progression (135, 140, 209). Moreover, inhibition of apoptosis slows cyst 
progression in mouse and rat models of PKD (140,209). Consistent with an 
acceleration of cyst progression in the kidneys of cux-1ΔCR1/cpk mice, we observed 
an increase in TUNEL labeling in the cystlining cells of cux-1ΔCR1/cpk mice 
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compared to cpk mice, and an increase in activated Caspase-3 in kidneys from cux-
1ΔCR1/cpk mice compared to cpk mice (Figure 4-6A-D).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-5.   Cux-1ΔCR1 protein binds to the p27 promoter when p27 is 
downregulated in cpk kidneys.  (A) Western blot for p27 in kidneys from 10-day-
old cpk and cux-1ΔCR1/cpk mice, and mean relative intensity  SEM of p27 levels. 
(*) Denotes a significant reduction in p27 protein levels in the kidneys of cux-
1ΔCR1/cpk mice compared to cpk mice. (B) EMSA performed on cpk (A p27 
promoter sequence (lanes 1 and 2) and an oligonucleotide control sequence, known 
to bind Cux-1 (lane 3) were incubated with cpk (anes 1 and 3) or cux-1ΔCR1/cpk 
(lane 2) nuclear extracts. There were more abundant levels of Cux-1ΔCR1 protein 
bound to p27 promoter (lane 2) compared to wild-type (lane 1).   
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Figure 4-6. Increased apoptosis occurs in cux-1ΔCR1/cpk mice.  (A) TUNEL 
labeling is increased in cyst lining cells of cux-1ΔCR1/cpk mice (p) compared to cpk 
kidneys (L). (B) Percent TUNEL positive cystic cells are elevated in cux-1ΔCR1/cpk 
kidneys. (C) Levels of activated caspase-3 are increased in cystic kidneys from cux-
1ΔCR1/cpk mice (lanes 1-2) compared to cpk mice (lanes 3-5).Bar, 100 µm. 
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Discussion 
We previously showed that Cux-1 is ectopically expressed in cystic kidneys 
isolated from Pkd1 null and cpk mice (135). In Pkd1 null mice, Cux-1 was 
ectopically expressed in cyst lining cells and in what appeared to be normal 
differentiated tubules, and was associated with abnormal cell proliferation.  In 
contrast, Cux-1 was not ectopically expressed in cystic kidneys isolated from 7- or 9-
day-old cpk mice (135). Rather, Cux-1 was upregulated in cystic kidneys from 20-
day-old cpk mice (19, 135), when cystogenesis was highly advanced, and there was 
little parenchyma remaining. Moreover, the expression of Cux-1 in the cysts was 
more closely associated with apoptosis than with cell proliferation. The difference in 
Cux-1 expression between these two animal models of PKD is unclear, but suggests 
that the molecular mechanisms of cyst growth between the Pkd1 null and cpk mice 
are different.      
   Cystic epithelial cells are thought to undergoe dedifferentiation and aberrant 
cell proliferation.  Bhunia et al. (148) demonstrated that the Polycystin-1 protein, 
where mutation is involved in ~85% of human ADPKD cases, regulates the cyclin 
kinase inhibitor p21. The ectopic expression of Cux-1ΔCR1 protein in cyst lining 
epithelial cells may play a role in cell proliferation leading to increased numbers of 
cysts in a more advanced developmental stage (Figure 4-1).  Tufarelli el al.(37) 
found that Cux-1ΔCR1 protein is upregulated in Spleen and Thymus.  It is unclear 
how Cux-1ΔCR1 protein levels are elevated compared to wild-type Cux-1 (p200) 
protein.   
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Cathepsin-L is involved in initiating the Cux-1 degradation pathway (32, 51).  
Our results revealed that in human ADPKD cystic cells and PKD1 knock out mice, 
increased levels of full-lenth Cux-1 (p200) protein were associated with reduced 
levels of nuclear Cathepsin-L (Figure 4-2 and Figure 4-4).  It is possible that 
increased amounts of Cux-1 (p200) lead to reduced nuclear Cathepsin-L levels which 
are then unable to initiate the proteolytic degradation pathway.  Nuclear Cathepsin-L 
levels are relatively elevated in cpk kidneys (Figure 4-4C) when Cux-1 (p200) 
expression is restricted to interstitial cells which may help to explain how Cux-1 
(p200) protein is not expressed in cystic epithelial cells.  However, Cux-1ΔCR1 
protein is ectopically expressed in cyst lining epithelial cells (Figure 4-1). One 
possibility is that since Cux-1ΔCR1 protein lacks a Cathepsin-L cleavage site 
(Figure 4-3), Cux-1ΔCR1 protein might avoid Cathepsin-L mediated proteolytic 
cleavage.  This may result in increased amounts of Cux-1ΔCR1 protein levels in cpk 
kidneys. 
Cux-1 overexpression in transgenic mice results in renal hyperplasia and 
downregulation of p27 (20).  We previously showed that p27 is upregulated in 
kidneys isolated from cpk mice, compared to age matched wild type mice (44).  
Therefore the observation that p27 protein expression levels were attenuated in cux-
1ΔCR1/cpk kidneys (Figure 4-5) may provide insight to why these mice have such a 
severe cpk phenotype in regard to aberrant cell proliferation.  We have previously 
shown that Cux-1 (p200) represses p27 promoter activity in a concentration 
dependent manner (20). The decreased expression of p27 in cystic kidneys 
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expressing the Cux-1ΔCR1 protein suggests that this protein can function similar to 
the Cux-1 (p200) protein.   Since Cux-1ΔCR1 protein in cpk kidneys binds more 
abundantly to p27 promoter (Figure 4-5b), which correlates with p27 downregulaton 
(Figure 4-5a), it is possible that increased Cux-1ΔCR1 protein facilitates p27 down 
regulation and rapid progression through the cell cycle resulting in increased cell 
proliferation and severe PKD observed within Chapter 4.   
Cystic epithelial cells undergoe apoptosis in cpk mice (140, 209).  Cux-1 is 
not abnormally expressed until the later stages of cystogenesis (post-natal day 20) 
where expression of Cux-1 is associated with increased apoptosis in cyst-lining cells 
(135).  Moreover, Ali et al. (136) showed that Caspase-3 activity is active during 
post-natal day 20 confirming that increased Apoptosis is occurring during the more 
advanced stages of the disease.  Furthermore, Tao et al. (209) demonstrated that 
caspase-3 gene knock out when crossed with cpk slows cpk disease progression.  
Therefore, increased Caspase-3 activity and apoptosis in cpk kidneys correlate with 
increased cpk cystic disease progression. Reduced TUNEL labeling and increased 
Caspase-3 expression in cux-1ΔCR1/cpk kidneys further supports data that cux-
1ΔCR1/cpk mice have severe PKD (Chapter 3).  The mechanism behind apoptosis in 
the cpk model and PKD in general is unclear.  In contrast to the results from Tao et 
al. (209) which demonstrated that gene reduction of Caspase-3 ameliorates PKD, 
Ostrom et al. (137) reported that reduced Pax2 gene dosage increases apoptosis and 
slows the progression of renal cystic disease.   The balance between apoptosis and 
cell proliferation may contribute to the net effect of cux-1∆CR1/cpk kidneys being 
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larger than cpk kidneys.  Enhanced apoptosis during advanced stages of PKD might 
be a biological response to try to limit aberrant cell proliferation.  However, the role 
of apoptosis beyond a marker for advanced cystic disease is poorly understood. 
The role of Cathepsin-L in regulating ectopic expression of Cux-1 during 
PKD requires further investigation and will be a topic for discussion in Chapter 5.   
The results presented in Chapter 4 show that cyst-lining epithelial cells ectopically 
express Cux-1∆CR1 protein and are undergoing cell proliferation, which may 
contribute to the accelerated PKD cyst maturation in cux-1∆CR1/cpk kidneys 
observed in Chapter 3.  Downregulation of the cyclin kinase inhibitor p27 within 
cux-1∆CR1/cpk mice may be linked to a possible increase in cell proliferation which 
may be responsible for advanced PKD.  Since Cux-1∆CR1 protein binds to p27 
promoter more abundantly than wild-type Cux-1 (37) and is associated with p27 
downregulation in cpk kidneys (Figure 4-5), a direct link between Cux-1 and p27 in 
regulating PKD has now been identified.   
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CHAPTER FIVE 
 
DISCUSSION, SUMMARY AND CONCLUSIONS 
  
The majority of information regarding Cux-1 function and expression pattern 
has come from studying the homologue of Cux-1 that is present in Drosophila which 
is called “Cut” (1, 3, 4).  The Malpighian tubules serve to provide renal function to 
the fly.   Mutational studies involving the drosophila cut gene demonstrated that 
mutations in cut result in defects in malphigian tubules ranging from moderate 
(defective morphogenesis) to severe (absence of malphigian tubules) (5-8).  Cux-1 is 
highly expressed in induced and uninduced mesenchyme, as well as in ureteric bud 
epithelium and S-shaped bodies in murine kidneys (19). The involvement of Cux-1 
in signaling pathways during kidney development in mammals is poorly understood.  
During wing development in Drosophila, multiple genetic interactions between Cut, 
Notch and the wnt/Wingless signaling pathways have been reported (reviewed in 
13).    
Previously, work from our lab has demonstrated that in the developing 
kidney, Cux-1 expression overlaps with that of Notch receptors (Notch 1-4) and 
ligands (Jagged-1,-2, and Delta 1) in the condensing mesenchyme, in pretubular 
aggregates (comma and S-shaped bodies), and in developing podocytes of capillary 
loop stage glomeruli (70) . Furthermore, Cux-1 was significantly up-regulated in a 
rat kidney epithelial cell lines (RKE) which constitutively express the Notch 1 
intracellular domain conferring active Notch 1 signaling.  RKE cells have elevated 
Cux-1 protein levels present with reduced levels of p27 protein.  Moreover, Cux-1 
 120
interacts with the Groucho homolog TLE-4, a corepressor recruited by Notch 
effector proteins. These results suggest that Cux-1 may function in the context of the 
Notch signaling pathway  during embryogenesis within developing kidneys. 
However, evidence of Notch signaling through Cux-1 has not been directly 
demonstrated as of this report.    
Cux-1 contains Ser and Thr residues within its cut repeat (CR) domains 
(CR1, CR2, CR3) as well as within its homeodomain (HD) which are targets for 
phosphorylation and dephosphorylation events as was described in Chapter 1.  PKC 
phosphorylation sites include Thr 415 (CR1 domain), Thr 804 (CR2 domain) and Ser 
987 (CR3 domain) (60).   Casein kinase II phosphorylates Ser 400 (CR1 domain), 
Ser 789 (CR2 domain) Ser 972 (CR3 domain) (59).  Cyclin A-CDK1 phosphorylates 
Ser 1237 (inbetween HD and CR3 domains) and Ser 1270 (within HD domain) (62).  
PKA phosphorylates Ser 1215 (located between the CR3 and HD domains) (61).  
Coqueret et al. demonstrated that cdc25 phosphatase activity dephosphorylates Cux-
1 which permits Cux-1 DNA binding and implicated Cux-1 as cell-cycle dependent 
transcription factors.  
Phosphorylation controls the activity of transcription factors and co-
regulators at different levels via the following: 1) adjusting the activity of chromatin 
remodeling complexes or enzymes that modify the chromatin package, 2) 
influencing the stability of transcription factors and their regulators, 3) restraining 
the subcellular localization of transcription factors, 4)  Modulating protein-protein 
interactions among transcription factors , coregulators and components of the basal 
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transcription complexes, and 5) altering the ability of transcription factors to bind to 
DNA (Reviewed in 210-214).  Numerous examples have been documented regarding 
the phenomenon of post-translational modification of transcription factors 
(Reviewed in 210-214).  Rapid post-translational modifications are very important 
during the cell-cycle and are known to regulate the effects of many transcription 
factors.    For example, phosphorylation of the retinoblastoma (RB) protein results in 
a change in conformation removing RB ability from stably binding to E2F protein  
and thus permitting E2F to be released and function as a transcription factor (213).  
Gupta et al. (76) found that RB is a co-repressor protein that interacts with Cux-1 to 
regulate cell-cycle controlled histone H4 transcription.  They found that Cux-1 
functions as the DNA binding subunit of the cell cycle controlled HiNF-D complex 
which is involved in regulating cell proliferation. HiNF-D interacts with all five 
classes (H1, H2A, H2B, H3, and H4) of the cell-cycle dependent histone genes. 
These histone genes are important in gene regulation and are transcriptionally and 
become activated at the G(1)/S phase transition independent of E2F activation. RB is 
an intrinsic component of the HiNF-D complex.  Gupta et al. (76) found that the 
Cux-1/RB interaction, similar to the E2F/RB interaction, occurs within the A/B large 
pocket (LP) of pRB.  Therefore it is conceivable, similar to how RB phosphorylation 
leads to conformational changes in RB resulting in the release of E2F factor, that 
phosphorylation/dephosphorylation of RB and/or Cux-1 may also affect RB/Cux-1 
protein-protein interactions.   
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We previously demonstrated that Cux-1 can bind to TLE-4 co repressor 
protein which is involved in transcriptional protein complex downstream of the 
Notch pathway (70).  Many transcription factors, (such as AP-1, HiFs and 
homeodomain box containing proteins) exist as protein homodimers or heterodimers 
or form complexes with many additional proteins (211, 212 for review).  The 
population of transcription factor binding partners at a given time or place during the 
cell-cycle appears to coordinate cell-cycle progression.  Cux-1 may exist in a 
complex with additional proteins such as TLE-4 in addition to interacting with other 
completely different proteins such as with RB in the HinF-D complex (76).  
Therefore it appears that Cux-1 may form different protein-protein complexes 
possibly in different cell-types during distinct time periods during development.  
Determination of the in vivo Cux-1 phosphorylation state during different time points 
in development has not yet been investigated.  Therefore Cux-1 function in regard to 
post-translational modification is still not clear within the developing kidney.        
CamKII, PKC, Cyclin-A CDK1 and cAMP-mediated PKA activity are all 
mitogenic factors that phosphorylate Cux-1 (59-62). Since phosphorylation of Cux-1 
is associated with reduced Cux-1 DNA binding ability, the observation that these 
mitogenic factors could possibly prevent Cux-1 binding and repression of target 
promoters such as the cyclin kinase inhibitors p21 and p27, whose repression favors 
accelerated cell-cycle progression, is quite puzzling.   However, the majority of the 
studies that identified phosphorylation events occurring within Cux-1 were 
performed in vitro in immortalized cells which may not provide full detail to what is 
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occurring within living kidney tissue.   Furthermore, some of these studies were 
performed in mammary tissue instead of within kidney tissue (61).  Residue specific 
Anti- phospho Cux-1 antobodies need to be generated to observe Cux-1 
phosphorylation state in vivo during different stages of kidney development.  
Cux-1 phosphorylation/dephosphorylation has been implicated in regulating 
the ability of Cux-1 to bind to DNA and thus regulate transcription of its gene targets 
(59-62). Based upon what is known about transcription factors and post-translational 
modifications of transcription factors (reviewed in 210-214), it is possible that Cux-1 
phosphorylation state determines Cux-1 binding partners within the nucleus. For 
example, Cux-1 in a phosphorylated state may discriminately interact with nuclear 
proteins which mask Cux-1 DNA binding domains in 3-dimensional conformation.  
In contrast, when Cux-1 is in a dephosphorylated state it may interact with a different 
set of co-repressor proteins which do not mask Cux-1 DNA binding domains and in 
fact may enhance the availability of those domains to be recognized by DNA.   An 
additional possibility is that when Cux-1 is in a phosphorylated state it is targeted for 
proteolytic cleavage more readily as a result of a conformational change that might 
unmask cleavage sites within Cux-1.  These possibilities are supported by Harada et 
al. (215) who recently found that Cux-1 p110 Cathepsin-L proteolytic cleavage 
product is recruited to the promoter of cell cycle-related targets preferentially during 
S phase of the cell-cycle.   Therefore the idea that post-translational modification of 
Cux-1 may alter recruitment of different transcriptional machinery to the site of a 
target promoter is strengthened. 
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The Cux-1 p110 protein lacks the CR1 domain which has been suggested to 
be an “autoinhibitory domain” involved in repressing the DNA binding ability of 
CR2 CR3 and HD (52). Yet it is also possible that the CR1 domain is structurally 
masking the CR2 CR3 and HD domains and thus preventing these domains access to 
DNA.  The C-terminal region of Cux-1 contains two active repression domains that 
can recruit histone deacytlase activity (48, 56).  Another possibility for how 
regulation of Cux-1 may affect Cux-1 function is that the cleavage of full length 
Cux-1 p200 to Cux-1 p110 provides greater access to the two C-terminal active 
repression domains within Cux-1 which may enhance repression.  Generation of a 
transgenic mouse that overexpresses Cux-1 p110 protein might be useful to 
determine the in vivo effect of Cux-1 proteolytic cleavage.  
The regulation of Cux-1 function may be further complicated by the 
possibility that Cux-1 intra- and inter protein conformational changes could be 
dependent upon site specific residue phosphorylation/dephosphorylation.  Residue 
specific phosphorylation has already been demonstrated both in vitro (59, 60, 62) 
and in vivo (61) within Cux-1. PKC, PKA, CamKII, phosphorylate different residues 
within Cux-1 (59-61).  PKC and Casein kinase II target residues within the CR1 
domain which are not present in Cux-1 p110 (59, 60).  Since single phosphorylation 
events within a protein are known to modify protein conformation, it is conceivable 
that the lack of signaling to these resides may also contribute to Cux-1 p110 
recruitment to the promoter.  Therefore, Cux-1 protein intramolecular and 
intermolecular protein interactions may also play a role in transcriptional activity.  
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The extent to which Cux-1 structural alterations occur in regard to proteolytic 
cleavage and phosphorylation/dephosphorylation are experiments that merit future 
investigation.  
The model that we proposed for Cux-1 function during kidney development 
(Figure 1-12) involves the binding of Cux-1 to p27 promoter to repress transcription 
in a Cux-1 concentration dependent manner.  However, based on what is understood 
about the process of transcriptional regulation by transcription factors (210-214) the 
observations of full length Cux-1 phosphorylation and dephosphorylation may only 
tell us part of the story.   Post-translational modification such as phosphorylation, 
acetylation, and proteolytic cleavage may play a role in mediating Cux-1 DNA 
binding ability (reviewed in 13), it is not clear how direct post-translational 
modification alters DNA binding in relation to additional protein-protein interactions 
occurring in vivo during kidney development.  Moreover, a comprehensive study on 
Cux-1 target gene promoter binding interactions and protein-protein interactions, 
during the various stages of kidney development has yet to be performed. 
 One of the goals of my dissertation work was to learn about the effect of 
Cux-1 on kidney development.  In Chapter 2, I discovered how inhibition of a 
serine/threonine phosphatase, Calcineurin, can reduce cell proliferation in 
developing metanephric kidneys. Calcineurin inhibition by treatment with 
Cyclosporin A resulted in increased amounts of phosphorylated Cux-1 (Figure 2-6) 
correlated with decreased cell proliferation (Figure 2-2) and increased p27 (Figure 
2-8)  expression within the nephrogenic zone where Cux-1 is normally expressed 
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(Figure 1-11).  These results suggest that Cux-1 in a phosphorylated state may be 
unable to repress p27 cyclin kinase inhibitor expression.  Calcineurin A α knockout 
mice had the same phenotype as that of CSA treated metanephric kidneys (Figure 2-
1 versus Figure 2-2).  However, the phosphorylation state of Cux-1 in Calcineurin A 
α knockout kidneys was not evaluated. 
Potential experiments derived from my studies in Chapter 2 should involve 
the direct testing of Cux-1 phosphorylation and dephosphorylation in mediating 
kidney development.  The best way to do this would be to develop mice with 
Alanine point mutations in place of the Ser and Thr residues that undergoe 
phosphorylation dephosphorylation within Cux-1. Individual Alanine amino acid 
replacement mice would be necessary to determine the extent of each residue 
involved in regulating kidney development. Another interesting experiment would be 
to determine by immunoprecipitation, the amount of phosphorylated Cux-1 present 
within the Cux-1 CMV transgenic kidneys.  The phenotype of Cux-1 CMV 
transgenic mice (20) may in fact be a consequence of reduced phosphorylated Cux-1 
protein.  Evaluation of Cux-1 phosphorylation levels versus unphosphorylated levels 
in transgenic mice need to be performed.  Experiments in the distant future might 
center on developing an easily phosphorylated Cux-1 construct that can be 
overexpressed in mice and cell lines.  It would also be interesting to see if the 
phenotype is opposite to that of the Cux-1 CMV transgenic mice. 
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The results from Chapter 2 imply that Calcineurin via a direct or indirect 
mechanism is involved in the regulation of Cux-1 
phosphorylation/dephosphorylation (Figure 5-1).   This is a very significant finding 
because it is the first direct evidence to establish a required pathway necessary for 
normal mouse kidney development involving Cux-1.  An in vitro experiment 
involving purified phosphorylated Cux-1 protein in the presence of activated 
Calcineurin should be performed to determine if Calcineurin can directly 
dephosphorylate Cux-1.  
 
 
 
 
 
Figure 5-1. A potential model of Cux-1 regulation by calcineurin. Our previous 
results show that Cux-1 down-regulates the expression of the cyclin kinase inhibitor 
p27 (20). Because p27 induces cell cycle arrest, increased Cux-1 expression or 
activity would result in increased cell cycle progression. Our present results show 
that inhibition of the phosphatase calcineurin by cyclosporin A (CsA) results in 
increased phospho-Cux-1, which is unable to bind DNA (59, 60), and suggests that 
Cux-1 activity may be regulated by calcineurin. In addition to down-regulation of 
p27 by Cux-1, CsA treatment may also result in p27 activation independent of Cux-
1. Image taken from Alclay et al. (242). 
 
Calcineurin phosphatase activity requires an increase in intracellular Calcium 
levels sufficient enough to bind Calmodulin (Reviewed in 170). Calcium-
Calmodulin in turn will form a complex with Calcineurin A (phosphatase activity) 
and B (regulatory) subunits and will then target serine and threonine residues on 
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target proteins for dephosphorylation.  It is not clear which serine and threonine 
residues of Cux-1 are targeted for dephosphorylation as a result of the Calcineurin 
pathway during kidney development.  Experiments involving the design of mice with 
point mutation replacement of distinct residues targeted for phosphorylation may 
provide further insight into the role of phosphorylation/ dephosphorylation during 
kidney development.   
 Polycystic kidney disease (PKD) is considered a developmental disorder.  
The study of primary apical cilia involved in the process of cystogenesis in PKD has 
been an area of great interest (185, 187).  The observation that all proteins that when 
mutated results in Polycystic Kidney Disease (Autosomal recessive and Autosomal 
dominant) co-localize to the nephron tubular primary apical cilia has lead to different 
thoughts on the manifestation of PKD (110).  Although ARPKD and ADPKD result 
from mutations in entirely different genes in rodents and man (98, 101), the 
phenomenon of cystogenesis may involve primary apical cilia common pathway 
(110, 185, 187).  It is thought that tubular urinary flow is detected by primary apical 
cilia bending which results in a mechano-signal transduction event involving a 
conformational change within Polycystin-1 protein which interacts with Polycystin-2 
through a C-tail, leading to the opening of the Polycystin-2 channel and the influx of 
Calcium into the cell (reviewed in 187).  The influx of intracellular calcium is then 
thought to maintain the nephron epithelial cell in a “differentiated state” while 
mutation in Polycystin  proteins lead to dedifferentiation, cell proliferation, and fluid 
secretion leading to cyst development (111, 216-220).  This may involve the 
 129
activation of genes by Calcium pathways which require further investigation.  
Mutation within PKD gene products, which serve as machinery for proper ciliary 
bending mechanosignal transduction, may lead to decreased intracellular Calcium 
entry into the cell as a result of a failure of proper Polycystin-1 regulation of 
Polycystin-2 Calcium channel activity (187, 216).  The consequences of decreased 
intracellular calcium may trigger nephron epithelial cells to be in a dedifferentiated 
state resulting in an alteration of cell polarity and aberrant cell proliferation (216).  
Regardless of what possible mechanism(s) are driving cystogenesis, there is 
sufficient evidence linking alteration of intracellular calcium to cystogenesis and 
ciliary mechanosignal transduction (216-222). 
This idea that PKD is a result of a defect in intracellular calcium levels 
(reduced calcium) ties in nicely with reports linking Polycystin-1 to the regulation of 
Polycystin-2 Calcium channel activity (223).   Moreover, Puri et al. (221) 
demonstrated that Polycystin-1 can activate the calcineurin/NFAT (nuclear factor of 
activated T-cells) signaling pathway through through the heterotrimeric Gα protein, 
(Gq) and mediate activation of phospholipase C (PLC).  They proposed a model 
whereby  Polycystin-1 signaling leads to a sustained elevation of intracellular Ca+2 
mediated by Polycystin-1 activation of Galpha(q) followed by PLC activation, 
release of Ca+2 from intracellular stores, and activation of store-operated Ca+2 entry, 
thus activating calcineurin and NFAT.     
The role of Cux-1 in kidney development is to regulate cell cycle progression 
through the repression of the cyclin kinase inhibitors p21 and p27 (Chapter 1).   Cux-
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1 is highly expressed in proliferating cells during kidney development (19, 20).  A 
hallmark of PKD is aberrant cell proliferation.  Since Cux-1 is developmentally 
expressed in proliferating cells and PKD is considered a developmental disorder 
involving renal tubular dedifferentiation and cell proliferation, the role of Cux-1 in 
PKD was investigated.  My results (Chapter 2) demonstrate that Calcineurin 
regulates Cux-1 phosphorylation state during kidney development.  Activation of 
Calcineurin activity requires elevated levels of intracellular Ca+2 (170).  Therefore, 
since inhibition of Calcineurin activity results in elevated phospho Cux-1 levels 
(Chapter 2), decreased intracellular calcium could lead to an increase in 
phosphorylated Cux-1.  However, it is not known if 
phosphorylation/dephosphorylation regulates Cux-1 function in PKD.  It is 
conceivable that the regulation of Cux-1 function during kidney development and in 
PKD is different in regard to the availability of potential protein substrates and 
signaling pathways.  This idea is supported by the observation that Cux-1 is not 
expressed in proliferating cells during early PKD in cpk cystic kidneys yet is 
ectopically expressed in Pkd1 knockout cystic kidneys during early development 
(135).    
Cux-1 is ectopically expressed in Pkd1 knockout mice (135), cpk mice (19) 
and in human ADPKD (Figure 4-2).  It is possible that ectopically expressed Cux-1 
protein levels serve to enhance mitotic signaling pathways by indirectly binding to 
transcriptional complexes such as RB/HinF-D, as it may normally function during 
G1-S-phase transition of the cell cycle (66-69). In the cpk mouse, Cux-1 expression 
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is restricted to interstitial cells and does not co-localize in proliferating cyst lining 
epithelial cells during the early stages of the disease (135). During the later stages of 
cpk disease (3 weeks), Cux-1 is ectopically expressed and co-localizes with 
proliferating cells (135).  This may indicate that as the disease progresses, Cux-1 
may participate in cell proliferation.  However, Cux-1 positive cyst-lining epithelial 
cells undergoe apoptosis at 3 weeks when the cyclin kinase inhibitors p21 and p27 
are upregulated (135). Upregulation of p21 and/or p27 may trigger apoptosis in cpk 
kidneys however that possibility has not been investigated.  It is also possible that 
there is decreased Calcineurin activity within cpk kidneys which could result in Cux-
1 in a phosphorylated state and unable to repress p21 and/or p27 gene expression.  
Although this is unclear and Calcineurin activity within cpk kidneys has not been 
evaluated.   During kidney development, upregulation of Cux-1 is correlated with 
downregulation of the cyclin kinase inhibitors p27 and is highly expressed in 
proliferating cells (19, 20).  Therefore, Cux-1 appears to function differently during 
kidney development and within the cpk model for PKD.     
Since Cux-1 is upregulated in PKD (19) previous work from our laboratory 
evaluated the overexpression of Cux-1 in transgenic mice which resulted in renal 
hyperplasia without the development of cystic kidneys (20). This observation 
suggested that Cux-1 may be necessary in PKD in regard to possibly contributing to 
cell proliferation but not sufficient by itself for the development of polycystic 
kidneys.  It was this idea coupled with the observation that overexpression of Cux-1 
in transgenic kidneys resulted in the downregulation of p27 (20) which became the 
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rationale for studying the effect of Cux-1 mutation in PKD.  Since overexpression of 
Cux-1 represses p27 expression, we predicted that the Cux-1 to p27 pathway may 
function as a “modifier” pathway involved in exacerbating or ameliorating PKD 
depending upon upstream factors that regulate Cux-1 expression and function.  Prior 
to the conclusion of my experiments in Chapter 3 there was no evidence that Cux-1 
was directly involved in PKD. When I crossed the Cux-1ΔCR1 gene onto cpk mice I 
found that Cux-1ΔCR1 accelerated PKD cystogenesis resulting in severe PKD 
(Figure 3-5).  These results established that Cux-1 contributes to PKD. Moreover, 
since Cux-1ΔCR1 gene alone does not result in cystic kidneys (37) but when present 
with the cpk gene accelerates disease (Chapter 3), the cux-1ΔCR1 gene can be 
considered a potential candidate modifying gene for PKD (Figure 5-2).  
The future directions from my studies in Chapter 3 would have to center 
around evaluation of the Cux-1ΔCR1/cpk phenotype on a congenic B6 background. 
The reason why this is necessary is because the mixed B6/129 background by which 
the animals in this chapter were analyzed on, may underscore the effect of a plethora 
of unknown genetic interactions that could act additively or subtract from the true 
effect of the Cux-1ΔCR1 genetic interaction with cpk (See 224 for review of effect of 
genetic background).  The cpk gene may be involved in genetic interactions with 
genes on the 129 background. Therefore, analyzing this phenotype when Cux-1ΔCR1 
is present on B6 with cpk may uncover with greater clarity the Cux-1ΔCR1/cpk 
genetic interaction.  
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Figure 5-2. cux-1ΔCR1 is a modifying gene for Polycystic Kidney Disease. Mice 
carrying the Cux-1ΔCR1 gene have normal kidneys. In contrast mice carrying the 
cpk gene develop polycystic kidneys.  The presence of both the Cux-1ΔCR1 and cpk 
genes within mice results in a more severe form of polycystic kidney disease.   
 
 
Tazón-Vega et al. (225) studied potential candidate modifying genes in 
ADPKD patients with mutations in the PKD-1 gene and were not able to identify a 
modifying gene for the disease.  They saw that angiotensin converting enzyme 
(ACE) had only a slight influence on the age of onset of end stage renal disease for 
PKD-1 mutant patients. However, Konoshita et al. (226) found that ACE 
polymorphism led to a more rapid onset of end stage renal disease.  Tazón-Vega et 
al. (225) were not able to correlate polymorphisms of epidermal growth factor 
receptor and TGFβ as being modifier genes.   Magistroni et al. (227) found that 
EGFR polymorphisms lead to earlier end stage renal disease but their data was not 
statistically significantly.  The cystic fibrosis (CF) gene which encodes the cystic 
fibrosis transmembrane conductance regulator (CFTR) was also studied in human 
patients and the presence of CF mutations within ADPKD patients were not 
statistically significant (228).  Walker et al.(229) found that ENOS (endothelial nitric 
Cux-1ΔCR1 cpk Cux-1ΔCR1/cpk
Normal Kidneys Cystic kidneys Large Cystic Kidneys
(non-cystic) large mature cysts
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oxide synthase) did not correlate with ADPKD severity.  Whole genome quantitative 
trait loci mapping of 114 selected pcy/pcy mice (68 with the mild PKD and 46 with 
severe PKD) identified two loci, MOP1 and MOP2 that strongly modulate PKD 
progression (230). Mrug et al. (128) demonstrated that the Kinesin family member 
12 gene is a potential candidate modifier gene in cpk cystic disease.  The results of 
my study (Chapter 3) provide Cux-1 as a target potential candidate modifier gene for 
ARPKD. Clinical screening for Cux-1 and the Kinesin family member 12 gene 
should be performed to evaluate genetic polymorphisms in correlation with disease 
severity in ARPKD patients.   
 The next issue became understanding the mechanism behind how Cux-
1ΔCR1/cpk mice have accelerated PKD.   In Chapter 4, I found that Cux-1ΔCR1 is 
ectopically expressed in proliferating cystic epithelial cells (Figure 4-1).  In regard 
to the phenomenon of accelerated PKD occurring within these animals, these results 
suggested a link between Cux-1ΔCR1 and cell proliferation.  It was also a surprising 
result since mutant Cux-1ΔCR1 carries the same promoter as wild-type Cux-1 (37).   
During the time of this discovery it was reported that Cux-1 undergoes a degradation 
pathway that is initiated by the nuclear protease Cathepsin-L (32, 33).   Under close 
examination of the region that was deleted in the Cux-1ΔCR1 mutation, we found 
that Cux-1ΔCR1 lacks a Cathepsin-L cleavage site (Figure 4-3).  The absent 
cleavage site may impair the ability of Cathepsin-L to proteolytically process Cux-
1ΔCR1.  This in turn could lead to the accumulation of Cux-1ΔCR1 protein which 
was observed in cpk cystic epithelial cells (Figure 4-1).  Furthermore, I found that 
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p27 is downregulated in Cux-1ΔCR1/cpk kidneys (Figure 4-5), where p27 is 
normally upregulated in cpk kidneys (Figure 1-17).  Therefore, the data I have 
presented within this dissertation suggests a possible mechanism that helps explain 
the accelerated PKD observed in Cux-1ΔCR1/cpk kidneys (Figure 5-3).  
The future directions from my studies in Chapter 4 should center on the 
ability of Cux-1ΔCR1 protein to avoid Cathepsin-L proteolytic cleavage. This can be 
accomplished by treating purified Cux-1ΔCR1 protein with different concentrations 
of Cathepsin-L or with the same concentration of Cathepsin-L at different time 
points in comparison with treatment with wild-type purified Cux-1.  Further analysis 
should involve the transfection of cells with Cux-1ΔCR1 to determine if 
overexpression of Cux-1ΔCR1 results in reduction of p27 promoter luciferase 
activity and rapid progression through the cell cycle as indicated by Flourescence 
associated cell sorting (FAC) analysis.  However, these in vitro results will only 
confirm or not confirm the in vivo data that I have already presented in my 
dissertation.  It would be very unclear if conflicting results were to be observed in 
vitro during these experiments.  The data could always be rationalized as being 
“different” from the naturally occurring events I observed in vivo.   
The involvement of Cux-1 in ADPKD needs to be confirmed in the same 
manner by which I have confirmed Cux-1 involvement in ARPKD. I think the 
overall critical next experiment should be to cross cux-1ΔCR1 gene onto any selected 
mouse model for ADPKD where cysts develop over a longer extended period of time 
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compared to the 1 month period in which cystic disease occurs postnatally in cpk 
mice.  The reason why this is important is because we have already established from 
my results that Cux-1 function seems to be different in ADPKD and ARPKD. 
Phenotypic alteration of the ADPKD phenotype would confirm the extent and 
involvement of Cux-1 with the disease which may further help to reveal differences 
between ADPKD and ARPKD.  
The results from this body of work link Cathepsin-L to the ectopic expression 
of Cux-1 in human and mouse ADPKD as well as mouse ARPKD. The nuclear 
expression of Cathepsin-L is inversely related to Cux-1 expression in human 
ADPKD and pkd1 null mice (Figure 4-1, Figure 4-2 and Figure 4-3). That is, there 
is decreased nuclear Cathepsin-L present when Cux-1 protein levels are upregulated.  
Cathepsin L isoforms that are devoid of a signal peptide were recently shown to be 
present in the nucleus where they proteolytically process the CCAAT-displacement 
protein/cut homeobox (CDP/Cux) transcription factor (32, 33). A role for nuclear 
Cathepsin L in cell proliferation could be inferred from the observation that the 
CDP/Cux processed isoform can accelerate entry into S phase (32, 33).  In renal 
carcinoma cells the proteolytic processing of CDP/Cux is augmented and correlates 
with increased cysteine protease expression and activity in the nucleus (231).  Goulet 
et al.(231) recently suggested that the increased protease activity could be a major 
factor involved in cell-cycle progression and increased cell proliferation occurring 
within these cells.  They showed that transformation by the ras oncogene causes 
rapid increases both in the production of short nuclear cathepsin L isoforms and in 
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the processing of CDP/Cux (231).  Evidence has linked PKD with cancer (232-234) 
in that aberrant cell proliferation and growth occurs in both diseases.  Therefore, the 
data within my dissertation strengthens the concept that PKD can be correlated with 
Cancer in regard to the observation that nuclear Cathepsin-L is highly expressed in 
PKD and Cux-1 protein appears to be more stable in ADPKD (Figure 4-2 and 
Figure 4-3).   
 
 
Figure 5-3. Model for accelerated PKD observed in Cux-1ΔCR1/cpk kidneys.  
Since Cux-1ΔCR1 protein lacks a Cathepsin-L cleavage site it may avoid proteolytic 
degradation and thus accumulate in cystic epithelial cells. Increased Cux-1ΔCR1 
protein can bind p27 promoter leading to the reduction of p27 expression levels. 
Reduced p27 favors rapid progression through the cell cycle resulting in increased 
numbers of cells dividing and aberrant cell proliferation.  Aberrant cell proliferation 
is a hallmark for cyst progression and development therefore leading to increased 
advanced stage cyst formation and increased cystic kidney size thus modifying the 
cpk phenotype.  
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My work has demonstrated that the Cux-1ΔCR1 gain-of-function mutation 
can exacerbate PKD in the cpk mouse and is correlated with downregulation of p27 
(Figure 3-4, Figure 3-5, Figure 3-6 and Figure 4-5). This suggests that Cux-1 can 
modify PKD.  However, the degree by which this mutation of Cux-1 is involved in 
generating new mitotic signaling pathways and/or altering pre-existing signaling 
pathways involved in PKD is not clear.  It is also conceivable that ectopic Cux-1 
expression in cells that were originally differentiated and then undergo 
dedifferentiation participate in the induction of apoptotic pathways.  
Previous studies have suggested that Cux-1 expression may be involved in 
apoptosis (135, 235).  Yet mutant Cux-1ΔCR1 protein is expressed in proliferating 
cells (Figure 4-1) and may help to drive cell proliferation by repressing the cyclin 
kinase inhibitor p27.   However, Cux-1ΔCR1 protein is expressed in cyst-lining 
epithelial cells undergoing apoptosis at post-natal day 10 (Figure 4-1).   Cux-1 and 
Cux-1ΔCR1 ectopic expression occurs in cystic epithelial cells that are undergoing 
apoptosis at 3 weeks (135) and 10 days of age (Figure 4-6) respectively within cpk 
kidneys.  Therefore, it appears that the cux-1ΔCR1/cpk post-natal day 10 cystic 
kidneys resemble 3-week old cpk kidneys.  Caspase expression and activity has been 
correlated with increased apoptosis occurring within cells (231). Truscott et al. (236) 
recently found that caspase activity can proteolytically cleave Cux-1 during S-phase 
and enhance Cux-1 function to accelerate cell-cycle progression.  It is possible that 
the increased activated Caspase-3 protein levels within cux-1ΔCR1/cpk mice (Figure 
4-6) contribute to the acceleration of cystic epithelial cells through the cell cycle 
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resulting in increased cell proliferation.  However, the role of Cux-1 in apoptotic 
pathways is not clear and it is less clear how apoptosis is involved in PKD.  
Therefore it may be too early at this stage to draw an analogy between Cux-1 and 
apoptotic pathways involved in PKD.   
Overexpression of Cux-1 in transgenic kidneys results in the downregulation 
of p27 (20).  This observation fits well with the observation that p27 is 
downregulated in ADPKD and pkd1 null mice where Cux-1 is upregulated (135).   
Since Cux-1 targets the cyclin kinase inhibitors p21 (55) and p27 (20) for repression 
Cux-1 may be involved in downregulation of these cyclin kinase inhibitors in PKD.  
Bhunia et al. (148) demonstrated that the Polycystin-1 protein signals through the 
JAK-STAT pathway to upregulate p21.  They found that when the pkd1 gene is 
mutated, Polycystin-1 signaling through JAK-STAT1 is altered resulting in increased 
p21.  It is possible that the JAK-STAT pathway directly or indirectly regulates Cux-1 
transcriptional expression or DNA binding ability and that Cux-1 is a downstream 
mediator of JAK-STAT signaling (Figure 5-4).  For example, Cux-1 may be in a 
phosphorylated state during normal Polycystin-1 JAK STAT signaling resulting in 
decreased Cux-1 p21 promoter DNA interactions leading to the upregulation of p21.  
In contrast, defective JAK-STAT signaling could result in the decreased ability of 
Cux-1 to become phosphorylated in turn triggering Cux-1 DNA binding which could 
lead to repression of p21 gene expression.  Future experiments should target JAK 
STAT signaling in regard to the expression and phosphorylation state of Cux-1.  
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Exposure of human epidermal carcinoma (A-431) cells to EGF results in a 
significant increase in EGFR, Stat-3 phosphorylation and increased p21 cyclin kinase 
inhibitor expression (237-239).  However, inhibition of EGFR by AG1478 fails to 
decrease EGF-induced Stat-3 phosphorylation (237). This suggests that EGF 
continues to drive Stat-3 phosphorylation through other receptors. It is interesting to 
note that p21 is downregulated in A-431 cells that are not stimulated with EGF (238) 
when Cux-1 protein levels are reduced (Chapter 3).  A-431 EGF stimulated cells 
were similar to that of Polycystin-1 transfected cells from Bhunia et al. (148), 
whereby stimulation of STAT leads to upregulation of p21 and decreased cell 
proliferation.  This suggests that the JAK STAT pathway, much like in PKD, is 
active within A-431 cells and may be involved in the regulation of Cux-1 and p21. 
Therefore, taken together the EGFR pathway and JAK STAT stimulation in addition 
to Polcystin-1 signaling to JAK STAT may regulate p21 expression through Cux-1 
expression level or phosphorylation state (Figure 5-4).  Whether or not Cux-1 is  
involved within the JAK STAT pathway still remains to be seen.  Transient or stable 
transfection experiments involving activation of JAK or STAT to determine Cux-1 
expression and phosphorylation state in correlation with p21 and/or p27 promoter 
luciferase activity might address some of those questions.    
Since Cux-1 is highly expressed in A-431 cells that are unstimulated with 
EGF (Chapter 3), it is very attractive to consider that Cux-1 is involved in repression 
of p21.  However, the EGF induced increase in p21 levels in A-431 cells is the result 
of post-transcriptional and post-translational stabilization (238).   Therefore, the 
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extent of Cux-1 regulation of p21 within these cells is unclear. Moreover, our results 
indicate that p27 is upregulated in A-431 cells unstimulated with EGF.  Cell cycle 
progression to mitosis in A-431 cells appears to involve p21 but probably not p27, 
however further experiments are required to confirm or reject this hypothesis.  The 
function of Cux-1 within these cells remains unclear.  
EGF elevates intracellular calcium in A-431 cells (239).  Epidermal growth 
factor stimulates the rapid accumulation of inositol (1,4,5)-trisphosphate and a rise in 
cytosolic calcium mobilized from intracellular stores in A-431 cells.  A-431 cells that 
are not stimulated with EGF highly express Cux-1 (Chapter 3) and undergo cell 
division in the presence of lower intracellular calcium levels (238, 239). Therefore, 
there is precedence for Cux-1 expression being regulated by EGFR and associated 
with reduced intracellular calcium levels and increased cell proliferation.  Deficient 
intracellular calcium and irregular EGFR activity present with aberrant cell 
proliferation has been demonstrated in PKD cystic epithelial cells (130, 163, 219, 
220, 222). Cux-1 is upregulated in cystic epithelial cells (135).  Therefore, the 
involvement of Cux-1 in PKD may be EGFR and calcium dependent as Cux-1 is 
similarly upregulated under the similar conditions within human epidermal 
carcinoma cells undergoing cell proliferation.   
My results in Chapter 2 implicate Calcineurin in the regulation of Cux-1 by 
dephosphorylation.  Dephosphorylation of Cux-1 has been demonstrated to activate 
Cux-1 DNA binding activity (55).  Activation of the Calcineurin pathway requires 
increased intracellular Calcium levels. Manzati et al. (240) and others (154, 155) 
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found that elevated intracellular calcium and PKC activity results in increased cell 
proliferation in cells that overexpress Polycystin-1 C-terminus.   Puri et al. (221) 
demonstrated that overexpression of the Polycystin-1 C-terminus resulted in 
activation of the Calcineurin/nFAT pathway.  Polycysin-1 has also been linked to 
regulating increases in intracellular calcium not only through complex with 
Polycystin-2, a calcium channel, at the cell membrane but also in the release of 
calcium from the endoplasmic reticulum (reviewed in 98, 101).  Therefore, another 
possible model for Cux-1 involved in PKD signaling is that a Polycystin-1 mediated 
increase in intracellular calcium leads to activation of Calcineurin which may 
directly or indirectly lead to Cux-1 dephosphorylation resulting in increased Cux-1 
DNA binding activity to repress p27 and aberrant cell proliferation (Figure 5-4). 
 Coqueret el al. (60) found that PKC phosphorylates Cux-1 which could 
inhibit Cux-1 DNA binding potential.  In PKD 85% of all human cases involve 
mutation in the PKD-1 gene which encodes Polycystin-1.  It is possible that altered 
PKC signaling leads to reduced levels of phosphorylated Cux-1, which would permit 
DNA binding and repress the p21 and p27 cyclin kinase inhibitors.  Transfection 
studies involving Polycystin-1 overexpression correlated with PKC, Cux-1 and p27 
expression and activity need to be conducted to fully address the existence of a 
Polycystin-1-PKC-Cux-1-p27 pathway.   
 The role of cAMP in PKD seems to involve induction of cell proliferation in 
cystic cells (159, 160, 163, 164).   cAMP can trigger activation of PKA which 
translocates into the nucleus and can stimulate activation of the CREB protein (211 
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for review). The activated CREB protein then binds to a CRE region, and is then 
bound to by a CBP (CREB binding protein) which coactivates it, allowing it to 
switch certain genes on or off.  Michl et al. (61) demonstrated that cAMP stimulation 
of PKA phosphorylates Cux-1 resulting in the reduction of Cux-1 DNA binding 
affinity within fibroblasts.  cAMP stimulation of HEK 293T cells transiently 
transfected with the C-terminus of Polycystin-1 did not show alterations in Cux-1 
expression (unpublished observation).  However, the phosphorylation state of Cux-1 
under these conditions was not evaluated.  Therefore, the role of cAMP in regulating 
Cux-1 in PKD is still unclear.    
Nakamura et al. (139) and others demonstrated that TGFβ is upregulated in 
cpk mice.  Michl et al. (166, 167) discovered that Cux-1 is a transcriptional target of 
TGFβ and that Cux-1 activates a transcriptional program regulating genes involved 
in cell motility, invasion, and extracellular matrix composition.  They found that 
Cux-1 expression is significantly increased in high-grade carcinomas and is inversely 
correlated with survival in breast cancer. From their results Michl et al. (166, 167) 
suggested that CUTL1 plays a central role in coordinating a gene expression 
program associated with cell motility and tumor progression.  Therefore, activation 
of TGFβ in PKD may trigger the upregulation/activation of Cux-1 leading to a 
“Cancer-like” phenotype in cystic epithelial cells involving increased cell motility 
and extracellular matrix composition which are characteristics of cystogenesis (233).   
The involvement of Cux-1 in PKD strengthens the idea that PKD cysts have 
characteristics similar to cancer/tumor growth.      
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Results from my dissertation demonstrated that Calcineurin is involved 
directly or indirectly in Cux-1 dephosphorylation during kidney development 
(Chapter 2). This was significant because it showed that regulation of Cux-1 
phosphorylation state is critical for proper kidney development.  I found that the cux-
1ΔCR1 gene accelerates PKD in the cpk mouse model for ARPKD establishing a 
role for Cux-1 in PKD (Chapter 3). This was also an important finding because it 
identified cux-1ΔCR1 gene as a candidate modifier gene for ARPKD.  The 
observation that Cux-1ΔCR1 protein is more stable in developing kidneys and 
ectopically expressed in cpk cystic epithelial cells which are simultaneously 
undergoing cell proliferation and apoptosis led to further insight into possible 
mechanisms behind accelerated cystogenesis (Chapter 4).  Moreover, it led to the 
observation that nuclear Cathepsin-L levels may help to determine Cux-1 expression 
in cpk, pkd1 knockout and human ADPKD as a possible explanation for the ectopic 
expression of Cux-1 in PKD. Further analysis revealed that the cyclin kinase 
inhibitor p27 is downregulated in Cux-1ΔCR1/cpk kidneys which may also help to 
explain severe PKD occurring within these mice (Chapter 4).  This is the fist 
evidence demonstrating that p27 downregulation can influence PKD severity in vivo.  
Taken together, the results from this dissertation have helped to advance scientific 
knowledge of kidney development and polycystic kidney disease.   
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Figure 5-4.  Summary of potential signaling pathways that may regulate Cux-1.  
This model depicts multiple signaling factors/pathways which have been linked to 
the regulation of Cux-1 within different cell types.  Established signaling pathways 
which occur in polycystic kidney disease are additionally represented in the context 
of similar factors which have been known to regulate Cux-1 activity (i.e. PKA, PKC) 
(13, 59-62).  The signaling mechanisms described in this model refer to the 
regulation of Cux-1 by post-translational modification.  Proteolytic cleavage 
(Caspase, Cathepsin-L) and dephosphorylation (Calcineurin pathway, Cdc 25 
phosphatase) of Cux-1 favor Cux-1 DNA binding activity which would favor Cux-1 
repression of the Cyclin Kinase Inhibitors p21 and p27 (13, 242, 243).  The Notch 
(70), WNT (244) and TGF-β (166) pathways have been demonstrated to correlate 
with augmented Cux-1 expression levels within different cell types while HinF-
D/RB was shown to act as a transcriptional co-repressor complex which involves 
Cux-1 in mediating transcriptional repression (66, 67).  The ability of Cux-1 to 
interact with co-repressors and to be highly expressed within cells would favor Cux-
1 mediated transcriptional repression of its gene targets.  Phosphorylation of Cux-1 
(PKA, PKC, and Cyclin A CDK1) has been demonstrated to inhibit Cux-1 DNA 
binding ability (reviewed in 13) which would prevent the ability of Cux-1 to repress 
p21 and p27.  (→) Indicates factors which lead to the expression or post-translational 
modification of Cux-1 which potentiates Cux-1 DNA binding activity. (→) Indicates 
pathways which lead to post-translational modification which inhibits Cux-1 
function. (→) Indicates factors and pathways which have upstream regulators of 
Cux-1, yet the mechanism of Cux-1 activity within these pathways is still unclear. 
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